{"ok":true,"data":[{"nctId":"NCT04396860","title":"Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma","sponsor":"National Cancer Institute (NCI)","sponsorClass":"OTHER","phases":["PHASE2","PHASE3"],"status":"COMPLETED","interventions":["Ipilimumab","Nivolumab","Temozolomide"],"startDate":"2020-09-01","firstPosted":"2020-05-21","lastUpdated":"2026-11-10","primaryCompletion":"2023-01-13","resultsFirstPosted":"2024-05-01","enrollment":159,"officials":[{"name":"Andrew B Lassman","role":"PRINCIPAL_INVESTIGATOR","affiliation":"NRG Oncology"}],"conditions":["Gliosarcoma","MGMT-Unmethylated Glioblastoma"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT07927491","title":"Surgical Window Study of CM93 in Subjects With Recurrent Glioblastoma (rGBM)","sponsor":"NYU Langone Health","sponsorClass":"OTHER","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","interventions":["CM93"],"startDate":"2026-12-01","firstPosted":"2026-11-10","lastUpdated":"2026-11-10","primaryCompletion":"2031-06-01","enrollment":72,"officials":[{"name":"J. Ricardo McFaline-Figueroa, MD, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"NYU Langone Health"}],"conditions":["Recurrent Glioblastoma With EGFR Mutation"],"siteCountries":["United States","United States","United States"]},{"nctId":"NCT07929909","title":"A Phase I Clinical Study of YN003 in the Treatment of Glioma","sponsor":"Beijing Inno Medicine Co., Ltd.","sponsorClass":"INDUSTRY","phases":["PHASE1"],"status":"RECRUITING","interventions":["YN003 Injection"],"startDate":"2026-10-27","firstPosted":"2026-11-10","lastUpdated":"2026-11-10","primaryCompletion":"2028-12-31","enrollment":50,"officials":[],"conditions":["Glioma","Glioblastoma","Brain Neoplasms"],"siteCountries":["United States","United States","United States","China","China"]},{"nctId":"NCT07389278","title":"Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)","sponsor":"Sabine Mueller, MD, PhD","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","interventions":["ADI-PEG 20 (Arginine deiminase pegylated)","Temozolomide (TMZ)"],"startDate":"2027-06-01","firstPosted":"2026-02-05","lastUpdated":"2026-11-09","primaryCompletion":"2032-06-30","enrollment":97,"officials":[{"name":"Sabine Mueller, MD, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of California, San Francisco"},{"name":"Tom Davidson, MD","role":"STUDY_CHAIR","affiliation":"Children's Hospital Los Angeles"}],"conditions":["Glioblastoma","High-Grade Glioma (WHO III-IV)","High-grade Glioma","Diffuse Midline Glioma, H3 K27M-Mutant","Diffuse Hemispheric Glioma, H3G34 Mutant"],"siteCountries":["United States"]},{"nctId":"NCT06917885","title":"CUE-102 in Recurrent Glioblastoma","sponsor":"David Reardon, MD","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["CUE-102"],"startDate":"2025-07-30","firstPosted":"2025-04-09","lastUpdated":"2026-11-09","primaryCompletion":"2027-01-31","enrollment":12,"officials":[{"name":"David Reardon, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Dana-Farber Cancer Institute"}],"conditions":["Recurrent Glioblastoma","Glioblastoma","Glioma, Malignant"],"siteCountries":["United States","United States"]},{"nctId":"NCT01906385","title":"Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)","sponsor":"Cerenome","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Rhenium Liposome Treatment"],"startDate":"2015-06-03","firstPosted":"2013-07-24","lastUpdated":"2026-11-09","primaryCompletion":"2027-04","enrollment":55,"officials":[{"name":"Andrew J Brenner, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"The Cancer Therapy and Research Center at UTHSCSA"}],"conditions":["Glioma"],"siteCountries":["United States","United States","United States","United States"]},{"nctId":"NCT07356973","title":"Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma","acronym":"OPTICAL","sponsor":"CRISM Therapeutics LTD","sponsorClass":"INDUSTRY","phases":["PHASE2"],"status":"RECRUITING","interventions":["irinotecan-ChemoSeed implementation into the resection cavity after surgical resection of GBM"],"startDate":"2026-08-20","firstPosted":"2026-01-21","lastUpdated":"2026-11-09","primaryCompletion":"2029-05","enrollment":147,"officials":[{"name":"Garth S Cruickshank, MBBS, PhD","role":"STUDY_CHAIR","affiliation":"Emeritus Professor of Neurosurgery, University of Birmingham UK"}],"conditions":["Glioblastoma"],"siteCountries":["United Kingdom"]},{"nctId":"NCT05432804","title":"Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment","sponsor":"National Cancer Institute (NCI)","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["Placebo Administration","Selinexor","Temozolomide"],"startDate":"2023-03-20","firstPosted":"2022-06-27","lastUpdated":"2026-11-09","primaryCompletion":"2027-06-30","enrollment":97,"officials":[{"name":"Jana L Portnow","role":"PRINCIPAL_INVESTIGATOR","affiliation":"City of Hope Comprehensive Cancer Center LAO"}],"conditions":["Recurrent Glioblastoma, IDH-Wildtype","Recurrent MGMT-Methylated Glioblastoma"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT04541082","title":"Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms","sponsor":"Jazz Pharmaceuticals","sponsorClass":"INDUSTRY","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["ONC206"],"startDate":"2020-10-26","firstPosted":"2020-09-09","lastUpdated":"2026-11-09","primaryCompletion":"2027-03-31","enrollment":35,"officials":[],"conditions":["Central Nervous System Neoplasms","Glioblastoma","Gliosarcoma, Adult","Anaplastic Oligodendroglioma","Anaplastic Astrocytoma","Pilocytic Astrocytoma","Oligodendroglioma","Gliomatosis Cerebri","Pleomorphic Xanthoastrocytoma","Anaplastic Pleomorphic Xanthoastrocytoma","Diffuse Midline Glioma, H3 K27M-Mutant","Ependymoma","Ependymoma, Anaplastic","Medulloblastoma","Teratoid Rhabdoid Tumor","Neuroectodermal Tumors, Primitive","Neuroectodermal Tumors","Anaplastic Meningioma","Atypical Meningioma","Choroid Plexus Neoplasms","Pineal Tumor","Diffuse Astrocytoma","Glial Tumor"],"siteCountries":["United States"]},{"nctId":"NCT07195591","title":"Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care","acronym":"BRIDGES","sponsor":"GT Medical Technologies, Inc.","sponsorClass":"INDUSTRY","phases":["PHASE3"],"status":"RECRUITING","interventions":["Temozolomide"],"startDate":"2025-12-10","firstPosted":"2025-09-26","lastUpdated":"2026-11-09","primaryCompletion":"2031-12","enrollment":766,"officials":[],"conditions":["Glioblastoma"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT07524140","title":"A First-in-Human Study of ZE94-0605 in Patients With Advanced Solid Tumors","sponsor":"Eilean Therapeutics","sponsorClass":"INDUSTRY","phases":["PHASE1"],"status":"RECRUITING","interventions":["ZE94-0605"],"startDate":"2026-06-25","firstPosted":"2026-04-13","lastUpdated":"2026-11-09","primaryCompletion":"2028-01","enrollment":60,"officials":[],"conditions":["Advanced Solid Tumor Cancer","Metastatic Solid Tumor"],"siteCountries":["Australia","Australia","Uzbekistan"]},{"nctId":"NCT06161519","title":"PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications","sponsor":"National Cancer Institute (NCI)","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["PLX038"],"startDate":"2024-01-31","firstPosted":"2023-12-08","lastUpdated":"2026-11-06","primaryCompletion":"2028-11-14","enrollment":146,"officials":[{"name":"Kevin A Camphausen, M.D.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"National Cancer Institute (NCI)"}],"conditions":["Glioma","Medulloblastoma","Ependymoma","Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT06556563","title":"EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma","acronym":"EF-41","sponsor":"NovoCure GmbH","sponsorClass":"INDUSTRY","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Temozolomide","Pembrolizumab","Placebo"],"startDate":"2025-02-03","firstPosted":"2024-08-16","lastUpdated":"2026-11-06","primaryCompletion":"2029-04","enrollment":741,"officials":[],"conditions":["Glioblastoma"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","Canada","Canada","Canada","Canada","Canada","Canada","Canada","Czechia","France","France","France","France","France","Germany","Germany","Germany","Israel","Israel","Israel","Israel","Italy","Italy","Italy","Italy","Italy","Italy","Italy","Japan","Japan","Japan","Japan","Japan","Japan","Japan","Japan","Japan","Japan","Japan","Japan","Poland","Poland","Poland","Spain","Spain","Spain","Spain","Spain","Spain","Spain","Spain","Spain","Spain","Switzerland","Switzerland","Switzerland","United Kingdom","United Kingdom","United Kingdom","United Kingdom","United Kingdom","United Kingdom","United Kingdom","United Kingdom","United Kingdom","United Kingdom","United Kingdom"]},{"nctId":"NCT05969860","title":"At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer","sponsor":"Mayo Clinic","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":[],"startDate":"2023-09-21","firstPosted":"2023-08-01","lastUpdated":"2026-11-06","primaryCompletion":"2027-12-01","enrollment":220,"officials":[{"name":"Roxana S. Dronca, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Mayo Clinic"}],"conditions":["Advanced Anal Carcinoma","Advanced Biliary Tract Carcinoma","Advanced Bladder Carcinoma","Advanced Breast Carcinoma","Advanced Carcinoid Tumor","Advanced Cervical Carcinoma","Advanced Colorectal Carcinoma","Advanced Gastric Carcinoma","Advanced Glioblastoma","Advanced Head and Neck Carcinoma","Advanced HER2 Positive Breast Carcinoma","Advanced Lung Carcinoma","Advanced Lung Small Cell Carcinoma","Advanced Malignant Germ Cell Tumor","Advanced Malignant Solid Neoplasm","Advanced Neuroendocrine Carcinoma","Advanced Ovarian Carcinoma","Advanced Pancreatic Carcinoma","Advanced Prostate Small Cell Neuroendocrine Carcinoma","Advanced Prostate Carcinoma","Hematopoietic and Lymphoid System Neoplasm","Multiple Myeloma","Myelodysplastic Syndrome","Advanced Basal Cell Carcinoma","Advanced Cholangiocarcinoma","Advanced Endometrial Carcinoma","Advanced Esophageal Carcinoma","Advanced Fallopian Tube Carcinoma","Advanced Hepatocellular Carcinoma","Advanced Liver Carcinoma","Advanced Lymphoma","Advanced Malignant Testicular Neoplasm","Advanced Melanoma","Advanced Merkel Cell Carcinoma","Advanced Penile Carcinoma","Advanced Primary Malignant Central Nervous System Neoplasm","Advanced Renal Cell Carcinoma","Advanced Sarcoma","Advanced Skin Squamous Cell Carcinoma","Advanced Urethral Carcinoma","Advanced Vaginal Carcinoma","Advanced Vulvar Carcinoma","Advanced Appendix Carcinoma","Advanced Gastroesophageal Junction Adenocarcinoma"],"siteCountries":["United States","United States"]},{"nctId":"NCT04319276","title":"Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma","sponsor":"Medical College of Wisconsin","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Gallium maltolate (500 mg)","Gallium maltolate (1,000 mg)","Gallium maltolate (1,500 mg)","Gallium maltolate (2,000 mg)","Gallium maltolate (2,500 mg)","Gallium maltolate (recommended phase 2 dose)"],"startDate":"2022-11-11","firstPosted":"2020-03-24","lastUpdated":"2026-11-06","primaryCompletion":"2025-02-13","enrollment":26,"officials":[{"name":"Jennifer Connelly, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Medical College of Wisconsin"}],"conditions":["Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT06641908","title":"Anti-GD2 ADC M3554 in Advanced Solid Tumors","sponsor":"EMD Serono Research & Development Institute, Inc.","sponsorClass":"INDUSTRY","phases":["PHASE1"],"status":"RECRUITING","interventions":["M3554"],"startDate":"2024-11-08","firstPosted":"2024-10-15","lastUpdated":"2026-11-05","primaryCompletion":"2027-04-16","enrollment":65,"officials":[{"name":"Medical Responsible","role":"STUDY_DIRECTOR","affiliation":"EMD Serono Research & Development Institute, Inc."}],"conditions":["Advanced Solid Tumor"],"siteCountries":["United States","United States","United States","Belgium","France","France","France","France","Japan","Switzerland","United Kingdom"]},{"nctId":"NCT05902169","title":"Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM","acronym":"SONOBIRD","sponsor":"CarThera","sponsorClass":"INDUSTRY","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Carboplatin","Lomustine","Temozolomide"],"startDate":"2024-01-29","firstPosted":"2023-06-13","lastUpdated":"2026-11-05","primaryCompletion":"2028-01-28","enrollment":560,"officials":[],"conditions":["Glioblastoma","Recurrent Glioblastoma","GBM"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","Austria","Belgium","Belgium","Belgium","Denmark","Denmark","France","France","France","France","Germany","Germany","Germany","Germany","Germany","Germany","Italy","Italy","Italy","Italy","Italy","Italy","Netherlands","Netherlands","Spain","Spain","Spain","Spain","Spain","Sweden","Sweden","Switzerland","Switzerland"]},{"nctId":"NCT02208362","title":"Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma","sponsor":"City of Hope Medical Center","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Arm 1: IL13Ra2-specific CAR Tcm cells","Arm 2: IL13Ra2-specific CAR Tcm cells","Arm 3: IL13Ra2-specific CAR Tcm cells","Arm 4: IL13Ra2-specific CAR Tcm cells","Arm 5: IL13Ra2-specific CAR Tn/mem cells"],"startDate":"2015-06-03","firstPosted":"2014-08-05","lastUpdated":"2026-11-04","primaryCompletion":"2021-02-08","resultsFirstPosted":"2024-10-30","enrollment":65,"officials":[{"name":"Behnam Badie","role":"PRINCIPAL_INVESTIGATOR","affiliation":"City of Hope Medical Center"}],"conditions":["Recurrent Glioblastoma","Recurrent Malignant Glioma","Recurrent WHO Grade II Glioma","Recurrent WHO Grade III Glioma","Refractory Glioblastoma","Refractory Malignant Glioma","Refractory WHO Grade II Glioma","Refractory WHO Grade III Glioma"],"siteCountries":["United States"]},{"nctId":"NCT05664243","title":"A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma","sponsor":"In8bio Inc.","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Autologous genetically modified gamma-delta T cells","Allogeneic genetically modified gamma-delta T cells"],"startDate":"2023-09-08","firstPosted":"2022-12-23","lastUpdated":"2026-11-04","primaryCompletion":"2026-12","enrollment":4,"officials":[{"name":"Louis B Nabors, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of Alabama at Birmingham"}],"conditions":["Glioblastoma"],"siteCountries":["United States","United States","United States","United States","United States"]},{"nctId":"NCT04765098","title":"Tamoxifen Versus Etoposide After First Recurrence in GBM Patients","sponsor":"AHS Cancer Control Alberta","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":["Tamoxifen","Etoposide"],"startDate":"2022-01-28","firstPosted":"2021-02-21","lastUpdated":"2026-11-04","primaryCompletion":"2026-12","enrollment":60,"officials":[],"conditions":["Glioblastoma Multiforme"],"siteCountries":["Canada"]},{"nctId":"NCT00788125","title":"Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors","sponsor":"City of Hope Medical Center","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"TERMINATED","interventions":["carboplatin","dasatinib","etoposide phosphate","ifosfamide","microarray analysis","western blotting"],"startDate":"2008-09-10","firstPosted":"2008-11-10","lastUpdated":"2026-11-04","primaryCompletion":"2010-04-30","resultsFirstPosted":"2022-04-27","whyStopped":"Terminated early due a shift in resources after lackluster performance of the drug.","enrollment":7,"officials":[{"name":"Judith K. Sato, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"City of Hope Medical Center"}],"conditions":["Brain and Central Nervous System Tumors","Childhood Germ Cell Tumor","Extragonadal Germ Cell Tumor","Kidney Cancer","Liver Cancer","Lymphoma","Neuroblastoma","Ovarian Cancer","Sarcoma","Testicular Germ Cell Tumor","Unspecified Childhood Solid Tumor, Protocol Specific"],"siteCountries":["United States"]},{"nctId":"NCT02062827","title":"Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma","acronym":"M032-HSV-1","sponsor":"University of Alabama at Birmingham","sponsorClass":"OTHER","phases":["PHASE1"],"status":"COMPLETED","interventions":["M032 (NSC 733972)"],"startDate":"2013-11-25","firstPosted":"2014-02-14","lastUpdated":"2026-11-04","primaryCompletion":"2022-09","resultsFirstPosted":"2024-02-02","enrollment":29,"officials":[{"name":"James M. Markert, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of Alabama at Birmingham"}],"conditions":["Recurrent Glioblastoma Multiforme","Progressive Glioblastoma Multiforme","Anaplastic Astrocytoma or Gliosarcoma"],"siteCountries":["United States"]},{"nctId":"NCT05139056","title":"Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas","sponsor":"City of Hope Medical Center","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":["Neural Stem Cells-expressing CRAd-S-pk7"],"startDate":"2023-05-02","firstPosted":"2021-12-01","lastUpdated":"2026-11-04","primaryCompletion":"2028-02-07","enrollment":36,"officials":[{"name":"Jana L Portnow, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"City of Hope Medical Center"}],"conditions":["Currently Only Enrolling Glioblastoma Patients at First Recurrence"],"siteCountries":["United States","United States","United States","United States"]},{"nctId":"NCT06095375","title":"Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients","acronym":"REGOMA-2","sponsor":"Istituto Oncologico Veneto IRCCS","sponsorClass":"OTHER","phases":["PHASE1"],"status":"COMPLETED","interventions":["Regorafenib","Temozolomide"],"startDate":"2022-07-04","firstPosted":"2023-10-23","lastUpdated":"2026-11-04","primaryCompletion":"2024-10-09","enrollment":21,"officials":[],"conditions":["Glioblastoma, IDH-wildtype","MGMT-Methylated Glioblastoma"],"siteCountries":["Italy","Italy"]},{"nctId":"NCT07464925","title":"A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma","sponsor":"Tetragon Biosciences Ltd","sponsorClass":"INDUSTRY","phases":["PHASE1"],"status":"RECRUITING","interventions":["GLIX1"],"startDate":"2026-04-20","firstPosted":"2026-03-11","lastUpdated":"2026-11-04","primaryCompletion":"2027-06","enrollment":30,"officials":[],"conditions":["Glioblastoma Multiforme of Brain","Glioma","Glioblastoma"],"siteCountries":["United States","United States","United States","United States"]},{"nctId":"NCT06325683","title":"Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma","sponsor":"National Cancer Institute (NCI)","sponsorClass":"OTHER","phases":["PHASE2"],"status":"SUSPENDED","interventions":["Lomustine","Nivolumab","Relatlimab"],"startDate":"2024-11-08","firstPosted":"2024-03-22","lastUpdated":"2026-11-03","primaryCompletion":"2029-07-15","whyStopped":"Scheduled Interim Monitoring","enrollment":184,"officials":[{"name":"Michael Lim","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Alliance for Clinical Trials in Oncology"}],"conditions":["Progressive Glioblastoma","Recurrent Glioblastoma"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT04765514","title":"Chemoradiotherapy Versus Chemotherapy for Elderly and Frail GBM Patients","sponsor":"AHS Cancer Control Alberta","sponsorClass":"OTHER","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Chemo-Radiotherapy with concurrent temozolomide."],"startDate":"2022-07-27","firstPosted":"2021-02-21","lastUpdated":"2026-11-03","primaryCompletion":"2032-06","enrollment":107,"officials":[],"conditions":["Glioblastoma Multiforme"],"siteCountries":["Canada","Canada"]},{"nctId":"NCT03919071","title":"Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma","sponsor":"National Cancer Institute (NCI)","sponsorClass":"OTHER","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Dabrafenib Mesylate","Trametinib Dimethyl Sulfoxide"],"startDate":"2020-02-20","firstPosted":"2019-04-18","lastUpdated":"2026-11-03","primaryCompletion":"2027-09-30","enrollment":58,"officials":[{"name":"Rishi R Lulla","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Children's Oncology Group"}],"conditions":["Anaplastic Astrocytoma","Anaplastic Astrocytoma, Not Otherwise Specified","Anaplastic Ganglioglioma","Anaplastic Pleomorphic Xanthoastrocytoma","Glioblastoma","Malignant Glioma","WHO Grade 3 Glioma","WHO Grade 4 Glioma"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","Puerto Rico"]},{"nctId":"NCT02015819","title":"Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas","sponsor":"City of Hope Medical Center","sponsorClass":"OTHER","phases":["PHASE1"],"status":"COMPLETED","interventions":["E. coli CD-expressing genetically modified neural stem cells","flucytosine","leucovorin calcium"],"startDate":"2014-10-28","firstPosted":"2013-12-19","lastUpdated":"2026-11-03","primaryCompletion":"2017-10-07","resultsFirstPosted":"2021-09-29","enrollment":16,"officials":[{"name":"Jana Portnow","role":"PRINCIPAL_INVESTIGATOR","affiliation":"City of Hope Medical Center"}],"conditions":["Adult Anaplastic Astrocytoma","Adult Anaplastic Oligodendroglioma","Adult Giant Cell Glioblastoma","Adult Glioblastoma","Adult Gliosarcoma","Recurrent Adult Brain Tumor","Anaplastic Oligoastrocytoma"],"siteCountries":["United States"]},{"nctId":"NCT04049669","title":"Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG","sponsor":"Theodore S. Johnson","sponsorClass":"OTHER","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Indoximod","Temozolomide","Cyclophosphamide","Etoposide","Lomustine"],"startDate":"2019-10-02","firstPosted":"2019-08-08","lastUpdated":"2026-11-02","primaryCompletion":"2026-09-21","enrollment":130,"officials":[{"name":"Theodore S Johnson, MD, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Augusta University"}],"conditions":["Glioblastoma","Medulloblastoma","Ependymoma","Diffuse Intrinsic Pontine Glioma"],"siteCountries":["United States","United States","United States","United States","United States"]},{"nctId":"NCT07326566","title":"Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII","sponsor":"Black Diamond Therapeutics, Inc.","sponsorClass":"INDUSTRY","phases":["PHASE2"],"status":"RECRUITING","interventions":["silevertinib in combination with temozolomide","temozolomide (TMZ)"],"startDate":"2026-05-05","firstPosted":"2026-01-08","lastUpdated":"2026-11-02","primaryCompletion":"2028-11","enrollment":162,"officials":[],"conditions":["Glioblastoma (GBM)","Newly Diagnosed Glioblastoma","GBM","Glioblastoma Multiforme (GBM)","Glioma","Central Nervous System Diseases","Brain Cancer"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT07180927","title":"DLL3 CAR-T Therapy Targeting Brain Tumors","sponsor":"Shenzhen Geno-Immune Medical Institute","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","interventions":["4SCAR DLL3 T cells"],"startDate":"2027-06-01","firstPosted":"2025-09-18","lastUpdated":"2026-11-02","primaryCompletion":"2028-05-31","enrollment":30,"officials":[],"conditions":["Glioblastoma of Cerebellum"],"siteCountries":["China"]},{"nctId":"NCT05106296","title":"Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer","sponsor":"Theodore S. Johnson","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":["Indoximod","Ibrutinib","Cyclophosphamide","Etoposide","Ibrutinib","Temozolomide"],"startDate":"2022-02-08","firstPosted":"2021-11-03","lastUpdated":"2026-11-02","primaryCompletion":"2028-03-30","enrollment":37,"officials":[{"name":"Theodore S. Johnson, MD, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Augusta University"}],"conditions":["Ependymoma","Medulloblastoma","Glioblastoma","Primary Brain Tumor"],"siteCountries":["United States"]},{"nctId":"NCT07909811","title":"Novel endOvascular Therapy With beVAcizumab and Cannabinoids for Glioblastoma","sponsor":"Unity Health Toronto","sponsorClass":"OTHER","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","interventions":["Bevacizumab"],"startDate":"2026-12-01","firstPosted":"2026-11-02","lastUpdated":"2026-11-02","primaryCompletion":"2027-12-01","enrollment":6,"officials":[],"conditions":["GBM"]},{"nctId":"NCT03970447","title":"A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma","acronym":"GBM AGILE","sponsor":"Global Coalition for Adaptive Research","sponsorClass":"OTHER","phases":["PHASE2","PHASE3"],"status":"RECRUITING","interventions":["Temozolomide","Lomustine","Regorafenib","Paxalisib","VAL-083","VT1021","Troriluzole","ADI-PEG 20","AZD1390","Tinostamustine"],"startDate":"2019-07-30","firstPosted":"2019-05-31","lastUpdated":"2026-11-02","primaryCompletion":"2028-06","enrollment":2250,"officials":[{"name":"Tim Cloughesy, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"GCAR CMO and GBM AGILE Global PI"}],"conditions":["Glioblastoma"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","Australia","Australia","Australia","Australia","Australia","Australia","Canada","Canada","Canada","Canada","France","France","France","Germany","Germany","Germany","Germany","Germany","Germany","Switzerland","Switzerland"]},{"nctId":"NCT02137759","title":"MRSI to Predict Response to RT/TMZ ± Belinostat in GBM","sponsor":"Emory University","sponsorClass":"OTHER","phases":["PHASE2"],"status":"COMPLETED","interventions":["Standard Temozolomide","Belinostat"],"startDate":"2014-05-07","firstPosted":"2014-05-14","lastUpdated":"2026-10-30","primaryCompletion":"2019-03-25","resultsFirstPosted":"2026-10-30","enrollment":29,"officials":[{"name":"Hui-Kuo Shu, MD, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Emory University"}],"conditions":["Glioblastoma Multiforme of Brain"],"siteCountries":["United States","United States"]},{"nctId":"NCT05303467","title":"A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM","acronym":"FRONTIER","sponsor":"Boston Scientific Corporation","sponsorClass":"INDUSTRY","phases":["PHASE1"],"status":"RECRUITING","interventions":[],"startDate":"2022-07-30","firstPosted":"2022-03-31","lastUpdated":"2026-10-30","primaryCompletion":"2027-01-31","enrollment":36,"officials":[{"name":"Riad Salem, M.D.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Northwestern University"},{"name":"Roger Stupp, M.D.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Northwestern University"}],"conditions":["Glioblastoma Multiforme","Recurrent Glioblastoma"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT03914768","title":"Immune Modulatory DC Vaccine Against Brain Tumor","sponsor":"Shenzhen Geno-Immune Medical Institute","sponsorClass":"OTHER","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","interventions":["Immunomodulatory DC vaccine to target DIPG and GBM"],"startDate":"2026-12-31","firstPosted":"2019-04-16","lastUpdated":"2026-10-30","primaryCompletion":"2029-05-31","enrollment":10,"officials":[{"name":"Lung-Ji Chang, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Shenzhen Geno-Immune Medical Institute"}],"conditions":["Diffuse Intrinsic Pontine Glioma or Glioblastoma"],"siteCountries":["China"]},{"nctId":"NCT07301268","title":"GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma","sponsor":"Mayo Clinic","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":["Bispecific CD80-lgG4Fc-IL-2v Fusion Protein GI-102","Pembrolizumab"],"startDate":"2026-08-03","firstPosted":"2025-12-24","lastUpdated":"2026-10-30","primaryCompletion":"2029-09-01","enrollment":36,"officials":[{"name":"Jian L Campian, MD, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Mayo Clinic"}],"conditions":["Glioblastoma, IDH-Wildtype","Progressive Astrocytoma, IDH-Mutant, Grade 4","Progressive Glioblastoma","Progressive Gliosarcoma","Recurrent Astrocytoma, IDH-Mutant, Grade 4","Recurrent Glioblastoma, IDH-Wildtype","Recurrent Gliosarcoma","Resectable Astrocytoma","Resectable Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT06946680","title":"IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Newly Diagnosed and Recurrent Pediatric High-grade Glioma (pHGG) and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (ndDIPG)","acronym":"Peds IMPACT","sponsor":"University of Florida","sponsorClass":"OTHER","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","interventions":["Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells"],"startDate":"2027-01","firstPosted":"2025-04-27","lastUpdated":"2026-10-30","primaryCompletion":"2030-12","enrollment":24,"officials":[{"name":"John Ligon, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of Florida"}],"conditions":["High-grade Glioma","Diffuse Intrinsic Pontine Glioma"],"siteCountries":["United States"]},{"nctId":"NCT04573140","title":"A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)","acronym":"PNOC020","sponsor":"University of Florida","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":["Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)"],"startDate":"2021-12-13","firstPosted":"2020-10-05","lastUpdated":"2026-10-30","primaryCompletion":"2027-07-01","enrollment":28,"officials":[{"name":"Elias Sayour, MD, PhD","role":"STUDY_CHAIR","affiliation":"University of Florida"}],"conditions":["Adult Glioblastoma","High Grade Glioma","WHO Grade III or IV Malignant Glioma"],"siteCountries":["United States","United States"]},{"nctId":"NCT03170141","title":"Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme","sponsor":"Shenzhen Geno-Immune Medical Institute","sponsorClass":"OTHER","phases":["PHASE1"],"status":"TERMINATED","interventions":["Antigen-specific IgT cells"],"startDate":"2017-05-31","firstPosted":"2017-05-30","lastUpdated":"2026-10-30","primaryCompletion":"2026-07-01","enrollment":30,"officials":[{"name":"Lung-Ji Chang, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Shenzhen Geno-Immune Medical Institute"}],"conditions":["Glioblastoma Multiforme of Brain","Brain Cancer"],"siteCountries":["China"]},{"nctId":"NCT07093814","title":"A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma","sponsor":"Guangzhou Virotech Pharmaceutical Co., Ltd.","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["VRT106"],"startDate":"2025-09-02","firstPosted":"2025-07-30","lastUpdated":"2026-10-29","primaryCompletion":"2028-12-31","enrollment":42,"officials":[{"name":"Chengcheng Guo","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Sun Yat-Sen University Cancer Center"}],"conditions":["Glioblastoma"],"siteCountries":["China","China","China","China","China","China","China","China","China","China","China"]},{"nctId":"NCT07902037","title":"A Study of SRN-101 Gene Therapy in Adults With Recurrent High-Grade Glioma (ALERT-1)","acronym":"ALERT-1","sponsor":"Siren Biotechnology","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","interventions":["SRN-101"],"startDate":"2026-12","firstPosted":"2026-10-28","lastUpdated":"2026-10-28","primaryCompletion":"2030-01","enrollment":40,"officials":[],"conditions":["Recurrent High Grade Gliomas","Glioblastoma (GBM)","Astrocytoma","Oligodendroglioma","Diffuse Hemispheric Glioma"]},{"nctId":"NCT07739017","title":"OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma","acronym":"OPAL","sponsor":"Olivia Newton-John Cancer Research Institute","sponsorClass":"OTHER","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","interventions":["CT-179"],"startDate":"2026-12","firstPosted":"2026-07-31","lastUpdated":"2026-10-28","primaryCompletion":"2028-06","enrollment":54,"officials":[],"conditions":["Recurrent Glioblastoma","Newly Diagnosed MGMT Unmethylated Glioblastoma"],"siteCountries":["Australia","Australia","Australia","Australia","Australia","Australia"]},{"nctId":"NCT06914128","title":"A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors","sponsor":"Bayer","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["BAY 3713372"],"startDate":"2025-03-21","firstPosted":"2025-04-06","lastUpdated":"2026-10-28","primaryCompletion":"2029-06-18","enrollment":450,"officials":[],"conditions":["MTAP-deleted Solid Tumors"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","Australia","Australia","Australia","Australia","Belgium","Belgium","Belgium","Belgium","China","China","China","China","China","Czechia","Czechia","Denmark","Denmark","Italy","Italy","Italy","Italy","Italy","Japan","Japan","Japan","Japan","Japan","Japan","Netherlands","Netherlands","Netherlands","Singapore","Singapore","Singapore","Spain","Spain","Spain","Spain","Spain","Spain","Spain","Spain","Sweden","Sweden","United Kingdom","United Kingdom"]},{"nctId":"NCT05765812","title":"A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma","sponsor":"Debiopharm International SA","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["Zedoresertib","Temozolomide"],"startDate":"2023-05-15","firstPosted":"2023-03-13","lastUpdated":"2026-10-28","primaryCompletion":"2028-09","enrollment":116,"officials":[{"name":"Study Director","role":"STUDY_DIRECTOR","affiliation":"Debiopharm International SA"}],"conditions":["Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype","Astrocytoma, Grade III"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","Spain","Spain","Spain","Spain","Spain","Spain","Spain","Switzerland"]},{"nctId":"NCT04590664","title":"Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma","sponsor":"Emory University","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"TERMINATED","interventions":["Verteporfin"],"startDate":"2021-01-15","firstPosted":"2020-10-19","lastUpdated":"2026-10-28","primaryCompletion":"2025-02-13","resultsFirstPosted":"2026-10-28","whyStopped":"PI Decision","enrollment":9,"officials":[{"name":"William L Read, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Emory University"}],"conditions":["Glioblastoma","Recurrent Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT07297212","title":"A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma","sponsor":"BioNTech SE","sponsorClass":"INDUSTRY","phases":["PHASE2"],"status":"RECRUITING","interventions":["Pumitamig","Bevacizumab","Temozolomide"],"startDate":"2026-01-15","firstPosted":"2025-12-22","lastUpdated":"2026-10-28","primaryCompletion":"2028-01","enrollment":75,"officials":[{"name":"BioNTech Responsible Person","role":"STUDY_DIRECTOR","affiliation":"BioNTech SE"}],"conditions":["Recurrent Glioblastoma"],"siteCountries":["China","China","China","China","China","China"]},{"nctId":"NCT06896110","title":"Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma","sponsor":"Andrew P. Groves","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ENROLLING_BY_INVITATION","interventions":["Nivolumab","Azacitidine (AZA)"],"startDate":"2025-06-05","firstPosted":"2025-03-26","lastUpdated":"2026-10-27","primaryCompletion":"2028-03","enrollment":34,"officials":[],"conditions":["Glioblastoma (GBM)","Diffuse Midline Glioma (DMG)","Astrocytoma, IDH-Mutant, Grade 4","Diffuse Hemispheric Glioma, H3 G34-Mutant","Gliosarcoma of Brain"],"siteCountries":["United States"]},{"nctId":"NCT04019002","title":"Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma","sponsor":"Susan Chang","sponsorClass":"OTHER","phases":["PHASE1"],"status":"TERMINATED","interventions":["Hyperpolarized Pyruvate (13C)"],"startDate":"2019-11-19","firstPosted":"2019-07-15","lastUpdated":"2026-10-27","primaryCompletion":"2025-09-30","resultsFirstPosted":"2026-10-27","whyStopped":"Slow Accrual","enrollment":17,"officials":[{"name":"Susan Chang, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of California, San Francisco"}],"conditions":["Glioblastoma","Recurrent Glioblastoma","Glioblastoma Multiforme"],"siteCountries":["United States"]},{"nctId":"NCT02152982","title":"Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","sponsor":"National Cancer Institute (NCI)","sponsorClass":"OTHER","phases":["PHASE2","PHASE3"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Temozolomide","Veliparib"],"startDate":"2014-12-15","firstPosted":"2014-06-02","lastUpdated":"2026-10-27","primaryCompletion":"2021-12-01","resultsFirstPosted":"2023-04-04","enrollment":447,"officials":[{"name":"Jann N Sarkaria","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Alliance for Clinical Trials in Oncology"}],"conditions":["Glioblastoma","Gliosarcoma"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","Puerto Rico"]},{"nctId":"NCT04216329","title":"Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma","sponsor":"National Cancer Institute (NCI)","sponsorClass":"OTHER","phases":["PHASE1"],"status":"COMPLETED","interventions":["Selinexor","Temozolomide"],"startDate":"2020-07-07","firstPosted":"2020-01-02","lastUpdated":"2026-10-27","primaryCompletion":"2023-09-29","resultsFirstPosted":"2024-10-15","enrollment":11,"officials":[{"name":"Kevin A Camphausen, M.D.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"National Cancer Institute (NCI)"}],"conditions":["Gliosarcoma","Newly Diagnosed","Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT07708961","title":"Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma","sponsor":"Mayo Clinic","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":["EGFR/EGFRvIII Inhibitor WSD0922-FU","Temozolomide"],"startDate":"2026-08-28","firstPosted":"2026-07-16","lastUpdated":"2026-10-26","primaryCompletion":"2036-08-31","enrollment":60,"officials":[{"name":"Sani H. Kizilbash, MD, MPH","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Mayo Clinic in Rochester"}],"conditions":["Glioblastoma, IDH-Wildtype"],"siteCountries":["United States","United States","United States"]},{"nctId":"NCT02974738","title":"A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)","sponsor":"Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","sponsorClass":"INDUSTRY","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Belzutifan"],"startDate":"2016-12-07","firstPosted":"2016-11-28","lastUpdated":"2026-10-26","primaryCompletion":"2018-01-12","enrollment":120,"officials":[{"name":"Medical Director","role":"STUDY_DIRECTOR","affiliation":"Merck Sharp & Dohme LLC"}],"conditions":["Advanced Solid Tumors","Solid Tumor","Solid Carcinoma","Solid Tumor, Adult","ccRCC","RCC, Clear Cell Adenocarcinoma","RCC","Kidney Cancer","Clear Cell Renal Cell Carcinoma","Renal Cell Carcinoma, Metastatic","Renal Cell Carcinoma Recurrent","Renal Cell Carcinoma, Clear Cell Adenocarcinoma","Glioblastoma","Glioblastoma, Adult","GBM","Glioblastoma Multiforme"]},{"nctId":"NCT04528680","title":"Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma","acronym":"SC9/ABX","sponsor":"Northwestern University","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Chemotherapy, albumin-bound paclitaxel","Chemotherapy, carboplatin"],"startDate":"2020-10-29","firstPosted":"2020-08-27","lastUpdated":"2026-10-26","primaryCompletion":"2027-12-31","enrollment":57,"officials":[{"name":"Roger Stupp, MD","role":"STUDY_CHAIR","affiliation":"Northwestern University"},{"name":"Adam M Sonabend, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Northwestern University"}],"conditions":["Glioblastoma","Gliosarcoma","GBM","Glioblastoma Multiforme","Glioblastoma, IDH-wildtype","Recurrent Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT04145115","title":"A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden","sponsor":"National Cancer Institute (NCI)","sponsorClass":"OTHER","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Ipilimumab","Nivolumab"],"startDate":"2020-12-24","firstPosted":"2019-10-30","lastUpdated":"2026-10-26","primaryCompletion":"2027-06-30","enrollment":37,"officials":[{"name":"Gavin P Dunn","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Alliance for Clinical Trials in Oncology"}],"conditions":["Astrocytoma, IDH-Mutant, Grade 4","Diffuse Glioma","Glioblastoma, IDH-Wildtype","Secondary Glioblastoma"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","Puerto Rico"]},{"nctId":"NCT05241392","title":"Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma","sponsor":"Beijing Tiantan Hospital","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["B7-H3-targeting CAR-T cells/TX103-CAR-T Cell Injection"],"startDate":"2022-01-27","firstPosted":"2022-02-15","lastUpdated":"2026-10-26","primaryCompletion":"2024-11-30","enrollment":30,"officials":[{"name":"Nan Ji, Dr.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Beijing Tiantan Hospital"}],"conditions":["Glioblastoma"],"siteCountries":["China"]},{"nctId":"NCT04015700","title":"Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma","sponsor":"Washington University School of Medicine","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Personalized neoantigen DNA vaccine supplied by Geneos Therapeutics","Plasmid encoded IL-12"],"startDate":"2020-07-14","firstPosted":"2019-07-11","lastUpdated":"2026-10-23","primaryCompletion":"2022-05-13","resultsFirstPosted":"2026-05-07","enrollment":9,"officials":[{"name":"Tanner M Johanns, M.D., Ph.D.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Washington University School of Medicine"}],"conditions":["Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT07544992","title":"Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas","sponsor":"City of Hope Medical Center","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":["Autologous Anti-EGFR/Anti-IL13Ralpha2 CAR T-cells"],"startDate":"2026-05-26","firstPosted":"2026-04-22","lastUpdated":"2026-10-23","primaryCompletion":"2031-11-04","enrollment":24,"officials":[{"name":"Behnam Badie","role":"PRINCIPAL_INVESTIGATOR","affiliation":"City of Hope Medical Center"}],"conditions":["Recurrent Astrocytoma, IDH-Mutant, Grade 4","Recurrent Glioblastoma, IDH-Wildtype"],"siteCountries":["United States"]},{"nctId":"NCT07346144","title":"Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma","acronym":"ADePT","sponsor":"Trogenix ltd","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["TGX-007","Valaciclovir"],"startDate":"2026-04-21","firstPosted":"2026-01-16","lastUpdated":"2026-10-23","primaryCompletion":"2030-03","enrollment":68,"officials":[],"conditions":["Glioblastoma (GBM)","High Grade Gliomas","Recurrent Glioblastoma","Newly Diagnosed Glioblastoma"],"siteCountries":["United States","United Kingdom"]},{"nctId":"NCT04214392","title":"Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma","sponsor":"City of Hope Medical Center","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery)","Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery)"],"startDate":"2020-05-26","firstPosted":"2020-01-02","lastUpdated":"2026-10-22","primaryCompletion":"2027-05-11","enrollment":19,"officials":[{"name":"Behnam Badie","role":"PRINCIPAL_INVESTIGATOR","affiliation":"City of Hope Medical Center"}],"conditions":["Recurrent Glioblastoma","Recurrent Malignant Glioma","Recurrent WHO Grade II Glioma","Recurrent WHO Grade III Glioma"],"siteCountries":["United States"]},{"nctId":"NCT07888647","title":"IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas","acronym":"STAR-VACC","sponsor":"German Cancer Research Center","sponsorClass":"OTHER","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","interventions":["IDH1-vac","IS-vac","Temozolomide (TMZ)","Imiquimod 5 % Cream"],"startDate":"2027-02-01","firstPosted":"2026-10-22","lastUpdated":"2026-10-22","primaryCompletion":"2034-02-01","enrollment":216,"officials":[{"name":"Michael Platten, Prof. Dr. med.","role":"STUDY_DIRECTOR","affiliation":"Department of Neurology | Universitätsmedizin Mannheim Medizinische Fakultät Mannheim der Universität Heidelberg"}],"conditions":["Astrocytoma, IDH-Mutant, Grade 3","Astrocytoma, IDH-Mutant, Grade 4"],"siteCountries":["Germany","Germany","Germany","Germany","Germany","Germany","Germany","Germany","Germany","Germany","Germany","Germany","Germany"]},{"nctId":"NCT04881032","title":"AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma","acronym":"NANO-GBM","sponsor":"Centre Jean Perrin","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Polysiloxane Gd-Chelates based nanoparticles (AGuIX)","Temozolomide"],"startDate":"2022-03-07","firstPosted":"2021-05-11","lastUpdated":"2026-10-22","primaryCompletion":"2026-11","enrollment":66,"officials":[{"name":"Juliette Moreau, Md","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Centre Jean Perrin"}],"conditions":["Glioblastoma"],"siteCountries":["France","France","France","France","France","France","France","France","France"]},{"nctId":"NCT02455557","title":"SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma","sponsor":"Roswell Park Cancer Institute","sponsorClass":"OTHER","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Montanide ISA 51 VG","Sargramostim","SVN53-67/M57-KLH Peptide Vaccine","Temozolomide"],"startDate":"2015-05-04","firstPosted":"2015-05-28","lastUpdated":"2026-10-22","primaryCompletion":"2019-10-23","resultsFirstPosted":"2021-02-01","enrollment":66,"officials":[{"name":"Robert Fenstermaker","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Roswell Park Cancer Institute"}],"conditions":["Glioblastoma","Gliosarcoma"],"siteCountries":["United States","United States","United States","United States","United States"]},{"nctId":"NCT06815029","title":"Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma","sponsor":"City of Hope Medical Center","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":["Chimeric Antigen Receptor T-Cell Therapy"],"startDate":"2025-06-17","firstPosted":"2025-02-07","lastUpdated":"2026-10-22","primaryCompletion":"2030-10-11","enrollment":27,"officials":[{"name":"Behnam Badie","role":"PRINCIPAL_INVESTIGATOR","affiliation":"City of Hope Medical Center"}],"conditions":["Recurrent Astrocytoma, IDH-Mutant, Grade 3","Recurrent Astrocytoma, IDH-Mutant, Grade 4","Recurrent Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT03491683","title":"INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)","sponsor":"Inovio Pharmaceuticals","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["INO-5401","INO-9012","Cemiplimab","Temozolomide"],"startDate":"2018-05-31","firstPosted":"2018-04-09","lastUpdated":"2026-10-22","primaryCompletion":"2027-12-31","enrollment":52,"officials":[{"name":"Jeffrey Skolnik, MD","role":"STUDY_DIRECTOR","affiliation":"Inovio Pharmaceuticals"}],"conditions":["Glioblastoma"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT05460507","title":"Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment","sponsor":"Cerenome","sponsorClass":"INDUSTRY","phases":["PHASE1"],"status":"RECRUITING","interventions":["Retreatment Rhenium Liposome"],"startDate":"2024-12-12","firstPosted":"2022-07-15","lastUpdated":"2026-10-21","primaryCompletion":"2028-03-01","enrollment":40,"officials":[{"name":"Andrew J Brenner, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"The Cancer Therapy and Research Center at UTHSCSA"}],"conditions":["Glioma"],"siteCountries":["United States"]},{"nctId":"NCT06810544","title":"Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss","sponsor":"Tango Therapeutics, Inc.","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["TNG456","abemaciclib"],"startDate":"2025-03-24","firstPosted":"2025-02-05","lastUpdated":"2026-10-21","primaryCompletion":"2027-03-31","enrollment":191,"officials":[{"name":"Adam Crystal, MD, PhD","role":"STUDY_DIRECTOR","affiliation":"Tango Therapeutics, Inc."}],"conditions":["Non Small Cell Lung Cancer","Glioma Glioblastoma Multiforme","Glioma, Malignant","Solid Tumor","Non-Small Cell Adenocarcinoma","Lung Cancer","Brain Tumor"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT07779798","title":"A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With Relapsed or Refractory Myeloid Malignancies, Advanced Solid Tumors, or Recurrent or Progressive Glioblastoma.","acronym":"TelOscope","sponsor":"Crossbow Therapeutics, Inc.","sponsorClass":"INDUSTRY","phases":["PHASE1"],"status":"RECRUITING","interventions":["CBX-663"],"startDate":"2026-08-04","firstPosted":"2026-08-21","lastUpdated":"2026-10-21","primaryCompletion":"2028-01","enrollment":120,"officials":[],"conditions":["Advanced Solid Tumors","Recurrent or Progressive Glioblastoma","Relapse or Refractory Myeloid Malignancies"],"siteCountries":["United States","United States","United States","United States"]},{"nctId":"NCT06455605","title":"D2C7-IT + 2141-V11 Combination Post-resection in rGBM","sponsor":"Darell Bigner","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":["D2C7-IT","2141 V11"],"startDate":"2025-03-17","firstPosted":"2024-06-12","lastUpdated":"2026-10-21","primaryCompletion":"2029-01-31","enrollment":46,"officials":[{"name":"Annick Desjardins, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Duke University"}],"conditions":["Recurrent Glioblastoma IDH Wildtype"],"siteCountries":["United States"]},{"nctId":"NCT06860594","title":"Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma","sponsor":"National Cancer Institute (NCI)","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":["Triapine"],"startDate":"2025-07-30","firstPosted":"2025-03-06","lastUpdated":"2026-10-21","primaryCompletion":"2027-06-30","enrollment":30,"officials":[{"name":"Stephanie M Yoon","role":"PRINCIPAL_INVESTIGATOR","affiliation":"City of Hope Comprehensive Cancer Center LAO"}],"conditions":["Astrocytoma, IDH-Mutant, Grade 2","Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant","Recurrent Adult Diffuse Midline Glioma, H3 K27-Mutant","Recurrent Astrocytoma, IDH-Mutant","Recurrent Astrocytoma, IDH-Mutant, Grade 3","Recurrent Astrocytoma, IDH-Mutant, Grade 4","Recurrent Glioblastoma, IDH-Wildtype"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT02177578","title":"Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","sponsorClass":"OTHER","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Temozolomide"],"startDate":"2014-07-08","firstPosted":"2014-06-27","lastUpdated":"2026-10-20","primaryCompletion":"2027-04","enrollment":60,"officials":[{"name":"Kristin Redmond, M.D.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"The SKCCC at Johns Hopkins"}],"conditions":["Glioblastoma Multiforme"],"siteCountries":["United States","United States","United States"]},{"nctId":"NCT03718767","title":"Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype","sponsor":"National Cancer Institute (NCI)","sponsorClass":"OTHER","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Nivolumab"],"startDate":"2019-03-27","firstPosted":"2018-10-24","lastUpdated":"2026-10-20","primaryCompletion":"2024-11-05","resultsFirstPosted":"2025-11-24","enrollment":62,"officials":[{"name":"Jing Wu, M.D.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"National Cancer Institute (NCI)"}],"conditions":["Glioma","Glioblastoma","High Grade Glioma","Low Grade Glioma","Malignant Glioma"],"siteCountries":["United States"]},{"nctId":"NCT07620548","title":"Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas","sponsor":"Washington University School of Medicine","sponsorClass":"OTHER","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","interventions":["Cemiplimab","Chemotherapy"],"startDate":"2026-11-30","firstPosted":"2026-06-02","lastUpdated":"2026-10-20","primaryCompletion":"2031-05-31","enrollment":99,"officials":[{"name":"Omar H Butt, M.D., Ph.D.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Washington University School of Medicine"}],"conditions":["Glioblastoma","Glioblastoma, IDH-wildtype","Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype"],"siteCountries":["United States","United States"]},{"nctId":"NCT05635734","title":"Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma","sponsor":"Cantex Pharmaceuticals","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"COMPLETED","interventions":["Azeliragon 5 mg","Azeliragon 10 mg","Azeliragon 20 mg"],"startDate":"2023-09-05","firstPosted":"2022-12-02","lastUpdated":"2026-10-19","primaryCompletion":"2026-04-30","enrollment":33,"officials":[{"name":"Juan Sepúlveda","role":"STUDY_CHAIR","affiliation":"Hospital Universitario 12 de Octubre"}],"conditions":["Glioblastoma"],"siteCountries":["Spain","Spain","Spain","Spain"]},{"nctId":"NCT04606316","title":"Surgical Nivolumab And Ipilimumab For Recurrent GBM","sponsor":"Gilbert Youssef","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Nivolumab-Placebo","Nivolumab","Ipilimumab-Placebo","Ipilimumab"],"startDate":"2021-02-01","firstPosted":"2020-10-28","lastUpdated":"2026-10-19","primaryCompletion":"2026-12-30","enrollment":63,"officials":[{"name":"Gilbert Youssef, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Dana-Farber Cancer Institute"}],"conditions":["Glioblastoma","GBM","Glioblastoma Multiforme","Grade IV Astrocytoma"],"siteCountries":["United States","United States","United States"]},{"nctId":"NCT01082926","title":"Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2","sponsor":"City of Hope Medical Center","sponsorClass":"OTHER","phases":["PHASE1"],"status":"COMPLETED","interventions":["therapeutic allogeneic lymphocytes","aldesleukin"],"startDate":"2011-03-22","firstPosted":"2010-03-09","lastUpdated":"2026-10-19","primaryCompletion":"2013-09-23","enrollment":6,"officials":[{"name":"Behnam Badie","role":"PRINCIPAL_INVESTIGATOR","affiliation":"City of Hope Medical Center"}],"conditions":["Anaplastic Astrocytoma","Anaplastic Ependymoma","Anaplastic Meningioma","Anaplastic Oligodendroglioma","Brain Stem Glioma","Ependymoblastoma","Giant Cell Glioblastoma","Glioblastoma","Gliosarcoma","Grade III Meningioma","Meningeal Hemangiopericytoma","Mixed Glioma","Pineal Gland Astrocytoma","Brain Tumor"],"siteCountries":["United States"]},{"nctId":"NCT05303519","title":"SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)","acronym":"SIGMA","sponsor":"Nuvation Bio Inc.","sponsorClass":"INDUSTRY","phases":["PHASE3"],"status":"RECRUITING","interventions":["safusidenib","Placebo"],"startDate":"2023-06-05","firstPosted":"2022-03-31","lastUpdated":"2026-10-19","primaryCompletion":"2028-12-01","enrollment":365,"officials":[],"conditions":["Glioma","Astrocytoma, Grade IV","IDH1-mutant Glioma","Astrocytoma, IDH-Mutant, Grade 3","Astrocytoma, IDH-Mutant, Grade 4","Astrocytoma, IDH-Mutant, Grade 2","Oligodendroglioma","Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","Australia","Australia","Australia","Australia","Australia","Australia","China","China","China","China","China","China","China","China","China"]},{"nctId":"NCT05734560","title":"D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients","sponsor":"Darell Bigner","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["D2C7-IT","2141-V11"],"startDate":"2023-09-06","firstPosted":"2023-02-21","lastUpdated":"2026-10-16","primaryCompletion":"2026-10-31","enrollment":50,"officials":[{"name":"Daniel Landi, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Duke University"}],"conditions":["Newly Diagnosed MGMT Unmethylated Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT05629702","title":"ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids","acronym":"ARISTOCRAT","sponsor":"University of Birmingham","sponsorClass":"OTHER","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Nabiximols","Temozolomide","Nabiximols-matched placebo"],"startDate":"2023-02-03","firstPosted":"2022-11-29","lastUpdated":"2026-10-16","primaryCompletion":"2027-10-07","enrollment":122,"officials":[{"name":"Fiona Collinson, MBBS, BSc, MRCP, FRCR, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of Leeds"}],"conditions":["Glioblastoma","Brain Tumor","Cannabis","Brain Tumor, Recurrent"],"siteCountries":["United Kingdom","United Kingdom","United Kingdom","United Kingdom","United Kingdom","United Kingdom","United Kingdom","United Kingdom","United Kingdom","United Kingdom","United Kingdom","United Kingdom","United Kingdom","United Kingdom","United Kingdom","United Kingdom","United Kingdom"]},{"nctId":"NCT06344130","title":"Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma","sponsor":"National Cancer Institute (NCI)","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":[],"startDate":"2024-10-01","firstPosted":"2024-04-03","lastUpdated":"2026-10-16","primaryCompletion":"2027-12-31","enrollment":28,"officials":[{"name":"Peter GK Mathen, M.D.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"National Cancer Institute (NCI)"}],"conditions":["Astrocytoma","Glioma","Recurrent Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT04555577","title":"Phase I Trial of DNA-PK Inhibitor (PEPOSERTIB ) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated and Recurrent Glioblastoma","sponsor":"M.D. Anderson Cancer Center","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Peposertib","Temozolomide"],"startDate":"2020-09-20","firstPosted":"2020-09-18","lastUpdated":"2026-10-16","primaryCompletion":"2027-12-31","enrollment":29,"officials":[{"name":"Nazanin Majd, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"M.D. Anderson Cancer Center"}],"conditions":["Glioblastoma","Gliosarcoma"],"siteCountries":["United States"]},{"nctId":"NCT07416188","title":"Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["LMP744"],"startDate":"2026-07-15","firstPosted":"2026-02-18","lastUpdated":"2026-10-16","primaryCompletion":"2030-12-31","enrollment":40,"officials":[{"name":"Sadhana Jackson, M.D.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"National Institute of Neurological Disorders and Stroke (NINDS)"}],"conditions":["Recurrent Glioblastoma","Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype","Relapsed Cancer","Recurrent Tumor","Glioblastoma Multiforme","Recurring Glioblastoma","Brain and Central Nervous System Tumors","Glioma","Glioblastomas","Grade IV Astrocytoma","GBM","Recurrent Glioma (Glioblastoma Multiforme)","High Grade Glioma","Glioma, Malignant","Brain Cancer"],"siteCountries":["United States"]},{"nctId":"NCT03423628","title":"A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer","sponsor":"AstraZeneca","sponsorClass":"INDUSTRY","phases":["PHASE1"],"status":"COMPLETED","interventions":["AZD1390","AZD1390","AZD1390"],"startDate":"2018-04-02","firstPosted":"2018-02-06","lastUpdated":"2026-10-15","primaryCompletion":"2026-08-31","enrollment":159,"officials":[{"name":"Patrick Wen","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Dana-Farber Cancer Institute"},{"name":"Brandon Imber","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Memorial Sloan Kettering Cancer Center"},{"name":"Mariza Daras","role":"PRINCIPAL_INVESTIGATOR","affiliation":"VCU Massey Cancer Center"},{"name":"Jan Drappatz","role":"PRINCIPAL_INVESTIGATOR","affiliation":"UPMC Hospital Radiation Oncology"},{"name":"Deborah Forst","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Massachusetts General Hospital"},{"name":"Anthony Chalmers","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Beatson West of Scotland Cancer Centre"},{"name":"Rajesh Jena","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Cambridge University Hospitals NHS Foundation Trust"},{"name":"Louise Murray","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of Leeds"},{"name":"Yoshitaka Narita","role":"PRINCIPAL_INVESTIGATOR","affiliation":"National Cancer Center Hospital"},{"name":"Yoshiki Arakawa","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Kyoto University Hospital"},{"name":"Kazuhiko Mishima","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Saitama Medical University International Medical Center"}],"conditions":["Recurrent Glioblastoma Multiforme","Primary Glioblastoma Multiforme","Brain Neoplasms, Malignant","Leptomeningeal Disease (LMD)"],"siteCountries":["United States","United States","United States","United States","United States","Japan","Japan","Japan","United Kingdom","United Kingdom","United Kingdom"]},{"nctId":"NCT04160494","title":"D2C7-IT With Atezolizumab for Recurrent Gliomas","sponsor":"Darell Bigner","sponsorClass":"OTHER","phases":["PHASE1"],"status":"COMPLETED","interventions":["D2C7-IT (6920 ng/mL via convection-enhanced delivery)","Atezolizumab (1200 mg every three weeks)","D2C7-IT (4613.2 ng/mL via convection-enhanced delivery)"],"startDate":"2020-02-25","firstPosted":"2019-11-13","lastUpdated":"2026-10-14","primaryCompletion":"2024-06-28","enrollment":14,"officials":[{"name":"Annick Desjardins, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Duke University"}],"conditions":["Malignant Glioma"],"siteCountries":["United States"]},{"nctId":"NCT07873996","title":"Tris-CAR-T Cell Therapy Targeting CD44 and CD133 in Newly Diagnosed Glioblastoma","acronym":"CAR-T","sponsor":"Beijing Tiantan Hospital","sponsorClass":"OTHER","phases":["PHASE2","PHASE3"],"status":"NOT_YET_RECRUITING","interventions":["Tris-CAR-T cell injection","Temozolomide (TMZ)"],"startDate":"2026-10-15","firstPosted":"2026-10-14","lastUpdated":"2026-10-14","primaryCompletion":"2030-10-15","enrollment":60,"officials":[{"name":"Wei Zhang, MD, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Beijing Tiantan Hospital"},{"name":"Tao Jiang, MD, PhD","role":"STUDY_CHAIR","affiliation":"Beijing Neurosurgical Institute"}],"conditions":["Newly Diagnosed Glioblastoma, IDH-wildtype"],"siteCountries":["China"]},{"nctId":"NCT07386002","title":"The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma","acronym":"GLIOMAX-101","sponsor":"T-MAXIMUM Pharmaceutical Inc","sponsorClass":"INDUSTRY","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","interventions":["Intracerebroventricular injection of MT027 UCAR-T Cell targeting B7H3"],"startDate":"2026-11-30","firstPosted":"2026-02-04","lastUpdated":"2026-10-14","primaryCompletion":"2028-12-13","enrollment":40,"officials":[],"conditions":["Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype"],"siteCountries":["United States","Taiwan","Taiwan","Taiwan"]},{"nctId":"NCT04385173","title":"Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma","sponsor":"Second Affiliated Hospital, Zhejiang University, School of Medicine","sponsorClass":"OTHER","phases":["PHASE1"],"status":"COMPLETED","interventions":["BP102 (B7-H3 CAR-T)"],"startDate":"2022-12-01","firstPosted":"2020-05-12","lastUpdated":"2026-10-13","primaryCompletion":"2026-09-01","enrollment":10,"officials":[],"conditions":["Recurrent Glioblastoma","Refractory Glioblastoma"],"siteCountries":["China"]},{"nctId":"NCT05533242","title":"Radioimmunotherapy With Lu-177 Labeled 6A10 Fab-fragments in Patients With Glioblastoma After Standard Treatment","acronym":"RIT in GBM","sponsor":"University Hospital Muenster","sponsorClass":"OTHER","phases":["PHASE1"],"status":"TERMINATED","interventions":["Lu-177 labeled 6A10-Fab-fragments"],"startDate":"2024-01-22","firstPosted":"2022-09-08","lastUpdated":"2026-10-13","primaryCompletion":"2026-09-28","whyStopped":"The remaining shelf-life of 1 component used in the manufacture of the study medication (SM) was insufficient to support further study conduct, and no additional material could be manufactured. Production of a new SM is planned for further projects.","enrollment":10,"officials":[{"name":"Walter Stummer, Prof.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University Hospital Muenster, Klinik und Poliklinik für Neurochirurgie"}],"conditions":["Glioblastom WHO Grade 4"],"siteCountries":["Germany","Germany","Germany","Germany","Germany","Germany","Germany"]},{"nctId":"NCT07862647","title":"TMZ + RT + 5-ALA + LIDU SDT System for Newly Diagnosed Butterfly Glioma","acronym":"CV01-104","sponsor":"Alpheus Medical, Inc.","sponsorClass":"INDUSTRY","phases":["PHASE1"],"status":"RECRUITING","interventions":["5-ALA"],"startDate":"2026-10-29","firstPosted":"2026-10-07","lastUpdated":"2026-10-09","primaryCompletion":"2027-10-30","enrollment":30,"officials":[],"conditions":["Glioblastom WHO Grade 4","GBM","bGBM","Butterfly GBM","Bihemispheric GBM","Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT07439172","title":"Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma.","acronym":"PRC","sponsor":"Cooper Norcross Health","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":["Pre-radiation temozolomide."],"startDate":"2026-07-13","firstPosted":"2026-02-27","lastUpdated":"2026-10-09","primaryCompletion":"2028-09","enrollment":70,"officials":[],"conditions":["High Grade Gliomas","Glioblastoma","Astrocytoma","Oligodendroglioma"],"siteCountries":["United States"]},{"nctId":"NCT06059690","title":"Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells","sponsor":"Jonsson Comprehensive Cancer Center","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":[],"startDate":"2023-09-06","firstPosted":"2023-09-29","lastUpdated":"2026-10-08","primaryCompletion":"2027-09-30","enrollment":50,"officials":[{"name":"Benjamin Ellingson, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of California at Los Angeles"}],"conditions":["Glioblastoma Multiforme","Glycolytic Index","Epidermal Growth Factor Receptor"],"siteCountries":["United States"]},{"nctId":"NCT03961971","title":"Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","sponsorClass":"OTHER","phases":["PHASE1"],"status":"COMPLETED","interventions":["MBG453"],"startDate":"2020-02-18","firstPosted":"2019-05-23","lastUpdated":"2026-10-07","primaryCompletion":"2022-11-16","enrollment":16,"officials":[{"name":"Lawrence Kleinberg, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Johns Hopkins University/Sidney Kimmel Cancer Center"}],"conditions":["Glioblastoma Multiforme"],"siteCountries":["United States","United States"]},{"nctId":"NCT03535350","title":"Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma","sponsor":"Case Comprehensive Cancer Center","sponsorClass":"OTHER","phases":["PHASE1"],"status":"COMPLETED","interventions":["Ibrutinib","Temozolomide (TMZ)"],"startDate":"2018-08-24","firstPosted":"2018-05-24","lastUpdated":"2026-10-06","primaryCompletion":"2023-04-04","enrollment":27,"officials":[{"name":"David Peereboom, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center"}],"conditions":["Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT06389591","title":"RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)","acronym":"ASPIRE","sponsor":"University of Florida","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["pp65 RNA loaded lipid particles, pp65 RNA-LPs (Drug Product 1 or DP1)","RNA loaded lipid particles, RNA-LPs (Drug Product 2 or DP2)"],"startDate":"2024-12-02","firstPosted":"2024-04-29","lastUpdated":"2026-10-06","primaryCompletion":"2026-12-01","enrollment":24,"officials":[{"name":"Ashley Ghiaseddin, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of Florida"}],"conditions":["Recurrent Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT06814496","title":"Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors","acronym":"RABBIT","sponsor":"University of Arizona","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["Tarlatamab"],"startDate":"2025-09-08","firstPosted":"2025-02-07","lastUpdated":"2026-10-06","primaryCompletion":"2030-05","enrollment":30,"officials":[{"name":"Charles Hsu, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of Arizona"},{"name":"Ricklie Julian, MD","role":"STUDY_CHAIR","affiliation":"University of Arizona"}],"conditions":["Melanoma","Medullary Thyroid Cancer","Sinonasal Undifferentiated Carcinoma","Esthesioneuroblastoma","Bladder Cancer","Testicular Cancer","Glioblastoma Multiforme","Cervical Cancer","Large Cell Neuroendocrine Carcinoma of the Lung","Non Small Cell Lung Cancer","Merkel Cell Carcinoma"],"siteCountries":["United States","United States","United States"]},{"nctId":"NCT03581292","title":"Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations","sponsor":"Children's Oncology Group","sponsorClass":"OTHER","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Temozolomide","Veliparib"],"startDate":"2018-11-06","firstPosted":"2018-07-10","lastUpdated":"2026-10-06","primaryCompletion":"2023-03-31","resultsFirstPosted":"2024-04-23","enrollment":38,"officials":[{"name":"Matthias A Karajannis","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Children's Oncology Group"}],"conditions":["Anaplastic Astrocytoma","Glioblastoma","Malignant Glioma"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","Australia","Australia","Australia","Australia","Australia","Australia","Australia","Canada","Canada","Canada","Canada","Canada","Canada","Canada","Canada","New Zealand","New Zealand","Puerto Rico"]},{"nctId":"NCT06011109","title":"Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab","sponsor":"Aveta Biomics, Inc.","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["APG-157"],"startDate":"2023-12-13","firstPosted":"2023-08-25","lastUpdated":"2026-10-05","primaryCompletion":"2026-12-31","enrollment":30,"officials":[{"name":"Nicole Shonka, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of Nebraska"},{"name":"Joon Uhm, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Mayo Clinic"}],"conditions":["Glioma","Glioblastoma Multiforme"],"siteCountries":["United States","United States"]},{"nctId":"NCT07859059","title":"Metronomic Temozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblastoma","sponsor":"University of Nebraska","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","interventions":["Dexbrompheniramine","Temozolomide"],"startDate":"2027-06-01","firstPosted":"2026-10-05","lastUpdated":"2026-10-05","primaryCompletion":"2030-06-01","enrollment":41,"officials":[{"name":"Nicole A Shonka, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of Nebraska"}],"conditions":["High Grade Glioma","Glioblastoma","Gliosarcoma"],"siteCountries":["United States"]},{"nctId":"NCT05465954","title":"Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma","sponsor":"Mayo Clinic","sponsorClass":"OTHER","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Efineptakin alfa","Pembrolizumab"],"startDate":"2023-01-24","firstPosted":"2022-07-20","lastUpdated":"2026-10-05","primaryCompletion":"2026-09-02","enrollment":53,"officials":[{"name":"Jian L. Campian, MD, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Mayo Clinic in Rochester"}],"conditions":["High Grade Astrocytic Tumor","Recurrent Glioblastoma, IDH-Wildtype","Recurrent Gliosarcoma"],"siteCountries":["United States"]},{"nctId":"NCT07521657","title":"Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma","acronym":"NF118","sponsor":"University of Alabama at Birmingham","sponsorClass":"OTHER","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","interventions":["mirdametinib with radiation","mirdametinib"],"startDate":"2027-01-01","firstPosted":"2026-04-13","lastUpdated":"2026-10-05","primaryCompletion":"2031-01-01","enrollment":55,"officials":[{"name":"Girish Dhall, MD","role":"STUDY_DIRECTOR","affiliation":"University of Alabama at Birmingham"}],"conditions":["Neurofibromatosis 1 (NF1)"],"siteCountries":["United States"]},{"nctId":"NCT06097975","title":"A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma","acronym":"NEO-GLITIPNI","sponsor":"Universitair Ziekenhuis Brussel","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Neo-adjuvant nivolumab and ipililumab IV + adjuvant nivolumab and ipililumab IV","Adjuvant nivolumab IV + nivolumab and ipililumab intracavitary"],"startDate":"2024-03-15","firstPosted":"2023-10-24","lastUpdated":"2026-10-02","primaryCompletion":"2027-06-01","enrollment":18,"officials":[],"conditions":["Recurrent Glioblastoma"],"siteCountries":["Belgium"]},{"nctId":"NCT06991101","title":"Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma","sponsor":"Baptist Health South Florida","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":["Ruxolitinib","Temozolomide"],"startDate":"2025-12-03","firstPosted":"2025-05-25","lastUpdated":"2026-10-02","primaryCompletion":"2030-12","enrollment":190,"officials":[{"name":"Manmeet Ahluwalia, M.D., MBA","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Baptist Health Herbert Wertheim Cancer Institute"}],"conditions":["Glioblastoma","Brain Cancer","Glioblastoma Multiforme","Glioblastoma Multiforme of Brain","Glioblastoma Multiforme, Adult","MGMT-Unmethylated Glioblastoma","MGMT-Methylated Glioblastoma"],"siteCountries":["United States","United States"]},{"nctId":"NCT04295759","title":"INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas","sponsor":"Pediatric Brain Tumor Consortium","sponsorClass":"OTHER","phases":["PHASE1"],"status":"COMPLETED","interventions":["INCB7839"],"startDate":"2020-07-27","firstPosted":"2020-03-04","lastUpdated":"2026-10-01","primaryCompletion":"2023-12-31","resultsFirstPosted":"2025-02-19","enrollment":13,"officials":[{"name":"Michelle Monje, MD, PhD","role":"STUDY_CHAIR","affiliation":"Stanford University and Lucile Packard Children's Hospital"}],"conditions":["Glioblastoma Multiforme","Anaplastic Astrocytoma","Anaplastic Oligodendroglioma","DIPG","High-grade Astrocytoma NOS","CNS Primary Tumor, NOS (Malignant Glioma)"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT00730613","title":"Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma","sponsor":"City of Hope Medical Center","sponsorClass":"OTHER","phases":["PHASE1"],"status":"COMPLETED","interventions":["therapeutic autologous lymphocytes","gene expression analysis"],"startDate":"2002-03-25","firstPosted":"2008-08-08","lastUpdated":"2026-10-01","primaryCompletion":"2011-08-01","enrollment":3,"officials":[{"name":"Stephen Forman, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"City of Hope Medical Center"}],"conditions":["Brain and Central Nervous System Tumors"]},{"nctId":"NCT02179086","title":"Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma","sponsor":"NRG Oncology","sponsorClass":"OTHER","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Temozolomide"],"startDate":"2014-12-04","firstPosted":"2014-07-01","lastUpdated":"2026-10-01","primaryCompletion":"2025-07-07","resultsFirstPosted":"2026-08-28","enrollment":624,"officials":[{"name":"Minesh P Mehta","role":"PRINCIPAL_INVESTIGATOR","affiliation":"NRG Oncology"}],"conditions":["Glioblastoma"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","Canada","Canada","Canada","Canada","Canada","Canada","Canada"]},{"nctId":"NCT03478462","title":"Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas","acronym":"CLOVER-2","sponsor":"Cellectar Biosciences, Inc.","sponsorClass":"INDUSTRY","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["CLR 131"],"startDate":"2019-04-30","firstPosted":"2018-03-27","lastUpdated":"2026-10-01","primaryCompletion":"2027-06-30","enrollment":30,"officials":[{"name":"Jarrod Longcor","role":"STUDY_DIRECTOR","affiliation":"Cellectar Biosciences"}],"conditions":["Pediatric Solid Tumor","Pediatric Lymphoma","Pediatric Brain Tumor","DIPG","Neuroblastoma","Ewing Sarcoma","Rhabdomyosarcoma","Osteosarcoma"],"siteCountries":["United States","United States","United States","United States","United States","United States","Australia","Canada"]},{"nctId":"NCT07285044","title":"The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas","sponsor":"Mayo Clinic","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":["Cancer Therapeutic Procedure","Cancer Therapeutic Procedure"],"startDate":"2025-12-18","firstPosted":"2025-12-16","lastUpdated":"2026-09-30","primaryCompletion":"2027-05-15","enrollment":27,"officials":[{"name":"Roxana S. Dronca, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Mayo Clinic"}],"conditions":["Amyloidosis","Basal Cell Carcinoma","Biliary Tract Carcinoma","Bladder Carcinoma","Breast Carcinoma","Cervical Carcinoma","Colorectal Carcinoma","Endometrial Carcinoma","Fallopian Tube Carcinoma","Gastroesophageal Junction Carcinoma","Glioblastoma","Head and Neck Carcinoma","Hematopoietic and Lymphatic System Neoplasm","Hepatocellular Carcinoma","Hodgkin Lymphoma","Lung Carcinoma","Malignant Solid Neoplasm","Mantle Cell Lymphoma","Melanoma","Merkel Cell Carcinoma","Multiple Myeloma","Myelodysplastic Syndrome","Ovarian Carcinoma","Pancreatic Carcinoma","Primary Peritoneal Carcinoma","Prostate Carcinoma","Renal Cell Carcinoma","Squamous Cell Carcinoma","Urothelial Carcinoma"],"siteCountries":["United States"]},{"nctId":"NCT06815432","title":"GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma","sponsor":"Baylor College of Medicine","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":["15.GPC3-CAR T cells"],"startDate":"2025-10-10","firstPosted":"2025-02-07","lastUpdated":"2026-09-30","primaryCompletion":"2029-12-05","enrollment":27,"officials":[{"name":"Ganesh Rao, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Baylor College of Medicine"}],"conditions":["Glioblastoma Multiforme of Brain"],"siteCountries":["United States"]},{"nctId":"NCT06855628","title":"Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic EfficacyiIn Glioblastoma (GBM)","sponsor":"Stanford University","sponsorClass":"OTHER","phases":["PHASE2"],"status":"COMPLETED","interventions":[],"startDate":"2025-01-30","firstPosted":"2025-03-04","lastUpdated":"2026-09-30","primaryCompletion":"2026-07-13","enrollment":2,"officials":[{"name":"Lawarence Recht","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Stanford University"}],"conditions":["Glioma","GBM"],"siteCountries":["United States"]},{"nctId":"NCT05739942","title":"Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma","sponsor":"Novartis Pharmaceuticals","sponsorClass":"INDUSTRY","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["[177Lu]Lu-NeoB","[68Ga]Ga-NeoB"],"startDate":"2024-05-15","firstPosted":"2023-02-22","lastUpdated":"2026-09-30","primaryCompletion":"2027-08-10","enrollment":42,"officials":[{"name":"Novartis Pharmaceuticals","role":"STUDY_DIRECTOR","affiliation":"Novartis Pharmaceuticals"}],"conditions":["Newly Diagnosed and Recurrent Glioblastoma"],"siteCountries":["United States","United States","United States","United States","United States","United States","France","Germany","Germany","Italy","Portugal","Spain","Spain","Spain","Spain","Spain"]},{"nctId":"NCT02344355","title":"A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme","sponsor":"Bryan Allen","sponsorClass":"OTHER","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Temozolomide","Ascorbic Acid"],"startDate":"2017-03-13","firstPosted":"2015-01-22","lastUpdated":"2026-09-30","primaryCompletion":"2027-12-31","enrollment":90,"officials":[{"name":"Bryan G. Allen, MD, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Assistant Professor, Department of Radiation Oncology, The University of Iowa"}],"conditions":["Glioblastoma Multiforme"],"siteCountries":["United States"]},{"nctId":"NCT05871021","title":"Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma","acronym":"PRIDE","sponsor":"University Hospital Tuebingen","sponsorClass":"OTHER","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":[],"startDate":"2024-04-10","firstPosted":"2023-05-23","lastUpdated":"2026-09-29","primaryCompletion":"2028-12-31","enrollment":107,"officials":[{"name":"Maximilian Niyazi, Prof. Dr.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University Hospital Tuebingen, Department of Radiation Oncology"}],"conditions":["Glioblastoma"],"siteCountries":["Germany","Germany","Germany","Germany","Germany","Germany","Germany","Germany","Germany"]},{"nctId":"NCT05864534","title":"Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma","sponsor":"Northwestern University","sponsorClass":"OTHER","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Balstilimab","Botensilimab","Liposomal Doxorubicin"],"startDate":"2024-01-19","firstPosted":"2023-05-18","lastUpdated":"2026-09-29","primaryCompletion":"2031-07-31","enrollment":25,"officials":[{"name":"Adam Sonabend, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Northwestern University"},{"name":"Roger Stupp, MD","role":"STUDY_DIRECTOR","affiliation":"Northwestern University"}],"conditions":["Newly Diagnosed Glioblastoma","Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype","Gliosarcoma","Glioblastoma Multiforme"],"siteCountries":["United States"]},{"nctId":"NCT05685004","title":"Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)","sponsor":"TVAX Biomedical","sponsorClass":"INDUSTRY","phases":["PHASE2","PHASE3"],"status":"ACTIVE_NOT_RECRUITING","interventions":["TVI-Brain-1","Temozolomide"],"startDate":"2023-12-27","firstPosted":"2023-01-13","lastUpdated":"2026-09-29","primaryCompletion":"2030-11","enrollment":120,"officials":[{"name":"Gary Wood, PhD","role":"STUDY_CHAIR","affiliation":"TVAX Biomedical, Inc"}],"conditions":["Glioblastoma Multiforme of Brain"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT07492316","title":"RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB)","acronym":"PNOC020 rMB","sponsor":"University of Florida","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)"],"startDate":"2026-04-24","firstPosted":"2026-03-25","lastUpdated":"2026-09-29","primaryCompletion":"2030-09-01","enrollment":24,"officials":[{"name":"Sabine Mueller, MD, PhD","role":"STUDY_CHAIR","affiliation":"University of California, San Francisco"},{"name":"Elias Sayour, MD, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of Florida"}],"conditions":["Recurrent Medulloblastoma"],"siteCountries":["United States"]},{"nctId":"NCT07145112","title":"Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma","sponsor":"University of California, Davis","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":["Lomustine"],"startDate":"2025-10-01","firstPosted":"2025-08-28","lastUpdated":"2026-09-28","primaryCompletion":"2027-03","enrollment":25,"officials":[{"name":"Orwa Aboud, MD, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of California, Davis"}],"conditions":["Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT05183204","title":"Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma","sponsor":"Weill Medical College of Cornell University","sponsorClass":"OTHER","phases":["PHASE2"],"status":"COMPLETED","interventions":["Paxalisib","Metformin"],"startDate":"2022-02-14","firstPosted":"2022-01-10","lastUpdated":"2026-09-25","primaryCompletion":"2026-08-10","enrollment":24,"officials":[{"name":"Howard Fine, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Weill Medical College of Cornell University"}],"conditions":["Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT04094610","title":"A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations","sponsor":"Turning Point Therapeutics, Inc.","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["Oral repotrectinib (TPX-0005)"],"startDate":"2020-03-12","firstPosted":"2019-09-19","lastUpdated":"2026-09-25","primaryCompletion":"2026-09-30","enrollment":75,"officials":[{"name":"Bristol-Myers Squibb","role":"STUDY_DIRECTOR","affiliation":"Bristol-Myers Squibb"}],"conditions":["Locally Advanced Solid Tumors","Metastatic Solid Tumors","Lymphoma","Primary CNS Tumors"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","Australia","Australia","Australia","Australia","Canada","Canada","Canada","Canada","Denmark","France","France","France","France","France","France","France","France","France","France","Italy","Italy","Italy","Italy","Singapore","Singapore","South Korea","South Korea","South Korea","South Korea","Spain","Spain","Spain","Spain","Spain","Spain","Spain","Spain","Spain","Spain","Spain","Taiwan","Taiwan","United Kingdom","United Kingdom","United Kingdom","United Kingdom","United Kingdom","United Kingdom"]},{"nctId":"NCT07422896","title":"A Phase I First-in-human Trial of Bvax (B-cell Vaccination) in Addition to Standard of Care Chemoradiotherapy for Newly Diagnosed Glioblastoma","acronym":"Bvax","sponsor":"Catalina Lee Chang","sponsorClass":"OTHER","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","interventions":["B-cell vaccination"],"startDate":"2026-12-01","firstPosted":"2026-02-20","lastUpdated":"2026-09-25","primaryCompletion":"2028-09-01","enrollment":25,"officials":[],"conditions":["Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT03896568","title":"MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma","sponsor":"M.D. Anderson Cancer Center","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":["Oncolytic Adenovirus Ad5-DNX-2401"],"startDate":"2019-02-12","firstPosted":"2019-04-01","lastUpdated":"2026-09-25","primaryCompletion":"2027-09-30","enrollment":36,"officials":[{"name":"Frederick F Lang","role":"PRINCIPAL_INVESTIGATOR","affiliation":"M.D. Anderson Cancer Center"}],"conditions":["IDH1 wt Allele","Recurrent Anaplastic Astrocytoma","Recurrent Glioblastoma","Recurrent Gliosarcoma","Recurrent Malignant Glioma"],"siteCountries":["United States"]},{"nctId":"NCT04115761","title":"Evaluate the Efficacy and Safety of ADCV01 as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients","sponsor":"Ever Supreme Bio Technology Co., Ltd.","sponsorClass":"INDUSTRY","phases":["PHASE2"],"status":"RECRUITING","interventions":["autologous dendritic cells"],"startDate":"2019-06-06","firstPosted":"2019-10-04","lastUpdated":"2026-09-24","primaryCompletion":"2027-12-30","enrollment":24,"officials":[{"name":"Wen-Liang Huang","role":"STUDY_DIRECTOR","affiliation":"Ever-Supreme Biotechnology"}],"conditions":["GBM"],"siteCountries":["Taiwan","Taiwan","Taiwan"]},{"nctId":"NCT06047379","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","sponsor":"Neonc Technologies, Inc.","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["NEO212 Oral Capsule","Ipilimumab","Pembrolizumab","Nivolumab","Regorafenib","Carboplatin","Paclitaxel","FOLFIRI Protocol","Bevacizumab"],"startDate":"2023-11-01","firstPosted":"2023-09-21","lastUpdated":"2026-09-24","primaryCompletion":"2027-02-28","enrollment":134,"officials":[{"name":"Tom Chen, MD, PhD","role":"STUDY_CHAIR","affiliation":"NeOnc Technologies"},{"name":"Josh Neman, PhD","role":"STUDY_DIRECTOR","affiliation":"NeOnc Technologies Holdings, Inc."}],"conditions":["Diffuse Astrocytoma, IDH-Mutant","Glioblastoma, IDH-wildtype","Brain Metastases, Adult","Cervical Cancer","Colorectal Cancer","Esophageal Cancer","Esophageal Squamous Cell Carcinoma","Gastric Cancer","Gastroesophageal Junction Adenocarcinoma","Head and Neck Squamous Cell Carcinoma","Melanoma","Merkel Cell Carcinoma","Microsatellite Instability-High Solid Malignant Tumor","Mismatch Repair Deficient Solid Malignant Tumor","Microsatellite Instability-High Colorectal Cancer","Mismatch Repair Deficient Colorectal Cancer","Non-small Cell Lung Cancer","Renal Cell Carcinoma","Small Cell Lung Cancer","Squamous Cell Carcinoma","Urothelial Carcinoma"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT07031765","title":"Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma","acronym":"Peds CHAMP1ON","sponsor":"University of Florida","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["exHSC","Nivolumab"],"startDate":"2025-07-25","firstPosted":"2025-06-22","lastUpdated":"2026-09-23","primaryCompletion":"2030-12","enrollment":12,"officials":[{"name":"John Ligon, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of Florida"}],"conditions":["Recurrent High-grade Glioma","Grade III Astrocytoma","Oligodendroglioma","Oligoastrocytoma","Ependymoma","Grade IV Astrocytoma"],"siteCountries":["United States"]},{"nctId":"NCT07821112","title":"Phase II Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Treated With Cesium-131 GammaTile®","acronym":"ENDURANCE","sponsor":"University of California, Irvine","sponsorClass":"OTHER","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","interventions":[],"startDate":"2026-10","firstPosted":"2026-09-15","lastUpdated":"2026-09-23","primaryCompletion":"2027-10","enrollment":20,"officials":[{"name":"Carlen Yuen, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Chao Family Comprehensive Cancer Center"}],"conditions":["Glioma","Glioblastoma","GBM","Glioma, Malignant","Astrocytoma","Oligodendroglioma","Elderly Glioblastoma","Elderly GBM"],"siteCountries":["United States"]},{"nctId":"NCT05353530","title":"IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma","acronym":"IMPACT","sponsor":"University of Florida","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells"],"startDate":"2023-07-25","firstPosted":"2022-04-29","lastUpdated":"2026-09-23","primaryCompletion":"2027-12","enrollment":39,"officials":[{"name":"Ashley Ghiaseddin, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of Florida"}],"conditions":["Glioblastoma Multiforme","Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT03174197","title":"Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma","sponsor":"M.D. Anderson Cancer Center","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"COMPLETED","interventions":["Atezolizumab","Temozolomide"],"startDate":"2017-06-30","firstPosted":"2017-06-02","lastUpdated":"2026-09-23","primaryCompletion":"2025-09-17","resultsFirstPosted":"2026-09-23","enrollment":60,"officials":[{"name":"Shiao-Pei S Weathers","role":"PRINCIPAL_INVESTIGATOR","affiliation":"M.D. Anderson Cancer Center"}],"conditions":["Glioblastoma","Gliosarcoma"],"siteCountries":["United States"]},{"nctId":"NCT06558214","title":"OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial","acronym":"OPTIMUS PRIME","sponsor":"University of Florida","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":["Pembrolizumab"],"startDate":"2024-12-10","firstPosted":"2024-08-16","lastUpdated":"2026-09-23","primaryCompletion":"2029-10","enrollment":20,"officials":[{"name":"Ashley Ghiaseddin, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of Florida"}],"conditions":["Recurrent Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT04729959","title":"Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma","sponsor":"National Cancer Institute (NCI)","sponsorClass":"OTHER","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Atezolizumab","Tocilizumab"],"startDate":"2022-03-11","firstPosted":"2021-01-29","lastUpdated":"2026-09-23","primaryCompletion":"2025-06-15","resultsFirstPosted":"2026-08-07","enrollment":61,"officials":[{"name":"Stephen J Bagley","role":"PRINCIPAL_INVESTIGATOR","affiliation":"NRG Oncology"}],"conditions":["Diffuse Astrocytoma, IDH-Wildtype","Recurrent Glioblastoma"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT05109728","title":"A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.","sponsor":"Novartis Pharmaceuticals","sponsorClass":"INDUSTRY","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["[177Lu]Lu-DOTA-TATE","[68Ga]Ga-DOTA-TATE"],"startDate":"2022-05-10","firstPosted":"2021-11-05","lastUpdated":"2026-09-22","primaryCompletion":"2025-12-03","enrollment":63,"officials":[{"name":"Novartis Pharmaceuticals","role":"STUDY_DIRECTOR","affiliation":"Novartis Pharmaceuticals"}],"conditions":["Glioblastoma"],"siteCountries":["United States","United States","United States","United States","France","France","Portugal","Spain","Spain","Spain","Spain","Spain","Switzerland","Switzerland"]},{"nctId":"NCT03197506","title":"Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma","sponsor":"Mayo Clinic","sponsorClass":"OTHER","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Pembrolizumab","Temozolomide"],"startDate":"2018-01-15","firstPosted":"2017-06-23","lastUpdated":"2026-09-22","primaryCompletion":"2024-07-16","resultsFirstPosted":"2026-03-25","enrollment":52,"officials":[{"name":"Ian F. Parney, MD, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Mayo Clinic in Rochester"}],"conditions":["Glioblastoma","Gliosarcoma","Supratentorial Glioblastoma"],"siteCountries":["United States","United States","United States"]},{"nctId":"NCT07831187","title":"Entacapone Plus Bevacizumab for Glioblastoma at First Recurrence","sponsor":"First Affiliated Hospital of Wenzhou Medical University","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","interventions":["Entacapone","Bevacizumab","Placebo"],"startDate":"2026-10-01","firstPosted":"2026-09-21","lastUpdated":"2026-09-21","primaryCompletion":"2029-09-30","enrollment":96,"officials":[{"name":"Qichuan Zhuge","role":"PRINCIPAL_INVESTIGATOR","affiliation":"First Affiliated Hospital of Wenzhou Medical University"}],"conditions":["Glioblastoma"],"siteCountries":["China"]},{"nctId":"NCT04977375","title":"Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma","sponsor":"Chirag G. Patil","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["Pembrolizumab"],"startDate":"2021-12-09","firstPosted":"2021-07-26","lastUpdated":"2026-09-21","primaryCompletion":"2027-12","enrollment":10,"officials":[{"name":"Chirag G Patil, MD, MS","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Cedars-Sinai Medical Center"}],"conditions":["Glioblastoma Multiforme"],"siteCountries":["United States"]},{"nctId":"NCT03223103","title":"Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma","sponsor":"Adilia Hormigo","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Poly-ICLC","Peptides"],"startDate":"2018-03-01","firstPosted":"2017-07-19","lastUpdated":"2026-09-21","primaryCompletion":"2029-05-12","enrollment":13,"officials":[{"name":"Adilia Hormigo, MD, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Albert Einstein College of Medicine"}],"conditions":["Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT07831369","title":"VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma","sponsor":"Inova Health Care Services","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":["Valproic Acid (VPA)","Irinotecan","Simvastatin"],"startDate":"2026-09-04","firstPosted":"2026-09-21","lastUpdated":"2026-09-21","primaryCompletion":"2027-09-30","enrollment":52,"officials":[{"name":"Adam Cohen, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Inova Health Care Services"}],"conditions":["Glioblastoma","Astrocytoma, IDH-Mutant, Grade 4"],"siteCountries":["United States"]},{"nctId":"NCT06804655","title":"Pharmacoscopy for Patients With Refractory Primary Brain Tumors","acronym":"EViDENCE-BT","sponsor":"University of Zurich","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":[],"startDate":"2026-09-11","firstPosted":"2025-02-03","lastUpdated":"2026-09-21","primaryCompletion":"2028-09-15","enrollment":40,"officials":[],"conditions":["Brain (Nervous System) Cancers","Glioblastoma","Glioma","Ependymoma","Medulloblastoma","Meningioma","Rare Primary Brain Tumors","Rare CNS Primary Tumors"],"siteCountries":["Switzerland","Switzerland","Switzerland"]},{"nctId":"NCT07089641","title":"ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial","sponsor":"Jonsson Comprehensive Cancer Center","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":["EGFR Inhibitor ERAS-801"],"startDate":"2025-07-28","firstPosted":"2025-07-28","lastUpdated":"2026-09-18","primaryCompletion":"2027-07-30","enrollment":50,"officials":[{"name":"Phioanh Nghiemphu","role":"PRINCIPAL_INVESTIGATOR","affiliation":"UCLA / Jonsson Comprehensive Cancer Center"}],"conditions":["Glioblastoma","Glioblastoma, IDH-Wildtype","Gliosarcoma","Recurrent Glioblastoma, IDH-Wildtype","Recurrent Gliosarcoma","Resectable Glioblastoma"],"siteCountries":["United States","United States"]},{"nctId":"NCT03587038","title":"OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma","sponsor":"University of Oklahoma","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["OKN 007","Temozolomide"],"startDate":"2018-09-03","firstPosted":"2018-07-16","lastUpdated":"2026-09-18","primaryCompletion":"2020-12-23","enrollment":27,"officials":[{"name":"James Battiste, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Principal Investigator"}],"conditions":["Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT03649880","title":"Feasibility of FMISO in Brain Tumors","sponsor":"OHSU Knight Cancer Institute","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":["¹⁸F-Fluoromisonidazole","Ferumoxytol","Gadolinium"],"startDate":"2019-06-01","firstPosted":"2018-08-28","lastUpdated":"2026-09-18","primaryCompletion":"2029-01-31","enrollment":77,"officials":[{"name":"Ramon Barajas","role":"PRINCIPAL_INVESTIGATOR","affiliation":"OHSU Knight Cancer Institute"}],"conditions":["IDH Wild Type Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT06816927","title":"Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab","acronym":"GIANT","sponsor":"Duke University","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":["Nivolumab","Relatlimab","TMZ"],"startDate":"2025-11-28","firstPosted":"2025-02-10","lastUpdated":"2026-09-17","primaryCompletion":"2029-06-01","enrollment":92,"officials":[],"conditions":["Newly Diagnosed Glioblastoma"],"siteCountries":["United States","United States","United States","Australia"]},{"nctId":"NCT07376304","title":"Intraoperative Ultrasound for Brain Tumor Surgery Enhanced by AI","acronym":"BrainUS-AI","sponsor":"Hospital del Rio Hortega","sponsorClass":"OTHER","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","interventions":[],"startDate":"2026-12","firstPosted":"2026-01-29","lastUpdated":"2026-09-17","primaryCompletion":"2027-12","enrollment":100,"officials":[],"conditions":["Brain Tumor Adult"]},{"nctId":"NCT03277638","title":"Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)","sponsor":"Case Comprehensive Cancer Center","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"COMPLETED","interventions":["Pembrolizumab at 7 days prior","Pembrolizumab at 14 days post","Pembrolizumab at 35 days post"],"startDate":"2017-11-29","firstPosted":"2017-09-11","lastUpdated":"2026-09-17","primaryCompletion":"2026-04-15","enrollment":32,"officials":[{"name":"Tiffany Hodges, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center"}],"conditions":["Glioblastoma, Adult"],"siteCountries":["United States"]},{"nctId":"NCT04808245","title":"A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas","acronym":"INTERCEPT-H3","sponsor":"German Cancer Research Center","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Tecentriq 1200 MG in 20 ML Injection","H3K27M peptide vaccine"],"startDate":"2023-02-15","firstPosted":"2021-03-22","lastUpdated":"2026-09-15","primaryCompletion":"2026-11","enrollment":15,"officials":[{"name":"Michael Platten, Prof.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"German Cancer Research Center Germany"}],"conditions":["Newly Diagnosed H3-mutated Glioma"],"siteCountries":["Germany","Germany","Germany","Germany","Germany","Germany","Germany","Germany"]},{"nctId":"NCT02974621","title":"Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma","sponsor":"National Cancer Institute (NCI)","sponsorClass":"OTHER","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Bevacizumab","Cediranib","Cediranib Maleate","Olaparib"],"startDate":"2017-12-07","firstPosted":"2016-11-28","lastUpdated":"2026-09-15","primaryCompletion":"2022-12-31","resultsFirstPosted":"2024-02-02","enrollment":70,"officials":[{"name":"Isabel Arrillaga-Romany","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Dana-Farber - Harvard Cancer Center LAO"}],"conditions":["Recurrent Glioblastoma"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT05474378","title":"B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme","sponsor":"Stanford University","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":["B7-H3CART"],"startDate":"2022-07-12","firstPosted":"2022-07-26","lastUpdated":"2026-09-15","primaryCompletion":"2027-02","enrollment":39,"officials":[{"name":"Reena Thomas, MD, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Stanford University"}],"conditions":["Brain and Nervous System"],"siteCountries":["United States"]},{"nctId":"NCT06132438","title":"Immunotherapy Targeting of Cytomegalovirus Antigens in Glioblastoma","sponsor":"Charlotte Lemech","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":["PEP-CMV vaccine"],"startDate":"2024-07-22","firstPosted":"2023-11-15","lastUpdated":"2026-09-15","primaryCompletion":"2027-09","enrollment":26,"officials":[],"conditions":["Glioblastoma"],"siteCountries":["Australia","Australia"]},{"nctId":"NCT05495295","title":"First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours","acronym":"PhAST","sponsor":"Phost'In Therapeutics","sponsorClass":"INDUSTRY","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["PhOx430","PhOx430"],"startDate":"2022-07-18","firstPosted":"2022-08-10","lastUpdated":"2026-09-15","primaryCompletion":"2024-11-04","enrollment":149,"officials":[{"name":"Alain Herrera, MD","role":"STUDY_DIRECTOR","affiliation":"Phost'In Therapeutics"},{"name":"Diego Tosi, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Institut du Cancer de Montpellier - Val d'Aurelle"}],"conditions":["Malignant Tumor","Advanced Solid Tumor","Glioblastoma Multiforme","Metastatic Cancer"],"siteCountries":["France","Italy","Italy","Italy"]},{"nctId":"NCT02704858","title":"Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma","sponsor":"Neonc Technologies, Inc.","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Perillyl alcohol"],"startDate":"2017-08-01","firstPosted":"2016-03-10","lastUpdated":"2026-09-14","primaryCompletion":"2026-11-30","enrollment":49,"officials":[{"name":"Thomas Chen, MD, PhD","role":"STUDY_CHAIR","affiliation":"NeOnc Technologies Holdings, Inc."},{"name":"Josh Neman, PhD","role":"STUDY_DIRECTOR","affiliation":"NeOnc Technologies Holdings, Inc."}],"conditions":["Glioblastoma Multiforme"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT05698524","title":"A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma","sponsor":"University of Nebraska","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":["PCI 24781","Temozolomide"],"startDate":"2023-06-26","firstPosted":"2023-01-26","lastUpdated":"2026-09-14","primaryCompletion":"2027-07","enrollment":24,"officials":[{"name":"Nicole A Shonka, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of Nebraska"}],"conditions":["Recurrent High Grade Glioma","Anaplastic Astrocytoma","Anaplastic Oligodendroglioma","Glioblastoma","Gliosarcoma"],"siteCountries":["United States"]},{"nctId":"NCT07452458","title":"Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma","sponsor":"NRG Oncology","sponsorClass":"OTHER","phases":["PHASE3"],"status":"RECRUITING","interventions":["Temozolomide"],"startDate":"2026-07-16","firstPosted":"2026-03-05","lastUpdated":"2026-09-10","primaryCompletion":"2030-01-15","enrollment":398,"officials":[{"name":"Jiayi Huang","role":"PRINCIPAL_INVESTIGATOR","affiliation":"NRG Oncology"}],"conditions":["Glioblastoma, IDH-Wildtype","MGMT-Unmethylated Glioblastoma"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT07349693","title":"Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma","acronym":"Cerebraca-02/3","sponsor":"Everfront Biotech Co., Ltd.","sponsorClass":"INDUSTRY","phases":["PHASE2","PHASE3"],"status":"NOT_YET_RECRUITING","interventions":["Cerebraca wafer","Temozolomide (for relapsed malignant glioma)"],"startDate":"2027-04-01","firstPosted":"2026-01-20","lastUpdated":"2026-09-10","primaryCompletion":"2029-03-30","enrollment":175,"officials":[],"conditions":["Recurrent Glioblastoma, IDH-Wildtype"],"siteCountries":["United States"]},{"nctId":"NCT07811297","title":"A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers","sponsor":"Advenchen Pharmaceuticals, LLC.","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","interventions":["AL58805","AL3818","Temozolomide (TMZ)","CCNU"],"startDate":"2026-09-01","firstPosted":"2026-09-10","lastUpdated":"2026-09-10","primaryCompletion":"2030-09-01","enrollment":138,"officials":[{"name":"Judy Chen","role":"STUDY_DIRECTOR","affiliation":"Advenchen Pharmaceuticals, LLC."},{"name":"Carlos K Matsuoka, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"UT MD Anderson Cancer Center"}],"conditions":["Endometrial Neoplasms","Ovarian Neoplasms","Soft Tissue Sarcoma (STS)","Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT05052957","title":"hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)","acronym":"hSTAR GBM","sponsor":"Leland Metheny","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":["P140K-MGMT","O6-benzylguanine","temozolomide","Filgrastim","carmustine"],"startDate":"2023-01-20","firstPosted":"2021-09-22","lastUpdated":"2026-09-10","primaryCompletion":"2026-11-01","enrollment":16,"officials":[{"name":"Leland Metheny, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center"}],"conditions":["Glioblastoma Multiforme","Glioblastoma Multiforme, Adult","Supratentorial Glioblastoma","Supratentorial Gliosarcoma"],"siteCountries":["United States"]},{"nctId":"NCT06329570","title":"Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)","sponsor":"NaviFUS Corporation","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"SUSPENDED","interventions":["Lumason","Bevacizumab"],"startDate":"2024-10-22","firstPosted":"2024-03-26","lastUpdated":"2026-09-09","primaryCompletion":"2027-12-31","whyStopped":"FDA reviewing","enrollment":10,"officials":[],"conditions":["Glioblastoma Multiforme","Glioblastoma","Glioma","Brain Tumor","Neoplasms","Neoplasms, Nerve Tissue"],"siteCountries":["United States"]},{"nctId":"NCT06934889","title":"Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma","sponsor":"Memorial Sloan Kettering Cancer Center","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":["ERAS-801","ABBV-637","ABBV-155","Temozolomide"],"startDate":"2025-04-07","firstPosted":"2025-04-18","lastUpdated":"2026-09-09","primaryCompletion":"2028-04","enrollment":60,"officials":[{"name":"Thomas Kaley, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Memorial Sloan Kettering Cancer Center"}],"conditions":["Glioblastoma","Gliosarcoma"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT03212274","title":"Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations","sponsor":"National Cancer Institute (NCI)","sponsorClass":"OTHER","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Olaparib"],"startDate":"2019-01-30","firstPosted":"2017-07-11","lastUpdated":"2026-09-09","primaryCompletion":"2025-04-02","resultsFirstPosted":"2026-06-17","enrollment":89,"officials":[{"name":"Patricia M LoRusso","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Yale University Cancer Center LAO"}],"conditions":["Advanced Malignant Solid Neoplasm","Glioblastoma","Recurrent Cholangiocarcinoma","Recurrent Glioma","Recurrent Malignant Solid Neoplasm","WHO Grade 2 Glioma","WHO Grade 3 Glioma"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT06410248","title":"Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma","sponsor":"Northwestern University","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":["Temozolomide","Triapine"],"startDate":"2024-07-23","firstPosted":"2024-05-13","lastUpdated":"2026-09-09","primaryCompletion":"2026-07-22","enrollment":22,"officials":[{"name":"Karan Dixit, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Northwestern University"}],"conditions":["Recurrent Glioblastoma, IDH-Wildtype","Recurrent WHO Grade 2 Glioma","Recurrent WHO Grade 3 Glioma","Recurrent WHO Grade 4 Glioma"],"siteCountries":["United States"]},{"nctId":"NCT06894225","title":"Proof-of-Concept Study of ACT001 in Adult Patients With Recurrent Glioblastoma Harbouring STAT3-High Signature","sponsor":"National Neuroscience Institute","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":["ACT001"],"startDate":"2025-03-22","firstPosted":"2025-03-25","lastUpdated":"2026-09-04","primaryCompletion":"2027-05","enrollment":12,"officials":[],"conditions":["Recurrent Glioblastoma"],"siteCountries":["Singapore"]},{"nctId":"NCT03911388","title":"HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors","sponsor":"M.D. Anderson Cancer Center","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":["G207"],"startDate":"2019-09-12","firstPosted":"2019-04-11","lastUpdated":"2026-09-04","primaryCompletion":"2026-09-01","enrollment":24,"officials":[{"name":"Gregory Friedman, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"M.D. Anderson Cancer Center"}],"conditions":["Neoplasms, Brain","Glioblastoma Multiforme","Glioblastoma of Cerebellum","Neoplasms","Astrocytoma","Astrocytoma, Cerebellar","Neuroectodermal Tumors","Neuroectodermal Tumors, Primitive","Cerebellar PNET, Childhood","Cerebellar Neoplasms","Cerebellar Neoplasms, Primary","Cerebellar Neoplasm, Malignant","Cerebellar Neoplasm Malignant Primary","Neoplasm Metastases","Neoplasm Malignant","Neoplasms, Neuroepithelial","Neoplasms, Germ Cell and Embryonal","Neoplasms by Histologic Type","Neoplasms, Glandular and Epithelial","Neoplasms, Nerve Tissue","Central Nervous System Neoplasms, Primary","Central Nervous System Neoplasms, Malignant","Nervous System Neoplasms","Neoplasms by Site","Brain Diseases","Central Nervous System Diseases","Nervous System Diseases","Medulloblastoma Recurrent","HSV","Virus","Pediatric Brain Tumor","Nervous System Cancer","Primitive Neuroectodermal Tumor (PNET) of Cerebellum"],"siteCountries":["United States","United States","United States"]},{"nctId":"NCT04991870","title":"Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM","sponsor":"M.D. Anderson Cancer Center","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":["Cord Blood-derived Expanded Allogeneic Natural Killer Cells"],"startDate":"2023-04-28","firstPosted":"2021-08-05","lastUpdated":"2026-09-04","primaryCompletion":"2027-01-31","enrollment":25,"officials":[{"name":"Shiao-Pei S Weathers, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"M.D. Anderson Cancer Center"}],"conditions":["Recurrent Gliosarcoma","Recurrent Supratentorial Glioblastoma","Supratentorial Gliosarcoma"],"siteCountries":["United States"]},{"nctId":"NCT02981940","title":"A Study of Abemaciclib in Recurrent Glioblastoma","sponsor":"Dana-Farber Cancer Institute","sponsorClass":"OTHER","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Abemaciclib"],"startDate":"2017-02-09","firstPosted":"2016-12-05","lastUpdated":"2026-09-04","primaryCompletion":"2024-06-30","resultsFirstPosted":"2025-09-02","enrollment":45,"officials":[{"name":"Ugonma Chukwueke, MD, MPH","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Dana-Farber Cancer Institute"}],"conditions":["Glioblastoma"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT04677049","title":"Study of Niacin in Glioblastoma","sponsor":"AHS Cancer Control Alberta","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Niacin CRT"],"startDate":"2021-03-18","firstPosted":"2020-12-21","lastUpdated":"2026-09-03","primaryCompletion":"2027-12","enrollment":59,"officials":[{"name":"Gloria Roldan Urgoiti, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Tom Baker Cancer Centre/Arthur J.E. Child Comprehensive Cancer Centre"}],"conditions":["Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype"],"siteCountries":["Canada"]},{"nctId":"NCT03657576","title":"Trial of C134 in Patients With Recurrent GBM","acronym":"C134-HSV-1","sponsor":"University of Alabama at Birmingham","sponsorClass":"OTHER","phases":["PHASE1"],"status":"COMPLETED","interventions":["C134"],"startDate":"2019-09-23","firstPosted":"2018-09-05","lastUpdated":"2026-09-03","primaryCompletion":"2024-10-25","resultsFirstPosted":"2025-07-03","enrollment":19,"officials":[{"name":"James Markert, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of Alabama at Birmingham"}],"conditions":["Glioblastoma Multiforme of Brain","Anaplastic Astrocytoma of Brain","Gliosarcoma of Brain"],"siteCountries":["United States"]},{"nctId":"NCT02337686","title":"Pembrolizumab in Treating Patients With Recurrent Glioblastoma","sponsor":"M.D. Anderson Cancer Center","sponsorClass":"OTHER","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Pembrolizumab"],"startDate":"2015-04-28","firstPosted":"2015-01-14","lastUpdated":"2026-09-03","primaryCompletion":"2017-05-24","resultsFirstPosted":"2023-01-11","enrollment":18,"officials":[{"name":"Vinay Puduvalli, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"M.D. Anderson Cancer Center"}],"conditions":["Recurrent Glioblastoma","Recurrent Gliosarcoma"],"siteCountries":["United States"]},{"nctId":"NCT06161974","title":"Study of Olutasidenib and Temozolomide in HGG","sponsor":"Rigel Pharmaceuticals","sponsorClass":"INDUSTRY","phases":["PHASE2"],"status":"RECRUITING","interventions":["Olutasidenib + TMZ"],"startDate":"2025-02-01","firstPosted":"2023-12-08","lastUpdated":"2026-09-01","primaryCompletion":"2029-06","enrollment":60,"officials":[{"name":"Santosh Valvi, FRACP, MSc","role":"STUDY_CHAIR","affiliation":"Perth Children's Hospital"},{"name":"Nicholas G Gottardo, MB FRACP PhD","role":"STUDY_CHAIR","affiliation":"Perth Children's Hospital"},{"name":"Michael J Fisher, MD","role":"STUDY_CHAIR","affiliation":"Children's Hospital of Philadelphia"},{"name":"Maryam Fouladi, MD","role":"STUDY_CHAIR","affiliation":"Nationwide Children's Hospital"}],"conditions":["High Grade Glioma","Astrocytoma","Astrocytoma, Grade III","Astrocytoma, Grade IV","Diffuse Intrinsic Pontine Glioma","WHO Grade III Glioma","WHO Grade IV Glioma","Metastatic Brain Tumor","Diffuse Midline Glioma, H3 K27M-Mutant","Thalamus Tumor","Spinal Tumor","IDH1 Mutation","IDH1 R132","IDH1 R132C","IDH1 R132H","IDH1 R132S","IDH1 R132G","IDH1 R132L","Oligodendroglioma"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","Australia","Australia","Australia","Canada","Canada","Germany","Netherlands","New Zealand","United Kingdom"]},{"nctId":"NCT05226494","title":"Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma","sponsor":"NanoPharmaceuticals LLC","sponsorClass":"INDUSTRY","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["fb-PMT"],"startDate":"2022-06-23","firstPosted":"2022-02-07","lastUpdated":"2026-08-31","primaryCompletion":"2027-06","enrollment":34,"officials":[{"name":"Nicholas Blondin, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Yale University"}],"conditions":["Glioma, Malignant"],"siteCountries":["United States"]},{"nctId":"NCT04201873","title":"Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma","sponsor":"Jonsson Comprehensive Cancer Center","sponsorClass":"OTHER","phases":["PHASE1"],"status":"COMPLETED","interventions":["Dendritic Cell Tumor Cell Lysate Vaccine","Pembrolizumab","Poly ICLC"],"startDate":"2020-01-08","firstPosted":"2019-12-17","lastUpdated":"2026-08-31","primaryCompletion":"2026-08-13","enrollment":46,"officials":[{"name":"Timothy F Cloughesy","role":"PRINCIPAL_INVESTIGATOR","affiliation":"UCLA / Jonsson Comprehensive Cancer Center"}],"conditions":["Recurrent Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT02142803","title":"TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors","sponsor":"National Cancer Institute (NCI)","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Bevacizumab","Sapanisertib"],"startDate":"2014-05-20","firstPosted":"2014-05-20","lastUpdated":"2026-08-28","primaryCompletion":"2020-12-31","resultsFirstPosted":"2023-10-04","enrollment":50,"officials":[{"name":"Lakshmi Nayak","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Dana-Farber Cancer Institute"}],"conditions":["Adult Glioblastoma","Endometrial Clear Cell Adenocarcinoma","Endometrial Serous Adenocarcinoma","Ovarian Clear Cell Cystadenocarcinoma","Ovarian Endometrioid Adenocarcinoma","Ovarian Mucinous Cystadenocarcinoma","Ovarian Serous Cystadenocarcinoma","Recurrent Fallopian Tube Carcinoma","Recurrent Malignant Uterine Corpus Neoplasm","Recurrent Ovarian Carcinoma","Recurrent Primary Peritoneal Carcinoma","Solid Neoplasm","Stage IIIA Fallopian Tube Cancer AJCC v7","Stage IIIA Ovarian Cancer AJCC v6 and v7","Stage IIIA Primary Peritoneal Cancer AJCC v7","Stage IIIB Fallopian Tube Cancer AJCC v7","Stage IIIB Ovarian Cancer AJCC v6 and v7","Stage IIIB Primary Peritoneal Cancer AJCC v7","Stage IIIC Fallopian Tube Cancer AJCC v7","Stage IIIC Ovarian Cancer AJCC v6 and v7","Stage IIIC Primary Peritoneal Cancer AJCC v7","Stage IV Fallopian Tube Cancer AJCC v6 and v7","Stage IV Ovarian Cancer AJCC v6 and v7","Stage IV Primary Peritoneal Cancer AJCC v7"],"siteCountries":["United States","United States","United States"]},{"nctId":"NCT07791264","title":"FPS-ZM1 With or Without Dexamethasone for Controlling Post Operative Cerebral Edema in Patients With Glioblastoma","sponsor":"City of Hope Medical Center","sponsorClass":"OTHER","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","interventions":["Dexamethasone","RAGE Antagonist FPS-ZM1"],"startDate":"2027-02-17","firstPosted":"2026-08-27","lastUpdated":"2026-08-27","primaryCompletion":"2028-08-28","enrollment":24,"officials":[{"name":"Jana L Portnow","role":"PRINCIPAL_INVESTIGATOR","affiliation":"City of Hope Medical Center"}],"conditions":["Glioblastoma","Malignant Glioma","Recurrent Glioblastoma","Recurrent Malignant Glioma"],"siteCountries":["United States"]},{"nctId":"NCT07789379","title":"Adebrelimab Plus Temozolomide ± Hyperbaric Oxygen for Primary Glioblastoma","sponsor":"Wei Jiang","sponsorClass":"OTHER","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","interventions":["Adebrelimab","Temozolomide"],"startDate":"2026-10-01","firstPosted":"2026-08-27","lastUpdated":"2026-08-27","primaryCompletion":"2028-10-01","enrollment":94,"officials":[],"conditions":["Glioblastoma"]},{"nctId":"NCT05236036","title":"Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma","sponsor":"Northwestern University","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Mycophenolate Mofetil","Temozolomide"],"startDate":"2022-08-08","firstPosted":"2022-02-11","lastUpdated":"2026-08-26","primaryCompletion":"2029-01-03","enrollment":86,"officials":[{"name":"Priya U Kumthekar, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Northwestern University"}],"conditions":["Astrocytoma","Glioblastoma","Glioblastoma, IDH-Wildtype","MGMT-Unmethylated Glioblastoma","Recurrent Glioblastoma"],"siteCountries":["United States","United States","United States"]},{"nctId":"NCT05039281","title":"Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma","sponsor":"M.D. Anderson Cancer Center","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Atezolizumab","Cabozantinib"],"startDate":"2022-09-23","firstPosted":"2021-09-09","lastUpdated":"2026-08-25","primaryCompletion":"2027-12-31","enrollment":47,"officials":[{"name":"Shiao-Pei S Weathers","role":"PRINCIPAL_INVESTIGATOR","affiliation":"M.D. Anderson Cancer Center"}],"conditions":["Recurrent Glioblastoma","Recurrent Gliosarcoma"],"siteCountries":["United States"]},{"nctId":"NCT07579208","title":"A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma","sponsor":"M.D. Anderson Cancer Center","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":["NK Cells","NK Cells"],"startDate":"2026-08-21","firstPosted":"2026-05-12","lastUpdated":"2026-08-25","primaryCompletion":"2028-07-30","enrollment":36,"officials":[{"name":"Chibawany Ene, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"M.D. Anderson Cancer Center"}],"conditions":["Phase 1","NK Cell","IL13Ra","EGFRvIII","Chimera Antigen Receptor (CAR)","NR3C1","Recurrent Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT05463848","title":"Surgical Pembro +/- Olaparib w TMZ for rGBM","sponsor":"L. Nicolas Gonzalez Castro, MD, PhD","sponsorClass":"OTHER","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Pembrolizumab","Olaparib","Temozolomide"],"startDate":"2022-10-21","firstPosted":"2022-07-19","lastUpdated":"2026-08-24","primaryCompletion":"2026-05-19","enrollment":52,"officials":[{"name":"Luis N Gonzalez Castro, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Dana-Farber Cancer Institute"}],"conditions":["Glioblastoma","Recurrent Glioblastoma"],"siteCountries":["United States","United States","United States","United States"]},{"nctId":"NCT07209241","title":"Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM","sponsor":"University of Pennsylvania","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["CART-EGFR-IL13Ra2 T cells"],"startDate":"2025-12-03","firstPosted":"2025-10-06","lastUpdated":"2026-08-21","primaryCompletion":"2042-11-01","enrollment":12,"officials":[{"name":"Stephen Bagley, MD, MSCE","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of Pennsylvania"}],"conditions":["Recurrent Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT00268385","title":"Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas","sponsor":"National Cancer Institute (NCI)","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Temozolomide","Vorinostat"],"startDate":"2005-12-16","firstPosted":"2005-12-22","lastUpdated":"2026-08-20","primaryCompletion":"2018-10-18","enrollment":83,"officials":[{"name":"Patrick Y Wen","role":"PRINCIPAL_INVESTIGATOR","affiliation":"National Cancer Institute (NCI)"}],"conditions":["Adult Anaplastic Astrocytoma","Adult Anaplastic Oligodendroglioma","Adult Giant Cell Glioblastoma","Adult Glioblastoma","Adult Gliosarcoma","Adult Mixed Glioma","Recurrent Adult Brain Neoplasm"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT07762716","title":"Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy","sponsor":"BreakBio Corp","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","interventions":["BreakVax","Ipilimumab 2.5 mg","Pembrolizumab","Temozolomide (TMZ)","Losartan and aspirin"],"startDate":"2026-09","firstPosted":"2026-08-13","lastUpdated":"2026-08-19","primaryCompletion":"2030-09","enrollment":10,"officials":[],"conditions":["Glioblastoma (GBM)"],"siteCountries":["United States"]},{"nctId":"NCT02977780","title":"INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)","sponsor":"David Reardon, MD","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":["Temozolomide","Neratinib","QBS10072S","Abemaciclib","CC-115"],"startDate":"2017-02-09","firstPosted":"2016-11-30","lastUpdated":"2026-08-19","primaryCompletion":"2028-02-01","enrollment":460,"officials":[{"name":"David Y Reardon, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Dana-Farber Cancer Institute"}],"conditions":["Glioblastoma"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT04903795","title":"BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma","acronym":"BRiTE","sponsor":"Mustafa Khasraw, MBChB, MD, FRCP, FRACP","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":["hEGFRvIII-CD3 (BRiTE)"],"startDate":"2026-08-17","firstPosted":"2021-05-27","lastUpdated":"2026-08-18","primaryCompletion":"2027-12-30","enrollment":18,"officials":[{"name":"Mustafa Khasraw, MBChB, MD, FRCP, FRACP","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Duke University"}],"conditions":["Newly Diagnosed Glioblastoma","Recurrent Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT06319027","title":"Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial","acronym":"GABLE","sponsor":"ECOG-ACRIN Cancer Research Group","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":["Gadolinium-Chelate"],"startDate":"2024-04-11","firstPosted":"2024-03-19","lastUpdated":"2026-08-18","primaryCompletion":"2027-05-31","enrollment":100,"officials":[{"name":"Daniel P Barboriak","role":"PRINCIPAL_INVESTIGATOR","affiliation":"ECOG-ACRIN Cancer Research Group"}],"conditions":["Glioblastoma, IDH-Wildtype"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT06492486","title":"Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow","acronym":"GLADIATOR","sponsor":"Tata Memorial Centre","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":[],"startDate":"2026-07-27","firstPosted":"2024-07-09","lastUpdated":"2026-08-17","primaryCompletion":"2028-07-30","enrollment":60,"officials":[{"name":"Archya Dasgupta","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Tata Memorial Centre"}],"conditions":["Diffuse Glioma","Glioblastoma","Adaptive Radiotherapy","Artificial Intelligence"],"siteCountries":["India"]},{"nctId":"NCT05607407","title":"Methimazole in Patients With Progressive Glioblastoma","sponsor":"Case Comprehensive Cancer Center","sponsorClass":"OTHER","phases":["PHASE2"],"status":"SUSPENDED","interventions":["Methimazole"],"startDate":"2023-01-30","firstPosted":"2022-11-07","lastUpdated":"2026-08-17","primaryCompletion":"2026-09","whyStopped":"On hold per study team","enrollment":19,"officials":[{"name":"David Peereboom, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center"}],"conditions":["Glioblastoma","Glioma"],"siteCountries":["United States"]},{"nctId":"NCT06894979","title":"Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma","sponsor":"Children's Oncology Group","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["ATM Kinase Inhibitor AZD1390"],"startDate":"2025-06-18","firstPosted":"2025-03-26","lastUpdated":"2026-08-17","primaryCompletion":"2028-03-31","enrollment":54,"officials":[{"name":"Erin K Barr","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Pediatric Early Phase Clinical Trial Network"}],"conditions":["Childhood Astrocytoma","Childhood Diffuse Intrinsic Pontine Glioma","Childhood Diffuse Midline Glioma","Childhood Glioblastoma","Childhood Malignant Glioma"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT06632236","title":"5G-EMERALD: Amivantamab in Malignant Brain Tumours","acronym":"5G-EMERALD","sponsor":"Institute of Cancer Research, United Kingdom","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Amivantamab"],"startDate":"2024-10-09","firstPosted":"2024-10-09","lastUpdated":"2026-08-17","primaryCompletion":"2027-07-01","enrollment":12,"officials":[{"name":"Juanita Lopez, MD, PhD","role":"STUDY_DIRECTOR","affiliation":"National Health Service, UK"}],"conditions":["Malignant Primary Gliomas","Glioblastoma Multiform (Grade IV Astrocytoma)","Diffuse Hemispheric Glioma, H3 G34-Mutant","Glioblastoma Multiforme (GBM)"],"siteCountries":["United Kingdom","United Kingdom"]},{"nctId":"NCT05095376","title":"Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma","sponsor":"NRG Oncology","sponsorClass":"OTHER","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Lomustine","Temozolomide"],"startDate":"2022-03-28","firstPosted":"2021-10-27","lastUpdated":"2026-08-17","primaryCompletion":"2026-02-12","enrollment":265,"officials":[{"name":"Fabio M Iwamoto","role":"PRINCIPAL_INVESTIGATOR","affiliation":"NRG Oncology"}],"conditions":["Glioblastoma","Gliosarcoma"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","Canada","Canada"]},{"nctId":"NCT06186401","title":"Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells","sponsor":"Hideho Okada, MD, PhD","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":["E-SYNC T Cells","Cyclophosphamide (non-investigational)","Fludarabine (non-investigational)"],"startDate":"2024-04-30","firstPosted":"2024-01-02","lastUpdated":"2026-08-13","primaryCompletion":"2027-12-31","enrollment":20,"officials":[{"name":"Jennifer Clarke, MD, MPH","role":"STUDY_CHAIR","affiliation":"University of California, San Francisco"}],"conditions":["EGFR Gene Mutation","Glioblastoma","MGMT-Unmethylated Glioblastoma","Recurrent Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT05450744","title":"131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)","acronym":"IPAX-2","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","sponsorClass":"INDUSTRY","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["131I-IPA"],"startDate":"2023-04-01","firstPosted":"2022-07-11","lastUpdated":"2026-08-13","primaryCompletion":"2027-06","enrollment":12,"officials":[],"conditions":["Neoplastic Disease","Glioblastoma","Glioblastoma Multiforme"],"siteCountries":["Australia","Australia","Australia","Austria","Netherlands"]},{"nctId":"NCT06614855","title":"A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma","sponsor":"James Markert, MD","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["C134","C134"],"startDate":"2025-06-02","firstPosted":"2024-09-26","lastUpdated":"2026-08-13","primaryCompletion":"2027-01-01","enrollment":12,"officials":[],"conditions":["Glioblastoma","Glioblastoma (GBM)","Astrocytoma","Astrocytoma, Grade III","Astrocytoma, Grade IV","Gliosarcoma, Adult","Gliosarcoma of Brain"],"siteCountries":["United States"]},{"nctId":"NCT03389802","title":"Phase I Study of APX005M in Pediatric Central Nervous System Tumors","sponsor":"Pediatric Brain Tumor Consortium","sponsorClass":"OTHER","phases":["PHASE1"],"status":"COMPLETED","interventions":["APX005M treatment for recurrent or refractory primary malignant CNS tumor patients","APX005M treatment for newly diagnosed DIPG patients"],"startDate":"2018-03-01","firstPosted":"2018-01-04","lastUpdated":"2026-08-13","primaryCompletion":"2023-09-30","resultsFirstPosted":"2024-10-10","enrollment":32,"officials":[{"name":"Ira Dunkel","role":"STUDY_CHAIR","affiliation":"Memorial Sloan Kettering Cancer Center"}],"conditions":["Glioblastoma Multiforme","High-grade Astrocytoma Not Otherwise Specified (NOS)","CNS Primary Tumor, Not Otherwise Specified (NOS)","Ependymoma, Not Otherwise Specified (NOS)","Diffuse Intrinsic Pontine Gliomas (DIPG)","Medulloblastoma"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT06147505","title":"XS005 Injection Combined With Stupp Regimen for Adjuvant Chemotherapy in Subjects With Primary Glioblastoma(GBM)","sponsor":"Dushu Lake Hospital Affiliated to Soochow University","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["XS005 Injection"],"startDate":"2023-10-29","firstPosted":"2023-11-27","lastUpdated":"2026-08-13","primaryCompletion":"2026-08-31","enrollment":13,"officials":[],"conditions":["Tumor"],"siteCountries":["China"]},{"nctId":"NCT07758062","title":"Levetiracetam Extended-Release Plus Stupp Protocol for Hypoxic IDH-Wildtype Glioblastoma","acronym":"ELITE","sponsor":"Tianjin Medical University General Hospital","sponsorClass":"OTHER","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","interventions":["Levetiracetam Extended-Release Granules","Temozolomide (TMZ)"],"startDate":"2026-09-01","firstPosted":"2026-08-11","lastUpdated":"2026-08-11","primaryCompletion":"2029-08-01","enrollment":140,"officials":[],"conditions":["Glioblastoma"],"siteCountries":["China"]},{"nctId":"NCT07100730","title":"Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma","acronym":"IPAX BrIGHT","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","sponsorClass":"INDUSTRY","phases":["PHASE3"],"status":"RECRUITING","interventions":["TLX-101-Tx + Lomustine"],"startDate":"2025-11-02","firstPosted":"2025-08-03","lastUpdated":"2026-08-11","primaryCompletion":"2027-07","enrollment":50,"officials":[],"conditions":["Neoplastic Disease","Glioblastoma","Glioblastoma (GBM)","Glioblastoma Multiform","Glioblastoma Multiforme, Adult","Glioblastoma Multiforme (GBM) WHO Grade IV"],"siteCountries":["Australia","Australia","Australia","Australia","Austria","Belgium","Belgium","Netherlands","Netherlands"]},{"nctId":"NCT07754734","title":"STUPP Regimen With or Without Lenvatinib for Newly Diagnosed Glioblastoma With MGMT Promoter Methylation","sponsor":"Dongguan People's Hospital","sponsorClass":"OTHER","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","interventions":["Lenvatinib","TMZ (Temozolomide)"],"startDate":"2026-08-10","firstPosted":"2026-08-10","lastUpdated":"2026-08-10","primaryCompletion":"2029-07-31","enrollment":138,"officials":[],"conditions":["Glioma","Glioblastoma (GBM)","MGMT-Methylated Glioblastoma"]},{"nctId":"NCT07501559","title":"A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)","sponsor":"Jecho Biopharmaceuticals Co., Ltd.","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["JL15003Injection"],"startDate":"2026-06-17","firstPosted":"2026-03-30","lastUpdated":"2026-08-10","primaryCompletion":"2030-04","enrollment":40,"officials":[],"conditions":["Recurrent Glioblastoma Multiforme(GBM)"],"siteCountries":["China"]},{"nctId":"NCT04197934","title":"WSD0922-FU for Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases","sponsor":"Mayo Clinic","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["EGFR/EGFRvIII Inhibitor WSD0922-FU"],"startDate":"2019-12-20","firstPosted":"2019-12-13","lastUpdated":"2026-08-10","primaryCompletion":"2022-10-30","enrollment":56,"officials":[{"name":"Sani H. Kizilbash, M.D., M.P.H.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Mayo Clinic in Rochester"}],"conditions":["Anaplastic Astrocytoma, IDH-Wildtype","Glioblastoma, IDH-Wildtype","Metastatic Lung Non-Small Cell Carcinoma","Metastatic Malignant Neoplasm in the Central Nervous System","Stage IV Lung Cancer AJCC v8"],"siteCountries":["United States","United States","United States"]},{"nctId":"NCT04469075","title":"Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields","sponsor":"Memorial Sloan Kettering Cancer Center","sponsorClass":"OTHER","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Clindamycin Phosphate","Triamcinolone Acetonide"],"startDate":"2020-07-09","firstPosted":"2020-07-13","lastUpdated":"2026-08-10","primaryCompletion":"2027-07","enrollment":48,"officials":[{"name":"Alina Markova, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Memorial Sloan Kettering Cancer Center"}],"conditions":["Glioblastoma","Recurrent Glioblastoma","Skin Toxicity"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT07751744","title":"Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma","sponsor":"Jubilant Therapeutics Inc.","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","interventions":["JBI-778"],"startDate":"2028-04-01","firstPosted":"2026-08-07","lastUpdated":"2026-08-07","primaryCompletion":"2030-03-31","enrollment":113,"officials":[],"conditions":["Brain Metastases From Solid Tumors","Leptomeningeal Disease","High Grade Glioma (HGG)","Glioblastoma (GBM)"]},{"nctId":"NCT02761070","title":"Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III","acronym":"RE-GEND","sponsor":"Kyorin University","sponsorClass":"OTHER","phases":["PHASE3"],"status":"COMPLETED","interventions":["Temozolomide","Bevacizumab"],"startDate":"2016-07-11","firstPosted":"2016-05-04","lastUpdated":"2026-08-07","primaryCompletion":"2025-04-17","enrollment":146,"officials":[{"name":"Motoo Nagane, M.D., Ph.D.","role":"STUDY_CHAIR","affiliation":"Kyorin University Faculty of Medicine, Department of Neurosurgery"}],"conditions":["Glioblastoma","Recurrence","Progression"],"siteCountries":["Japan","Japan","Japan","Japan","Japan","Japan","Japan","Japan","Japan","Japan","Japan","Japan","Japan","Japan","Japan","Japan","Japan","Japan","Japan","Japan","Japan","Japan","Japan","Japan","Japan","Japan","Japan","Japan","Japan","Japan","Japan","Japan","Japan","Japan","Japan","Japan","Japan"]},{"nctId":"NCT07733674","title":"Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)","acronym":"RMX-VH","sponsor":"Radiomedix, Inc.","sponsorClass":"INDUSTRY","phases":["PHASE1"],"status":"RECRUITING","interventions":["203Pb-RMX-VHPIB injection"],"startDate":"2026-08-15","firstPosted":"2026-07-29","lastUpdated":"2026-08-07","primaryCompletion":"2026-12-31","enrollment":20,"officials":[{"name":"Ebrahim Delpassand, MD, FACNM","role":"STUDY_CHAIR","affiliation":"Radiomedix, Inc."}],"conditions":["Glioblastoma Multiforme (GBM)","Pancreatic Ductal Adenocarcinoma (PDAC)"],"siteCountries":["United States"]},{"nctId":"NCT03862430","title":"A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM","acronym":"RESTORE","sponsor":"NuvOx LLC","sponsorClass":"INDUSTRY","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["NanO2TM","Placebo Saline Infusion"],"startDate":"2023-03-31","firstPosted":"2019-03-05","lastUpdated":"2026-08-06","primaryCompletion":"2027-06-30","enrollment":87,"officials":[],"conditions":["Glioblastoma Multiforme"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT01837862","title":"A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas","sponsor":"Julie Krystal","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Mebendazole","Vincristine","Carboplatin","Temozolomide","Bevacizumab","Irinotecan"],"startDate":"2013-10-22","firstPosted":"2013-04-23","lastUpdated":"2026-08-06","primaryCompletion":"2027-03","enrollment":10,"officials":[{"name":"Julie Krystal, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Northwell Health"}],"conditions":["Pilomyxoid Astrocytoma","Pilocytic Astrocytoma","Glioma, Astrocytic","Optic Nerve Glioma","Pleomorphic Xanthoastrocytoma","Glioblastoma Multiforme","Anaplastic Astrocytoma","Gliosarcoma","Diffuse Intrinsic Pontine Glioma","DIPG","Low-grade Glioma","Brainstem Glioma"],"siteCountries":["United States"]},{"nctId":"NCT05565118","title":"Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression","sponsor":"Case Comprehensive Cancer Center","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":[],"startDate":"2024-04-09","firstPosted":"2022-10-04","lastUpdated":"2026-08-06","primaryCompletion":"2026-12","enrollment":10,"officials":[{"name":"Jennifer Yu, MD, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center"}],"conditions":["High Grade Glioma","Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT07003542","title":"A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas","sponsor":"Case Comprehensive Cancer Center","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":["Sitagliptin"],"startDate":"2026-03-16","firstPosted":"2025-06-04","lastUpdated":"2026-08-06","primaryCompletion":"2027-06","enrollment":48,"officials":[{"name":"David Peereboom, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Case Comprehensive Cancer Center, Cleveland Clinic Taussig Cancer Institute"}],"conditions":["Glioblastoma","Brain Tumor"],"siteCountries":["United States"]},{"nctId":"NCT05708352","title":"A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment","sponsor":"Cedars-Sinai Medical Center","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":[],"startDate":"2023-06-27","firstPosted":"2023-02-01","lastUpdated":"2026-08-05","primaryCompletion":"2028-09-30","enrollment":170,"officials":[{"name":"Jethro Hu, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Cedars-Sinai Medical Center"}],"conditions":["Glioblastoma Multiforme"],"siteCountries":["United States","United States","United States","United States","United States"]},{"nctId":"NCT03643549","title":"Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17)","acronym":"BORTEM-17","sponsor":"Haukeland University Hospital","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["Bortezomib and Temozolomide Phase IB","Bortezomib and Temozolomide Phase II"],"startDate":"2018-08-30","firstPosted":"2018-08-22","lastUpdated":"2026-08-04","primaryCompletion":"2026-12-30","enrollment":63,"officials":[{"name":"Dorota Goplen, MD, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Haukeland University Hospital"}],"conditions":["Glioblastoma"],"siteCountries":["Norway","Norway"]},{"nctId":"NCT03868943","title":"Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma","acronym":"JAZZ","sponsor":"Wake Forest University Health Sciences","sponsorClass":"OTHER","phases":["PHASE2"],"status":"TERMINATED","interventions":["Soliramfetol"],"startDate":"2021-01-27","firstPosted":"2019-03-11","lastUpdated":"2026-08-03","primaryCompletion":"2021-11-22","resultsFirstPosted":"2025-10-21","whyStopped":"Axsome has conducted a review of the ongoing IST program and are unable to continue supporting this study","enrollment":2,"officials":[{"name":"Roy Strowd, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Wake Forest University Health Sciences"}],"conditions":["Glioma","Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT06069726","title":"A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial","acronym":"MOAB","sponsor":"Duke University","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":["Atezolizumab"],"startDate":"2024-03-21","firstPosted":"2023-10-06","lastUpdated":"2026-07-31","primaryCompletion":"2028-01-01","enrollment":80,"officials":[{"name":"Mustafa Khasraw, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Duke University"}],"conditions":["Recurrent Glioblastoma"],"siteCountries":["United States","United States","United States","United States"]},{"nctId":"NCT05781321","title":"Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study","sponsor":"Mayo Clinic","sponsorClass":"OTHER","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Fluorodopa F 18","Temozolomide"],"startDate":"2023-03-23","firstPosted":"2023-03-23","lastUpdated":"2026-07-30","primaryCompletion":"2026-11-30","enrollment":170,"officials":[{"name":"William G. Breen, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Mayo Clinic in Rochester"},{"name":"Roman O. Kowalchuk, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Mayo Clinic in Rochester"}],"conditions":["Glioblastoma"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT07735819","title":"Positron Emission Tomography/Computed Tomography (PET/CT) Imaging in Patients Diagnosed With a Glioma","sponsor":"Barbara Ann Karmanos Cancer Institute","sponsorClass":"OTHER","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","interventions":["Minocycline 200mg/day"],"startDate":"2026-09","firstPosted":"2026-07-30","lastUpdated":"2026-07-30","primaryCompletion":"2031-06-30","enrollment":61,"officials":[{"name":"Csaba Juhasz, M.D.,Ph.D.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Wayne State University"}],"conditions":["Low Grade Glioma","Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT01339052","title":"Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma","sponsor":"L. Nicolas Gonzalez Castro, MD, PhD","sponsorClass":"OTHER","phases":["PHASE2"],"status":"COMPLETED","interventions":["BKM120"],"startDate":"2011-09","firstPosted":"2011-04-20","lastUpdated":"2026-07-27","primaryCompletion":"2016-10","resultsFirstPosted":"2017-06-14","enrollment":65,"officials":[{"name":"Luis N Gonzalez Castro, M.D. PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Dana-Farber Cancer Institute"}],"conditions":["Glioblastoma"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT05256290","title":"Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations","sponsor":"Black Diamond Therapeutics, Inc.","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["silevertinib (BDTX-1535) monotherapy"],"startDate":"2022-03-31","firstPosted":"2022-02-25","lastUpdated":"2026-07-22","primaryCompletion":"2025-11-03","enrollment":200,"officials":[{"name":"Black Diamond Therapeutics","role":"STUDY_DIRECTOR","affiliation":"Black Diamond Therapeutics"}],"conditions":["Non-Small Cell Lung Cancer","Advanced Non-Small Cell Squamous Lung Cancer","Metastatic Lung Non-Small Cell Carcinoma","Metastatic Lung Cancer","NSCLC","Advanced Lung Carcinoma","Epidermal Growth Factor Receptor C797S","Epidermal Growth Factor Receptor G719X","EGF-R Positive Non-Small Cell Lung Cancer","EGFR-TKI Resistant Mutation"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT04521686","title":"Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations","sponsor":"Eli Lilly and Company","sponsorClass":"INDUSTRY","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["LY3410738","Gemcitabine","Cisplatin","Durvalumab"],"startDate":"2020-10-01","firstPosted":"2020-08-20","lastUpdated":"2026-07-22","primaryCompletion":"2023-07-17","enrollment":200,"officials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","role":"STUDY_DIRECTOR","affiliation":"Eli Lilly and Company"}],"conditions":["Cholangiocarcinoma","Chondrosarcoma","Glioma","Any Solid Tumor"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","Australia","France","France","Hong Kong","Japan","Japan","Japan","Japan","Japan","Singapore","South Korea","South Korea","Spain","Spain","Taiwan","Taiwan"]},{"nctId":"NCT05879250","title":"WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma","sponsor":"Northwestern University","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":["STAT3 Inhibitor WP1066"],"startDate":"2024-05-22","firstPosted":"2023-05-30","lastUpdated":"2026-07-22","primaryCompletion":"2027-12-27","enrollment":39,"officials":[{"name":"Amy Heimberger","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Northwestern University"}],"conditions":["Glioblastoma, IDH-Wildtype","MGMT-Unmethylated Glioblastoma"],"siteCountries":["United States","United States"]},{"nctId":"NCT06973096","title":"CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy","sponsor":"University of Pennsylvania","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["CART-EGFR-IL13Ra2 cells","Rituximab or Rituximab biosimilar","Fludarabine + Cyclophosphamide combination"],"startDate":"2025-07-18","firstPosted":"2025-05-15","lastUpdated":"2026-07-22","primaryCompletion":"2042-07","enrollment":9,"officials":[{"name":"Stephen Bagley, MD, MSCE","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of Pennsylvania"}],"conditions":["Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT06672575","title":"A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma","sponsor":"M.D. Anderson Cancer Center","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["Ivonescimab"],"startDate":"2025-01-30","firstPosted":"2024-11-04","lastUpdated":"2026-07-21","primaryCompletion":"2028-01-31","enrollment":45,"officials":[{"name":"Anuj D Patel, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"M.D. Anderson Cancer Center"}],"conditions":["Glioblastoma"],"siteCountries":["United States","United States"]},{"nctId":"NCT07715097","title":"Survivin-Targeted Dendritic Cell (DC) Cell Injection for Newly Diagnosed Glioblastoma","sponsor":"Beijing Tricision Biotherapeutics Inc","sponsorClass":"INDUSTRY","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","interventions":["Survivin-targeted DC Cell Injection"],"startDate":"2026-09-30","firstPosted":"2026-07-20","lastUpdated":"2026-07-20","primaryCompletion":"2028-09-30","enrollment":30,"officials":[],"conditions":["Glioblastoma"]},{"nctId":"NCT04900792","title":"A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma","acronym":"XACT-Fe-GBM-01","sponsor":"Bryan Allen","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Ferumoxytol injection","Pharmacological ascorbate","Temozolomide"],"startDate":"2023-02-28","firstPosted":"2021-05-25","lastUpdated":"2026-07-20","primaryCompletion":"2025-05-13","resultsFirstPosted":"2026-07-20","enrollment":16,"officials":[{"name":"John M. Buatti, MD","role":"STUDY_DIRECTOR","affiliation":"University of Iowa"}],"conditions":["Glioblastoma","Glioblastoma Multiforme"],"siteCountries":["United States"]},{"nctId":"NCT06177964","title":"Lerapolturev (PVSRIPO) in GBM","sponsor":"Darell Bigner","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":["Lerapolturev","Lomustine Pill"],"startDate":"2024-07-15","firstPosted":"2023-12-20","lastUpdated":"2026-07-20","primaryCompletion":"2029-02","enrollment":92,"officials":[{"name":"Madison Shoaf, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Duke University"}],"conditions":["Recurrent Supratentorial Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT07225621","title":"Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma","sponsor":"Alpheus Medical, Inc.","sponsorClass":"INDUSTRY","phases":["PHASE2"],"status":"RECRUITING","interventions":["5-ALA HCl + LIDU SDT","Placebo + Sham SDT"],"startDate":"2026-01-28","firstPosted":"2025-11-06","lastUpdated":"2026-07-17","primaryCompletion":"2027-12","enrollment":103,"officials":[],"conditions":["Glioblastoma","GBM"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT07707973","title":"Nimotuzumab Combined With the Stupp Regimen for Postoperative Residual Glioblastoma","acronym":"Nimotuzumab","sponsor":"Tianjin First Central Hospital","sponsorClass":"OTHER","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","interventions":["nimotuzumab","Temozolomide"],"startDate":"2026-07-03","firstPosted":"2026-07-16","lastUpdated":"2026-07-16","primaryCompletion":"2028-01-03","enrollment":50,"officials":[],"conditions":["Glioma, Malignant"]},{"nctId":"NCT04623931","title":"Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas","sponsor":"M.D. Anderson Cancer Center","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":["Temozolomide"],"startDate":"2020-01-30","firstPosted":"2020-11-10","lastUpdated":"2026-07-16","primaryCompletion":"2026-12-31","enrollment":40,"officials":[{"name":"Debra N Yeboa","role":"PRINCIPAL_INVESTIGATOR","affiliation":"M.D. Anderson Cancer Center"}],"conditions":["Anaplastic Astrocytoma, IDH-Wildtype","Anaplastic Oligoastrocytoma","Anaplastic Oligodendroglioma","Diffuse Astrocytoma, IDH-Wildtype","Glioblastoma","Oligoastrocytoma","Oligodendroglioma","WHO Grade II Glioma","WHO Grade III Glioma"],"siteCountries":["United States"]},{"nctId":"NCT05660369","title":"CARv3-TEAM-E T Cells in Glioblastoma","sponsor":"Marcela V. Maus, M.D.,Ph.D.","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":["CARv3-TEAM-E T cells"],"startDate":"2023-03-22","firstPosted":"2022-12-21","lastUpdated":"2026-07-14","primaryCompletion":"2026-09-01","enrollment":21,"officials":[{"name":"William Curry, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Massachusetts General Hospital"}],"conditions":["Glioblastoma","Malignant Glioma","Recurrent Glioblastoma","Recurrent Glioma"],"siteCountries":["United States"]},{"nctId":"NCT04743310","title":"Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System","sponsor":"John Yu","sponsorClass":"OTHER","phases":["PHASE2"],"status":"COMPLETED","interventions":["tozuleristide"],"startDate":"2021-09-30","firstPosted":"2021-02-08","lastUpdated":"2026-07-10","primaryCompletion":"2025-03-06","resultsFirstPosted":"2026-07-10","enrollment":50,"officials":[{"name":"John Yu, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Cedars-Sinai Medical Center"}],"conditions":["Central Nervous System Tumor"],"siteCountries":["United States"]},{"nctId":"NCT04485949","title":"A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma","sponsor":"Imvax","sponsorClass":"INDUSTRY","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["IGV-001 Cell Immunotherapy","Placebo","SOC: Temozolomide"],"startDate":"2023-03-20","firstPosted":"2020-07-24","lastUpdated":"2026-07-09","primaryCompletion":"2027-01","enrollment":99,"officials":[],"conditions":["Glioblastoma"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT06448286","title":"PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glioblastoma","sponsor":"Jonsson Comprehensive Cancer Center","sponsorClass":"OTHER","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","interventions":["Temozolomide"],"startDate":"2026-12-01","firstPosted":"2024-06-07","lastUpdated":"2026-07-07","primaryCompletion":"2030-12-01","enrollment":60,"officials":[{"name":"Kunal S Patel, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"UCLA / Jonsson Comprehensive Cancer Center"}],"conditions":["Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT05835687","title":"Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors","sponsor":"St. Jude Children's Research Hospital","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["B7-H3-CAR T cells"],"startDate":"2023-04-27","firstPosted":"2023-04-28","lastUpdated":"2026-07-06","primaryCompletion":"2026-06-04","enrollment":29,"officials":[{"name":"Christopher DeRenzo, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"St. Jude Children's Research Hospital"},{"name":"Kelsey Bertrand, MD, MSc","role":"PRINCIPAL_INVESTIGATOR","affiliation":"St. Jude Children's Research Hospital"},{"name":"Giedre Krenciute, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"St. Jude Children's Research Hospital"}],"conditions":["Central Nervous System Neoplasms","Atypical Teratoid/Rhabdoid Tumor","Diffuse Midline Glioma, H3 K27M-Mutant","Ependymoma","High Grade Glioma","Glioblastoma","Medulloblastoma"],"siteCountries":["United States"]},{"nctId":"NCT06455189","title":"Magnetic Resonance Fingerprinting Guided Extended Resection in Glioblastomas","sponsor":"Case Comprehensive Cancer Center","sponsorClass":"OTHER","phases":["PHASE1"],"status":"WITHDRAWN","interventions":[],"startDate":"2025-12","firstPosted":"2024-06-12","lastUpdated":"2026-07-01","primaryCompletion":"2029-06-01","whyStopped":"Terminated IRB","enrollment":0,"officials":[{"name":"Chaitra Badve, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center"},{"name":"Tiffany Hodges, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center"}],"conditions":["Glioblastoma","Brain Tumor"],"siteCountries":["United States"]},{"nctId":"NCT05698199","title":"Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)","sponsor":"Immunomic Therapeutics, Inc.","sponsorClass":"INDUSTRY","phases":["PHASE1"],"status":"COMPLETED","interventions":["ITI-1001"],"startDate":"2023-08-21","firstPosted":"2023-01-26","lastUpdated":"2026-07-01","primaryCompletion":"2026-02-11","enrollment":10,"officials":[],"conditions":["Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT06805305","title":"DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)","sponsor":"Diakonos Oncology Corporation","sponsorClass":"INDUSTRY","phases":["PHASE2"],"status":"RECRUITING","interventions":["DOC1021","Temodar (Temozolomide)"],"startDate":"2025-03-17","firstPosted":"2025-02-03","lastUpdated":"2026-07-01","primaryCompletion":"2030-03","enrollment":180,"officials":[],"conditions":["Glioblastoma (GBM)"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT06061809","title":"N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma","sponsor":"ImmunityBio, Inc.","sponsorClass":"INDUSTRY","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Bevacizumab","PD-L1 t-haNK","N-803"],"startDate":"2024-08-07","firstPosted":"2023-09-29","lastUpdated":"2026-07-01","primaryCompletion":"2029-12-31","enrollment":34,"officials":[],"conditions":["Glioblastoma"],"siteCountries":["United States","United States","United States","United States"]},{"nctId":"NCT06388733","title":"A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma","sponsor":"Ivy Brain Tumor Center","sponsorClass":"OTHER","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Niraparib","Temozolomide"],"startDate":"2024-06-19","firstPosted":"2024-04-29","lastUpdated":"2026-07-01","primaryCompletion":"2027-12","enrollment":450,"officials":[{"name":"Nader Sanai, MD","role":"STUDY_CHAIR","affiliation":"Ivy Brain Tumor Center"}],"conditions":["Glioblastoma","GBM","Brain Neoplasms, Adult, Malignant","Brain Tumor"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","Australia","Australia","Australia","Australia","Canada","Canada","Canada","Canada","Canada","France","France","France","France","France","France","France","France","France","France","Germany","Germany","Germany","Germany","Germany","Germany","Germany","Germany","Italy","Italy","Italy","Italy","Italy","Italy","Italy","Italy","Netherlands","Netherlands","Norway","Norway","Spain","Spain","Spain","Spain","Spain","Spain","Spain","Spain","Spain","Spain","Spain","Spain","Switzerland","Switzerland","Switzerland","Switzerland","United Kingdom","United Kingdom","United Kingdom","United Kingdom","United Kingdom","United Kingdom","United Kingdom","United Kingdom"]},{"nctId":"NCT07244835","title":"A Study of DEG6498 in Participants With Solid Tumors","sponsor":"Degron Therapeutics Co.","sponsorClass":"INDUSTRY","phases":["PHASE1"],"status":"RECRUITING","interventions":["DEG6498"],"startDate":"2025-11-13","firstPosted":"2025-11-24","lastUpdated":"2026-06-30","primaryCompletion":"2028-12","enrollment":100,"officials":[],"conditions":["Malignant Neoplasms"],"siteCountries":["China","China","China"]},{"nctId":"NCT05627323","title":"CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma","sponsor":"Chimeric Therapeutics","sponsorClass":"INDUSTRY","phases":["PHASE1"],"status":"TERMINATED","interventions":["CHM-1101 CAR-T cells"],"startDate":"2023-06-06","firstPosted":"2022-11-25","lastUpdated":"2026-06-29","primaryCompletion":"2026-04-30","whyStopped":"IND application withdrawn","enrollment":1,"officials":[],"conditions":["Glioblastoma Multiforme of Brain"],"siteCountries":["United States","United States"]},{"nctId":"NCT05326464","title":"Tofacitinib in Recurrent GBM Patients","sponsor":"University of Texas Southwestern Medical Center","sponsorClass":"OTHER","phases":["PHASE3"],"status":"COMPLETED","interventions":["Tofacitinib 10mg","Temozolomide","Lomustine"],"startDate":"2022-10-07","firstPosted":"2022-04-13","lastUpdated":"2026-06-29","primaryCompletion":"2025-02-18","resultsFirstPosted":"2026-06-29","enrollment":18,"officials":[{"name":"Michael Youssef, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Assistant Professor"}],"conditions":["Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT07284628","title":"Vortioxetine for Newly Diagnosed Glioblastoma","acronym":"ReVoGlio","sponsor":"University of Zurich","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":["Vortioxetine"],"startDate":"2026-06-24","firstPosted":"2025-12-16","lastUpdated":"2026-06-29","primaryCompletion":"2029-06","enrollment":78,"officials":[],"conditions":["Glioblastoma"],"siteCountries":["Switzerland"]},{"nctId":"NCT00209989","title":"Phase II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme","sponsor":"Institut Claudius Regaud","sponsorClass":"OTHER","phases":["PHASE2"],"status":"COMPLETED","interventions":["Zarnestra"],"startDate":"2005-10","firstPosted":"2005-09-21","lastUpdated":"2026-06-26","primaryCompletion":"2011-06","enrollment":27,"officials":[{"name":"Elizabeth MOYAL, Dr","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Institut Claudius Regaud"}],"conditions":["Glioblastoma Multiforme"],"siteCountries":["France","France"]},{"nctId":"NCT06157541","title":"T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma","acronym":"TCaP","sponsor":"Queensland Institute of Medical Research","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Allogeneic cytomegalovirus-specific T cells","Pembrolizumab"],"startDate":"2024-02-08","firstPosted":"2023-12-06","lastUpdated":"2026-06-26","primaryCompletion":"2025-10-02","enrollment":58,"officials":[{"name":"Rajiv Khanna, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"QIMR Berghofer Medical Research Institute"}],"conditions":["Glioblastoma Multiforme","Astrocytoma, Grade IV"],"siteCountries":["Australia","Australia","Australia","Australia"]},{"nctId":"NCT05120284","title":"Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)","sponsor":"University of Florida","sponsorClass":"OTHER","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Dichloroacetate (DCA)","Genotype"],"startDate":"2022-07-01","firstPosted":"2021-11-15","lastUpdated":"2026-06-26","primaryCompletion":"2026-07-01","enrollment":40,"officials":[{"name":"Peter Stacpoole, PhD, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of Florida"}],"conditions":["Glioblastoma Multiforme"],"siteCountries":["United States","United States"]},{"nctId":"NCT07670026","title":"Intensified Adjuvant Therapy for High-Risk Newly Diagnosed Glioblastoma With Subtotal Resection or Short-Term Progression","sponsor":"Second Affiliated Hospital, Zhejiang University, School of Medicine","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":["Sintilimab","Bevacizumab","Temozolomide"],"startDate":"2025-12-01","firstPosted":"2026-06-25","lastUpdated":"2026-06-25","primaryCompletion":"2027-12-01","enrollment":31,"officials":[],"conditions":["Glioblastoma"],"siteCountries":["China"]},{"nctId":"NCT07468136","title":"Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas","sponsor":"Mayo Clinic","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["Eflornithine","Retifanlimab"],"startDate":"2026-06-23","firstPosted":"2026-03-12","lastUpdated":"2026-06-24","primaryCompletion":"2030-10-25","enrollment":33,"officials":[{"name":"Terence C. Burns, MD, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Mayo Clinic"}],"conditions":["Anaplastic Oligodendroglioma","Astrocytoma, IDH-Mutant, Grade 3","Astrocytoma, IDH-Mutant, Grade 4","Diffuse Astrocytoma","Glioblastoma, IDH-Wildtype","Malignant Glioma"],"siteCountries":["United States"]},{"nctId":"NCT05590689","title":"Radiodynamic Therapy (RDT) With Gliolan in Patients With First Recurrence of Brain Tumor","acronym":"ALA-RDTinGBM","sponsor":"Universität Münster","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["Gliolan"],"startDate":"2022-11-09","firstPosted":"2022-10-21","lastUpdated":"2026-06-23","primaryCompletion":"2028-01","enrollment":34,"officials":[{"name":"Walter Stummer, Prof. Dr.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University Hospital Muenster"}],"conditions":["Glioblastoma"],"siteCountries":["Germany"]},{"nctId":"NCT04225039","title":"Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma","sponsor":"University of Pennsylvania","sponsorClass":"OTHER","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["INCMGA00012","INCAGN01876","SRS"],"startDate":"2020-06-23","firstPosted":"2020-01-13","lastUpdated":"2026-06-23","primaryCompletion":"2022-09-08","resultsFirstPosted":"2023-09-15","enrollment":39,"officials":[{"name":"Stephen Bagley, MD, MSCE","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of Pennsylvania"}],"conditions":["Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT04678648","title":"A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies","sponsor":"RasCal Therapeutics, Inc.","sponsorClass":"INDUSTRY","phases":["PHASE1"],"status":"RECRUITING","interventions":["RSC-1255 Dose Escalation","RSC-1255 Dose Expansion"],"startDate":"2021-03-03","firstPosted":"2020-12-22","lastUpdated":"2026-06-23","primaryCompletion":"2026-12-15","enrollment":134,"officials":[{"name":"Michael Mann, MD","role":"STUDY_DIRECTOR","affiliation":"RasCal Therapeutics, Inc."}],"conditions":["Advanced Malignant Solid Neoplasm","RAS Mutation","Lung Cancer","Colon Cancer","Glioblastoma","Pancreatic Cancer"],"siteCountries":["United States","United States","United States"]},{"nctId":"NCT07392957","title":"Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma","sponsor":"Washington University School of Medicine","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["CTX-009","CTX-471"],"startDate":"2026-06-16","firstPosted":"2026-02-06","lastUpdated":"2026-06-22","primaryCompletion":"2029-06-30","enrollment":54,"officials":[{"name":"Tanner M Johanns, MD, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Washington University School of Medicine"}],"conditions":["Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT07541781","title":"Sitagliptin in Recurrent/Progressive Grade 4 Glioma","sponsor":"Kailin Yang, MD, PhD","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":["Sitagliptin","Bevacizumab"],"startDate":"2026-06-11","firstPosted":"2026-04-21","lastUpdated":"2026-06-17","primaryCompletion":"2029-06-11","enrollment":45,"officials":[{"name":"Kailin Yang, MD, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of Iowa"}],"conditions":["Glioma","Glioblastoma","Recurrent Glioma","Recurrent Glioblastoma","Grade 4 Malignant Glioma of Brain (Disorder)"],"siteCountries":["United States"]},{"nctId":"NCT04323046","title":"Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults","sponsor":"Sabine Mueller, MD, PhD","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Nivolumab"],"startDate":"2020-10-02","firstPosted":"2020-03-26","lastUpdated":"2026-06-15","primaryCompletion":"2028-06-30","enrollment":9,"officials":[{"name":"Tom Davidson (tdavidson@chla.usc.edu), MD","role":"STUDY_CHAIR","affiliation":"Children's Hospital Los Angeles"}],"conditions":["Glioblastoma","Malignant Glioma","Recurrent Glioblastoma","Recurrent Malignant Glioma","Recurrent Grade III Glioma","Grade III Glioma"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","Australia","Australia","Australia","Australia","Australia","Australia"]},{"nctId":"NCT07422363","title":"Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma","sponsor":"National Cancer Institute (NCI)","sponsorClass":"OTHER","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","interventions":["Cemiplimab"],"startDate":"2026-12-04","firstPosted":"2026-02-20","lastUpdated":"2026-06-12","primaryCompletion":"2027-02-28","enrollment":30,"officials":[{"name":"Megan Mantica","role":"PRINCIPAL_INVESTIGATOR","affiliation":"UPMC Hillman Cancer Center LAO"}],"conditions":["Recurrent Glioblastoma, IDH-Wildtype","Recurrent Gliosarcoma","Recurrent WHO Grade 4 Glioma"]},{"nctId":"NCT07643870","title":"Human ADME Study of [14C]-AZD1390","sponsor":"AstraZeneca","sponsorClass":"INDUSTRY","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","interventions":["AZD1390"],"startDate":"2026-06-30","firstPosted":"2026-06-12","lastUpdated":"2026-06-12","primaryCompletion":"2028-04-12","enrollment":8,"officials":[],"conditions":["Advanced Solid Malignancies"],"siteCountries":["United Kingdom","United Kingdom"]},{"nctId":"NCT04732065","title":"ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors","acronym":"PNOC023","sponsor":"Sabine Mueller, MD, PhD","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":["ONC206"],"startDate":"2021-08-23","firstPosted":"2021-02-01","lastUpdated":"2026-06-11","primaryCompletion":"2027-05-31","enrollment":208,"officials":[{"name":"Sabine Mueller, MD, PhD","role":"STUDY_CHAIR","affiliation":"University of California, San Francisco"}],"conditions":["Diffuse Midline Glioma (DMG)","Glioblastoma","Recurrent Ependymoma","Recurrent Malignant Central Nervous System Neoplasm","Spinal Cord Glioma","World Health Organization (WHO) Grade III Glioma","CNS Tumor","Central Nervous System Tumor"],"siteCountries":["United States","United States","United States","United States","United States","Netherlands","Switzerland"]},{"nctId":"NCT03866109","title":"A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT","acronym":"TEM-GBM","sponsor":"Genenta Science","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"TERMINATED","interventions":["Temferon"],"startDate":"2019-03-05","firstPosted":"2019-03-07","lastUpdated":"2026-06-11","primaryCompletion":"2026-05-27","whyStopped":"LVLP (pt GBM-01034) took place on 27may2026. The 2 remaining slots allocated by the protocol for the additional cohort to generate safety data prior to study Part B will not be filled. No safety concerns. Benefit-risk profile unchanged.","enrollment":25,"officials":[{"name":"Gaetano Finocchiaro, MD","role":"STUDY_CHAIR","affiliation":"Ospedale San Raffaele"}],"conditions":["Glioblastoma Multiforme"],"siteCountries":["Italy","Italy","Italy"]},{"nctId":"NCT05283330","title":"Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors","sponsor":"Orano Med Theranostics, SAS","sponsorClass":"INDUSTRY","phases":["PHASE1"],"status":"RECRUITING","interventions":["²¹²Pb-DOTAM-GRPR1"],"startDate":"2022-12-22","firstPosted":"2022-03-16","lastUpdated":"2026-06-11","primaryCompletion":"2027-01","enrollment":48,"officials":[],"conditions":["Cervical Cancer","Breast Cancer","Colon Cancer","NSCLC","mCRPC (Metastatic Castration-resistant Prostate Cancer)","Glioblastoma","Nonsmall Cell Lung Cancer"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT06622434","title":"New Adjuvant Vaccine in Glioblastoma, a Phase 1/2a Study","acronym":"NAVIG-1","sponsor":"Assistance Publique - Hôpitaux de Paris","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["immunization"],"startDate":"2024-11-08","firstPosted":"2024-10-02","lastUpdated":"2026-06-11","primaryCompletion":"2028-03-08","enrollment":35,"officials":[{"name":"Antoine CARPENTIER, Pr","role":"STUDY_CHAIR","affiliation":"APHP- Hôpital Saint Louis"}],"conditions":["Newly Diagnosed Glioblastoma"],"siteCountries":["France","France","France"]},{"nctId":"NCT05053880","title":"A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme","sponsor":"Accendatech USA Inc.","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["ACT001","ACT001 + Pembrolizumab"],"startDate":"2021-09-22","firstPosted":"2021-09-23","lastUpdated":"2026-06-10","primaryCompletion":"2024-10-25","enrollment":48,"officials":[{"name":"Doug Cai, MD","role":"STUDY_DIRECTOR","affiliation":"Accendatech USA Inc."}],"conditions":["Recurrent Glioblastoma Multiforme(GBM)"],"siteCountries":["United States"]},{"nctId":"NCT07635173","title":"SM-1 Combined With Temozolomide in Subjects With Refractory or Recurrent High-Grade Gliomas","sponsor":"Shenzhen Zhenxing Medical Technology Co., Ltd","sponsorClass":"OTHER","phases":["PHASE1"],"status":"COMPLETED","interventions":["SM-1,TMZ"],"startDate":"2022-09-19","firstPosted":"2026-06-09","lastUpdated":"2026-06-09","primaryCompletion":"2024-04-22","enrollment":35,"officials":[],"conditions":["Glioma","Glioblastomas (GBM)","High Grade Gliomas"],"siteCountries":["China"]},{"nctId":"NCT05218408","title":"CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type","acronym":"CYNK001GBM02","sponsor":"Celularity Incorporated","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"WITHDRAWN","interventions":["CYNK-001 systemic and Intra cavity administration"],"startDate":"2021-09","firstPosted":"2022-02-01","lastUpdated":"2026-06-08","primaryCompletion":"2021-10-23","whyStopped":"No participants were enrolled. Study was withdrawn prior to treatment initiation.","enrollment":0,"officials":[{"name":"sharmila koppisetti, MD","role":"STUDY_DIRECTOR","affiliation":"Celularity Incorporated"}],"conditions":["Astrocytoma, Grade IV","Glioblastoma","Giant Cell Glioblastoma","Glioblastoma Multiforme"]},{"nctId":"NCT05904119","title":"Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study","acronym":"LEGATO","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","sponsorClass":"OTHER","phases":["PHASE3"],"status":"RECRUITING","interventions":["Lomustine"],"startDate":"2024-03-15","firstPosted":"2023-06-15","lastUpdated":"2026-06-08","primaryCompletion":"2027-09","enrollment":411,"officials":[{"name":"Matthias Preusser, Prof.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"EORTC Study Coordinator"},{"name":"Giuseppe Minniti, Dr.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"EORTC Study Coordinator"}],"conditions":["First Progression of Glioblastoma"],"siteCountries":["Austria","Austria","Austria","Belgium","Belgium","Belgium","Belgium","Belgium","Belgium","Czechia","Denmark","France","France","France","France","France","France","France","France","France","France","Germany","Germany","Germany","Germany","Germany","Germany","Germany","Germany","Germany","Italy","Italy","Italy","Italy","Italy","Netherlands","Netherlands","Netherlands","Norway","Norway","Spain","Spain","Spain","Switzerland","Switzerland"]},{"nctId":"NCT03011671","title":"Study of Acetazolamide With Temozolomide in Adults With Newly Diagnosed or Recurrent Malignant Glioma","sponsor":"University of Chicago","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Acetazolamide","Temozolomide"],"startDate":"2018-10-03","firstPosted":"2017-01-05","lastUpdated":"2026-06-05","primaryCompletion":"2026-12","enrollment":10,"officials":[{"name":"Bakhtiar Yamini, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of Chicago"}],"conditions":["Malignant Glioma of Brain"],"siteCountries":["United States"]},{"nctId":"NCT07223034","title":"A Study of 177Lu-PSMA-617 in People With Gliomas","sponsor":"Memorial Sloan Kettering Cancer Center","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":["Temozolomide","177Lu-PSMA-617"],"startDate":"2025-10-27","firstPosted":"2025-10-31","lastUpdated":"2026-06-04","primaryCompletion":"2027-10","enrollment":20,"officials":[{"name":"Brandon Imber, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Memorial Sloan Kettering Cancer Center"}],"conditions":["Glioma","Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4)","Glioblastoma, IDH-wildtype","Diffuse Midline Glioma, H3 K27-Altered","Diffuse Hemispheric Glioma, H3 G34-mutant","Diffuse Pediatric-type High-grade Glioma, H3-wildtype and IDH-wildtype"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT02649582","title":"Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients","acronym":"ADDIT-GLIO","sponsor":"University Hospital, Antwerp","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Dendritic cell vaccine plus temozolomide chemotherapy"],"startDate":"2015-12","firstPosted":"2016-01-07","lastUpdated":"2026-06-04","primaryCompletion":"2027-07","enrollment":20,"officials":[{"name":"Zwi N Berneman, MD, PhD","role":"STUDY_DIRECTOR","affiliation":"Antwerp University Hospital, Division of Hematology and Center for Cell Therapy and Regenerative Medicine"},{"name":"Marika Rasschaert, MD, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Antwerp University Hospital (UZA), Division of Oncology"}],"conditions":["Glioblastoma Multiforme of Brain"],"siteCountries":["Belgium"]},{"nctId":"NCT03514069","title":"Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma","sponsor":"Case Comprehensive Cancer Center","sponsorClass":"OTHER","phases":["PHASE1"],"status":"COMPLETED","interventions":["ruxolitinib","temozolomide"],"startDate":"2018-06-05","firstPosted":"2018-05-02","lastUpdated":"2026-06-04","primaryCompletion":"2021-08-27","enrollment":60,"officials":[{"name":"David Peereboom, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center"}],"conditions":["Glioma","Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT04547777","title":"Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma","sponsor":"Darell Bigner","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":["D2C7-IT","2141-V11"],"startDate":"2021-07-09","firstPosted":"2020-09-14","lastUpdated":"2026-06-04","primaryCompletion":"2027-06","enrollment":90,"officials":[{"name":"Annick Desjardins, MD,FRCPC","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Duke University"}],"conditions":["Glioma, Malignant"],"siteCountries":["United States"]},{"nctId":"NCT06607692","title":"Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).","acronym":"LUPARPED","sponsor":"Fundación de investigación HM","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["Olaparib; 177Lu-DOTATATE"],"startDate":"2024-09-20","firstPosted":"2024-09-23","lastUpdated":"2026-06-04","primaryCompletion":"2029-07","enrollment":25,"officials":[{"name":"Marta Osuna Marco, PhD","role":"STUDY_DIRECTOR","affiliation":"HM Monteprincipe"}],"conditions":["Solid Tumor Cancer","Medulloblastoma","High Risk Neuroblastoma","High Grade Gliomas","Meningioma","Paraganglioma","Pheochromocytoma","Neuroendocrine Tumours (NET)","Adrenal Tumours","DIPG","Glioblastoma","Glioblastoma (GBM)","Osteosarcoma Recurrent","Carcinoma Adrenal","Synovial Sarcomas","Esthesioneuroblastoma","Neuroblastoma Recurrent","Solid Tumor Refractory to Conventional Treatment","Medulloblastoma Recurrent","Paraganglioma/ Phaeochromocytoma","Ependymoma","Ependymoma Recurrent"],"siteCountries":["Spain"]},{"nctId":"NCT07628062","title":"Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation","sponsor":"ImmunityBio, Inc.","sponsorClass":"INDUSTRY","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","interventions":["Nogapendekin Alfa Inbakicept (NAI)","hAd5-HPV Vaccine (IBRX-042)","Nab-Paclitaxel","Cisplatin"],"startDate":"2026-07-22","firstPosted":"2026-06-04","lastUpdated":"2026-06-04","primaryCompletion":"2030-12-31","enrollment":70,"officials":[],"conditions":["HPV-Positive Oropharyngeal Squamous Cell Carcinoma","Oropharyngeal Squamous Cell Carcinoma","Head and Neck Cancer"]},{"nctId":"NCT06806228","title":"Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma/Diffuse Midline Glioma and Response to Treatment (Regardless of Mutation Status)","sponsor":"Petrov, Andrey","sponsorClass":"OTHER","phases":["PHASE1"],"status":"SUSPENDED","interventions":["S-Gboxin"],"startDate":"2026-05-20","firstPosted":"2025-02-04","lastUpdated":"2026-06-03","primaryCompletion":"2027-10-10","whyStopped":"The study protocol will be changed","enrollment":10,"officials":[],"conditions":["Glioblastoma Multiforme","Diffuse Midline Glioma, H3 K27M-Mutant","Gliosarcoma","Giant Cell Glioblastoma","GBM"],"siteCountries":["Georgia","Kazakhstan","Ukraine"]},{"nctId":"NCT04978727","title":"A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma","sponsor":"Children's Oncology Group","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years","SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years","SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years"],"startDate":"2022-07-01","firstPosted":"2021-07-27","lastUpdated":"2026-06-02","primaryCompletion":"2027-12-31","enrollment":35,"officials":[{"name":"Clare Twist, MD","role":"STUDY_CHAIR","affiliation":"Roswell Park Comprehensive Cancer Center"}],"conditions":["Medulloblastoma","Glioblastoma Multiforme","Anaplastic Astrocytoma","High-grade Astrocytoma NOS","Anaplastic Oligodendroglioma","Anaplastic Ependymoma","Ependymoma","Diffuse Intrinsic Pontine Glioma"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","Canada"]},{"nctId":"NCT05271240","title":"Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM","sponsor":"Northwell Health","sponsorClass":"OTHER","phases":["PHASE3"],"status":"RECRUITING","interventions":["Repeated Superselective Intraarterial Cerebral infusion (SIACI) of Bevacizumab (Avastin) with Temozolomide and Radiation","Temozolomide and Radiation Alone"],"startDate":"2022-04-27","firstPosted":"2022-03-08","lastUpdated":"2026-06-01","primaryCompletion":"2027-04-01","enrollment":432,"officials":[{"name":"John Boockvar, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Feinstein Institute for Medical Research/Lenox Hill Hospital"}],"conditions":["Glioblastoma","Glioblastoma Multiforme","Glioma, Malignant","GBM","Brain Cancer","Glioblastoma, IDH-wildtype","Glioblastoma Multiforme, Adult"],"siteCountries":["United States"]},{"nctId":"NCT01386710","title":"Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma","sponsor":"Northwell Health","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"SUSPENDED","interventions":["Bevacizumab and Carboplatin","Bevacizumab and Carboplatin"],"startDate":"2011-09","firstPosted":"2011-07-01","lastUpdated":"2026-06-01","primaryCompletion":"2027-12","whyStopped":"PI left previous institution study will reopen at new institution.","enrollment":54,"officials":[{"name":"John Boockvar, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Lenox Hill Hospital"}],"conditions":["Glioblastoma Multiforme","Anaplastic Astrocytoma"],"siteCountries":["United States"]},{"nctId":"NCT03897491","title":"PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma","sponsor":"photonamic GmbH & Co. KG","sponsorClass":"INDUSTRY","phases":["PHASE2"],"status":"TERMINATED","interventions":["5-aminolevulinic acid"],"startDate":"2021-09-03","firstPosted":"2019-04-01","lastUpdated":"2026-06-01","primaryCompletion":"2026-04-08","whyStopped":"Low recruitment activities of clinical trial sites.","enrollment":17,"officials":[{"name":"Walter Stummer, Prof. Dr.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Universitätsklinikum Münster"}],"conditions":["Glioblastoma"],"siteCountries":["Germany","Germany","Germany"]},{"nctId":"NCT03213002","title":"Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM","acronym":"CAPTEM","sponsor":"Northwell Health","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["Capecitabine","Temozolomide"],"startDate":"2017-06-13","firstPosted":"2017-07-11","lastUpdated":"2026-06-01","primaryCompletion":"2028-06","enrollment":67,"officials":[{"name":"John Boockvar, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Lenox Hill Hospital-Northwell Health"}],"conditions":["Glioblastoma Multiforme (GBM)","Glioblastoma","Glioma of Brain","Glioblastoma, Adult","Brain Tumor","Brain Tumor, Primary","Brain Tumor Adult","Cancer","Brain Cancer"],"siteCountries":["United States"]},{"nctId":"NCT04222309","title":"Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM)","sponsor":"Northwell Health","sponsorClass":"OTHER","phases":["PHASE1"],"status":"SUSPENDED","interventions":[],"startDate":"2020-01-06","firstPosted":"2020-01-09","lastUpdated":"2026-06-01","primaryCompletion":"2027-01-31","whyStopped":"Per IRB closed and opened a new study.","enrollment":10,"officials":[{"name":"John Boockvar, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Northwell Health"}],"conditions":["Glioma","Glioma, Malignant","Glioblastoma","Glioblastoma Multiforme","Glioblastoma Multiforme of Brain","GBM","Brain Cancer"],"siteCountries":["United States"]},{"nctId":"NCT02861898","title":"Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma","sponsor":"Northwell Health","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["Intra-arterial Cetuximab","Intra-arterial Mannitol"],"startDate":"2016-06","firstPosted":"2016-08-10","lastUpdated":"2026-06-01","primaryCompletion":"2028-12","enrollment":33,"officials":[],"conditions":["Glioblastoma","Brain Cancer","Brain Neoplasm","Brain Tumor","Brain Neoplasm, Malignant","EGFR Gene Overexpression","GBM"],"siteCountries":["United States"]},{"nctId":"NCT01269853","title":"Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA","sponsor":"Northwell Health","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["Bevacizumab","Bevacizumab"],"startDate":"2010-10","firstPosted":"2011-01-04","lastUpdated":"2026-06-01","primaryCompletion":"2028-10","enrollment":54,"officials":[{"name":"John Boockvar, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Feinstein Institute for Medical Research"}],"conditions":["Glioblastoma Multiforme","Anaplastic Astrocytoma"],"siteCountries":["United States"]},{"nctId":"NCT05843253","title":"Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant","sponsor":"Nationwide Children's Hospital","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":["Ribociclib","Everolimus","Temozolomide (TMZ)"],"startDate":"2024-08-22","firstPosted":"2023-05-06","lastUpdated":"2026-05-29","primaryCompletion":"2029-08-31","enrollment":120,"officials":[{"name":"Margot Lazow, MD","role":"STUDY_CHAIR","affiliation":"Nationwide Children's Hospital"},{"name":"Maryam Fouladi, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Nationwide Children's Hospital"}],"conditions":["High Grade Glioma","Diffuse Intrinsic Pontine Glioma","Anaplastic Astrocytoma","Glioblastoma","Glioblastoma Multiforme","Diffuse Midline Glioma, H3 K27M-Mutant","Metastatic Brain Tumor","WHO Grade III Glioma","WHO Grade IV Glioma","Diffuse Hemispheric Glioma, H3 G34-Mutant"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","Australia","Australia","Australia","Australia","Canada","Canada","Germany","New Zealand","United Kingdom"]},{"nctId":"NCT06264388","title":"DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma","sponsor":"Ashish Shah","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":["DB107-RRV","DB107-FC"],"startDate":"2024-05-01","firstPosted":"2024-02-20","lastUpdated":"2026-05-28","primaryCompletion":"2034-05-01","enrollment":33,"officials":[{"name":"Ashish Shah, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of Miami"}],"conditions":["High Grade Glioma","Anaplastic Astrocytoma"],"siteCountries":["United States"]},{"nctId":"NCT07605364","title":"Testing the Addition of an Anti-Cancer Drug, Mycophenolate Mofetil, to the Usual Treatment (Radiation Therapy and Temozolomide) for Advanced Brain Cancer","sponsor":"Alliance for Clinical Trials in Oncology","sponsorClass":"OTHER","phases":["PHASE2","PHASE3"],"status":"NOT_YET_RECRUITING","interventions":["Temozolomide (TMZ)","Mycophenolate Mofetil"],"startDate":"2026-06-10","firstPosted":"2026-05-26","lastUpdated":"2026-05-26","primaryCompletion":"2029-09-30","enrollment":422,"officials":[{"name":"Priya Kumthekar, MD","role":"STUDY_CHAIR","affiliation":"Alliance for Clinical Trials in Oncology"},{"name":"Yoshie Umemura, MD, MS","role":"STUDY_CHAIR","affiliation":"Alliance for Clinical Trials in Oncology"}],"conditions":["Advanced Glioblastoma"]},{"nctId":"NCT03688178","title":"DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab","acronym":"DERIVe","sponsor":"Annick Desjardins, MD","sponsorClass":"OTHER","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Human CMV pp65-LAMP mRNA-pulsed autologous DCs","Temozolomide","Varlilumab","Td","Unpulsed DCs"],"startDate":"2020-08-26","firstPosted":"2018-09-28","lastUpdated":"2026-05-22","primaryCompletion":"2027-03-31","enrollment":43,"officials":[{"name":"Annick Desjardins, MD, FRCPC","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Duke University"}],"conditions":["Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT05736406","title":"A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma","sponsor":"Hemerion Therapeutics","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 200 J/cm^2","5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 400 J/cm^2"],"startDate":"2024-02-20","firstPosted":"2023-02-21","lastUpdated":"2026-05-22","primaryCompletion":"2026-03-06","enrollment":12,"officials":[{"name":"Jan Drappatz, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"UPMC Presbyterian Shadyside Hospital, Pittsburgh, PA"}],"conditions":["Primary Glioblastoma"],"siteCountries":["United States","France"]},{"nctId":"NCT07604285","title":"A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma","acronym":"NOVA-GBM","sponsor":"Myosin Therapeutics Inc.","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","interventions":["MT-125"],"startDate":"2026-07","firstPosted":"2026-05-22","lastUpdated":"2026-05-22","primaryCompletion":"2027-03","enrollment":36,"officials":[],"conditions":["Glioblastoma"],"siteCountries":["United States","United States","United States"]},{"nctId":"NCT04477200","title":"Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma","sponsor":"University of Michigan Rogel Cancer Center","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Mycophenolate Mofetil","Temozolomide","Mycophenolate Mofetil","Mycophenolate Mofetil"],"startDate":"2020-08-05","firstPosted":"2020-07-20","lastUpdated":"2026-05-14","primaryCompletion":"2025-01-06","resultsFirstPosted":"2026-05-14","enrollment":68,"officials":[{"name":"Nathan Clarke, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of Michigan Rogel Cancer Center"}],"conditions":["Recurrent Glioblastoma","Recurrent Gliosarcoma","Recurrent Astrocytoma, Grade IV","Newly Diagnosed Glioblastoma","Newly Diagnosed Gliosarcoma","Newly Diagnosed Astrocytoma, Grade IV"],"siteCountries":["United States"]},{"nctId":"NCT00906893","title":"Evaluation of [18F]-FMISO for Non Operated Glioblastoma","acronym":"MISOGLIO","sponsor":"University Hospital, Bordeaux","sponsorClass":"OTHER","phases":["PHASE2"],"status":"COMPLETED","interventions":[],"startDate":"2009-06","firstPosted":"2009-05-21","lastUpdated":"2026-05-14","primaryCompletion":"2012-01","enrollment":14,"officials":[{"name":"Aymeri HUCHET, PHU","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University Hospital, Bordeaux"}],"conditions":["Glioblastoma"],"siteCountries":["France"]},{"nctId":"NCT04003649","title":"IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM","sponsor":"City of Hope Medical Center","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells","Ipilimumab","Nivolumab"],"startDate":"2019-12-02","firstPosted":"2019-07-01","lastUpdated":"2026-05-14","primaryCompletion":"2024-12-18","enrollment":20,"officials":[{"name":"Behnam Badie, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"City of Hope Medical Center"}],"conditions":["Recurrent Glioblastoma","Refractory Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT02192359","title":"Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas","sponsor":"City of Hope Medical Center","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Carboxylesterase-expressing Allogeneic Neural Stem Cells","Irinotecan","Irinotecan Hydrochloride"],"startDate":"2016-04-05","firstPosted":"2014-07-16","lastUpdated":"2026-05-11","primaryCompletion":"2022-02-21","resultsFirstPosted":"2024-04-29","enrollment":18,"officials":[{"name":"Jana L Portnow","role":"PRINCIPAL_INVESTIGATOR","affiliation":"City of Hope Medical Center"}],"conditions":["Recurrent Anaplastic Astrocytoma","Recurrent Anaplastic Oligoastrocytoma","Recurrent Anaplastic Oligodendroglioma","Recurrent Glioblastoma","Recurrent Gliosarcoma","Recurrent Malignant Glioma","Recurrent WHO Grade III Glioma"],"siteCountries":["United States"]},{"nctId":"NCT03382977","title":"Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects","sponsor":"VBI Vaccines Inc.","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"TERMINATED","interventions":["VBI-1901","Carmustine","Lomustine"],"startDate":"2017-12-06","firstPosted":"2017-12-26","lastUpdated":"2026-05-08","primaryCompletion":"2025-07-30","whyStopped":"VBI Bankruptcy","enrollment":70,"officials":[{"name":"Francisco Diaz-Mitoma, MD","role":"STUDY_DIRECTOR","affiliation":"Variation Biotechnologies Inc."}],"conditions":["Glioblastoma Multiforme"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT04105374","title":"Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma","sponsor":"NRG Oncology","sponsorClass":"OTHER","phases":["PHASE2","PHASE3"],"status":"WITHDRAWN","interventions":["Extended Release Flucytosine","Temozolomide","Vocimagene Amiretrorepvec"],"startDate":"2020-01-31","firstPosted":"2019-09-26","lastUpdated":"2026-05-07","primaryCompletion":"2025-11-30","whyStopped":"NCI approval withdrawn","enrollment":0,"officials":[{"name":"Manmeet S Ahluwalia","role":"PRINCIPAL_INVESTIGATOR","affiliation":"NRG Oncology"}],"conditions":["Anaplastic Astrocytoma","Glioblastoma","Oligodendroglioma","Supratentorial Glioblastoma"]},{"nctId":"NCT02331498","title":"Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme","acronym":"PAZOGLIO","sponsor":"Centre Antoine Lacassagne","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Pazopanib"],"startDate":"2015-06","firstPosted":"2015-01-06","lastUpdated":"2026-05-06","primaryCompletion":"2027-02","enrollment":51,"officials":[{"name":"Christine LOVERA","role":"STUDY_DIRECTOR","affiliation":"Centre Antoine Lacassagne"}],"conditions":["Glioblastoma Multiforme"],"siteCountries":["France"]},{"nctId":"NCT07569042","title":"A Rollover Study of NBM-BMX in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma","sponsor":"Novelwise Pharmaceutical Corporation","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["NBM-BMX Capsule","Temozolomide"],"startDate":"2026-04-20","firstPosted":"2026-05-06","lastUpdated":"2026-05-06","primaryCompletion":"2029-09-30","enrollment":15,"officials":[],"conditions":["Malignant Neoplasm of Brain"],"siteCountries":["Taiwan","Taiwan","Taiwan"]},{"nctId":"NCT07343986","title":"Study of Low-Intensity Focused Ultrasound in Combination With Immunotherapy in Newly Diagnosed Unmethylated Glioblastoma","acronym":"BATs FUS","sponsor":"University of Virginia","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":["anti-EGFR bispecific-armed T cells"],"startDate":"2026-03-23","firstPosted":"2026-01-15","lastUpdated":"2026-05-06","primaryCompletion":"2027-12","enrollment":12,"officials":[{"name":"Camilo Fadul, M.D.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of Virginia"}],"conditions":["Glioblastoma (GBM)"],"siteCountries":["United States"]},{"nctId":"NCT05557292","title":"RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma","sponsor":"Nicholas Butowski","sponsorClass":"OTHER","phases":["PHASE1"],"status":"TERMINATED","interventions":["RMC-5552"],"startDate":"2023-04-03","firstPosted":"2022-09-28","lastUpdated":"2026-05-06","primaryCompletion":"2025-12-31","whyStopped":"Drug no longer provided by sponsor","enrollment":7,"officials":[{"name":"Nicholas Butowski, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of California, San Francisco"}],"conditions":["Glioblastoma","Recurrent Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT06649851","title":"G-CSF After Chemo-radiation in Patients With Glioblastoma","sponsor":"Massachusetts General Hospital","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":["Granulocyte Colony Stimulating Factor (G-CSF)"],"startDate":"2025-04-02","firstPosted":"2024-10-21","lastUpdated":"2026-05-05","primaryCompletion":"2027-01-31","enrollment":60,"officials":[{"name":"Jorg Dietrich, MD, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Massachusetts General Hospital"}],"conditions":["MGMT-Methylated Glioblastoma","Glioblastoma (GBM)","Newly Diagnosed Glioblastoma Multiforme"],"siteCountries":["United States"]},{"nctId":"NCT04968366","title":"Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery","sponsor":"Beijing Tiantan Hospital","sponsorClass":"OTHER","phases":["PHASE1"],"status":"COMPLETED","interventions":["Autologous dendritic cells pulsed with multiple neoantigen peptides.","Temozolomide adjuvant chemotherapy"],"startDate":"2021-07-30","firstPosted":"2021-07-20","lastUpdated":"2026-05-04","primaryCompletion":"2024-04-30","enrollment":11,"officials":[{"name":"Nan Ji, Dr.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Beijing Tiantan Hospital"}],"conditions":["Glioblastoma Multiforme of Brain"],"siteCountries":["China"]},{"nctId":"NCT06176066","title":"PH Sensitive MRI Based Resections of Glioblastoma","sponsor":"University of California, Los Angeles","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":[],"startDate":"2025-08-05","firstPosted":"2023-12-19","lastUpdated":"2026-05-04","primaryCompletion":"2030-07-01","enrollment":18,"officials":[],"conditions":["Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT05743595","title":"Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma","sponsor":"Washington University School of Medicine","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Personalized Neoantigen DNA vaccine","Retifanlimab"],"startDate":"2023-10-27","firstPosted":"2023-02-24","lastUpdated":"2026-05-04","primaryCompletion":"2026-04-07","enrollment":27,"officials":[{"name":"Tanner M Johanns, M.D., Ph.D.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Washington University School of Medicine"}],"conditions":["Unmethylated Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT03797326","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)","sponsor":"Merck Sharp & Dohme LLC","sponsorClass":"INDUSTRY","phases":["PHASE2"],"status":"COMPLETED","interventions":["Pembrolizumab","Lenvatinib"],"startDate":"2019-02-12","firstPosted":"2019-01-09","lastUpdated":"2026-05-04","primaryCompletion":"2024-10-28","resultsFirstPosted":"2025-11-17","enrollment":611,"officials":[{"name":"Medical Director","role":"STUDY_DIRECTOR","affiliation":"Merck Sharp & Dohme LLC"}],"conditions":["Advanced Solid Tumors","Triple Negative Breast Cancer","Ovarian Cancer","Gastric Cancer","Colorectal Cancer","Glioblastoma","Biliary Tract Cancers","Pancreatic Cancer"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","Argentina","Argentina","Argentina","Argentina","Argentina","Argentina","Australia","Australia","Australia","Canada","Canada","Canada","Canada","Canada","Canada","Canada","Chile","Chile","Chile","Chile","Colombia","Colombia","Colombia","Colombia","France","France","France","France","France","France","Germany","Germany","Germany","Germany","Germany","Germany","Israel","Israel","Israel","Israel","Israel","Italy","Italy","Italy","Italy","Russia","Russia","Russia","Russia","Russia","Russia","South Korea","South Korea","South Korea","Spain","Spain","Spain","Spain","Switzerland","Switzerland","Switzerland","Switzerland","Switzerland","Switzerland","Taiwan","Taiwan","Thailand","Thailand","Thailand","United Kingdom","United Kingdom","United Kingdom","United Kingdom","United Kingdom"]},{"nctId":"NCT07560865","title":"First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma","sponsor":"Masonic Cancer Center, University of Minnesota","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":["FT536"],"startDate":"2026-04-23","firstPosted":"2026-05-01","lastUpdated":"2026-05-01","primaryCompletion":"2028-06-01","enrollment":9,"officials":[],"conditions":["Astrocytoma","Glioblastoma","Progressive Disease"],"siteCountries":["United States"]},{"nctId":"NCT05283109","title":"ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM","acronym":"ETAPA I","sponsor":"Mustafa Khasraw, MBChB, MD, FRCP, FRACP","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Tumor Associated Antigen Peptide Vaccine P30-EPS Vaccine","Hiltonol"],"startDate":"2023-08-30","firstPosted":"2022-03-16","lastUpdated":"2026-04-30","primaryCompletion":"2025-04-11","resultsFirstPosted":"2026-04-30","enrollment":24,"officials":[{"name":"Mustafa Khasraw, MBChB, MD, FRCP, FRACP","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Duke University"}],"conditions":["Glioma, Malignant"],"siteCountries":["United States"]},{"nctId":"NCT06012695","title":"NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma","sponsor":"Novelwise Pharmaceutical Corporation","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["NBM-BMX Capsule","Temozolomide"],"startDate":"2023-08-11","firstPosted":"2023-08-25","lastUpdated":"2026-04-29","primaryCompletion":"2028-05-30","enrollment":79,"officials":[],"conditions":["Malignant Neoplasm","Malignant Neoplasm of Brain"],"siteCountries":["Taiwan","Taiwan","Taiwan","Taiwan"]},{"nctId":"NCT04922723","title":"Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma","acronym":"PRIDE","sponsor":"West Virginia University","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Daratumumab"],"startDate":"2022-10-03","firstPosted":"2021-06-11","lastUpdated":"2026-04-28","primaryCompletion":"2026-12","enrollment":16,"officials":[{"name":"Sonikpreet Aulakh, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"WVU Cancer Institute"}],"conditions":["Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT06039709","title":"Sonodynamic Therapy in Patients With Recurrent GBM","acronym":"GBM 001","sponsor":"Shayan Moosa, MD","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":["5-ALA and Low-Intensity Focused Ultrasound (SDT)"],"startDate":"2024-01-31","firstPosted":"2023-09-15","lastUpdated":"2026-04-28","primaryCompletion":"2026-12","enrollment":11,"officials":[{"name":"Shayan Moosa, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"UVA"}],"conditions":["Recurrent Glioblastoma","Glioblastoma Multiforme","GBM"],"siteCountries":["United States"]},{"nctId":"NCT07551336","title":"Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma","sponsor":"Beijing Biotech","sponsorClass":"INDUSTRY","phases":["PHASE1"],"status":"RECRUITING","interventions":["Dual-target CAR-NK cells","Cyclophosphamide","Fludarabine"],"startDate":"2026-03-02","firstPosted":"2026-04-24","lastUpdated":"2026-04-24","primaryCompletion":"2027-04-14","enrollment":36,"officials":[],"conditions":["Malignant Glioma","High-Grade Gliomas","Glioblastoma","Recurrent High-Grade Gliomas","Recurrent Glioblastoma"],"siteCountries":["China"]},{"nctId":"NCT05565521","title":"UNITy-BasED MR-Linac Adaptive Simultaneous Integrated Hypofractionated Boost Trial for High Grade Glioma in the Elderly","acronym":"UNITED2","sponsor":"Sunnybrook Health Sciences Centre","sponsorClass":"OTHER","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":[],"startDate":"2022-12-13","firstPosted":"2022-10-04","lastUpdated":"2026-04-24","primaryCompletion":"2027-12-31","enrollment":55,"officials":[],"conditions":["Glioblastoma Multiforme, Adult","Glioblastoma, IDH-mutant"],"siteCountries":["Canada"]},{"nctId":"NCT03383978","title":"Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma","acronym":"CAR2BRAIN","sponsor":"Johann Wolfgang Goethe University Hospital","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":["NK-92/5.28.z","Ezabenlimab"],"startDate":"2017-12-01","firstPosted":"2017-12-27","lastUpdated":"2026-04-23","primaryCompletion":"2027-12-31","enrollment":42,"officials":[{"name":"Michael C Burger, PD Dr. med.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Johann W. Goethe University Hospital, Frankfurt am Main, Germany"}],"conditions":["Glioblastoma"],"siteCountries":["Germany","Germany","Germany","Germany","Germany"]},{"nctId":"NCT05366179","title":"Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc","sponsor":"UNC Lineberger Comprehensive Cancer Center","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":["CAR.B7-H3T cells infusion"],"startDate":"2022-09-02","firstPosted":"2022-05-09","lastUpdated":"2026-04-22","primaryCompletion":"2030-05-30","enrollment":36,"officials":[{"name":"Felicia Cao, MD, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"UNC Lineberger Comprehensive Cancer Center"}],"conditions":["Glioblastoma Multiforme"],"siteCountries":["United States"]},{"nctId":"NCT06336291","title":"A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence","acronym":"GLIOSTELLA","sponsor":"Philogen S.p.A.","sponsorClass":"INDUSTRY","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["L19TNF","L19TNF","L19TNF","Lomustine","Lomustine"],"startDate":"2024-05-22","firstPosted":"2024-03-28","lastUpdated":"2026-04-21","primaryCompletion":"2026-06","enrollment":90,"officials":[],"conditions":["Glioblastoma"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT05917145","title":"ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade Glioma","sponsor":"Mayo Clinic","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":["WSD0628"],"startDate":"2024-01-17","firstPosted":"2023-06-23","lastUpdated":"2026-04-21","primaryCompletion":"2028-05-31","enrollment":94,"officials":[{"name":"William G. Breen, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Mayo Clinic"},{"name":"Jann N. Sarkaria, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Mayo Clinic"}],"conditions":["Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT07462507","title":"Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1","sponsor":"Washington University School of Medicine","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":["[C-11]-CS1P1"],"startDate":"2026-04-16","firstPosted":"2026-03-10","lastUpdated":"2026-04-21","primaryCompletion":"2031-06-30","enrollment":104,"officials":[{"name":"Tammie L.S. Benzinger, M.D., Ph.D.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Washington University School of Medicine"}],"conditions":["Central Nervous System Cancer","Brain Metastases"],"siteCountries":["United States"]},{"nctId":"NCT02287428","title":"Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM","sponsor":"Dana-Farber Cancer Institute","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Personalized NeoAntigen Peptides","Pembrolizumab","Temozolomide","Temozolomide","Poly-ICLC"],"startDate":"2014-11","firstPosted":"2014-11-10","lastUpdated":"2026-04-17","primaryCompletion":"2027-02","enrollment":56,"officials":[{"name":"David A. Reardon, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Dana-Farber Cancer Institute"}],"conditions":["Glioblastoma"],"siteCountries":["United States","United States"]},{"nctId":"NCT04817254","title":"Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma","sponsor":"National Cancer Institute (NCI)","sponsorClass":"OTHER","phases":["PHASE2"],"status":"COMPLETED","interventions":["TMZ","ipilimumab 3mg/kg","Nivolumab","ipilimumab 1mg/kg"],"startDate":"2021-12-08","firstPosted":"2021-03-26","lastUpdated":"2026-04-17","primaryCompletion":"2026-03-20","enrollment":47,"officials":[{"name":"Kevin A Camphausen, M.D.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"National Cancer Institute (NCI)"}],"conditions":["Glioblastoma","Gliosarcoma","Malignant Glioma"],"siteCountries":["United States"]},{"nctId":"NCT04762069","title":"A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme","sponsor":"CNS Pharmaceuticals, Inc.","sponsorClass":"INDUSTRY","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Berubicin","Lomustine"],"startDate":"2021-05-18","firstPosted":"2021-02-21","lastUpdated":"2026-04-15","primaryCompletion":"2026-04-27","enrollment":252,"officials":[{"name":"Sandra Silberman, MD, PhD","role":"STUDY_CHAIR","affiliation":"CNS Pharmaceuticals, Inc."}],"conditions":["Glioblastoma Multiforme, Adult"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","France","France","France","France","France","France","France","Italy","Italy","Spain","Spain","Spain","Spain","Spain","Spain","Switzerland"]},{"nctId":"NCT05275478","title":"Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors","sponsor":"Tango Therapeutics, Inc.","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"TERMINATED","interventions":["TNG908"],"startDate":"2022-03-23","firstPosted":"2022-03-11","lastUpdated":"2026-04-15","primaryCompletion":"2025-12-30","whyStopped":"Sponsor Decision - Business Decisions","enrollment":110,"officials":[{"name":"Maxim Pimkin, MD, PhD","role":"STUDY_DIRECTOR","affiliation":"Tango Therapeutics, Inc."}],"conditions":["Locally Advanced Solid Tumor"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","France","France","France","France","France"]},{"nctId":"NCT03451799","title":"Ketogenic Diet in Combination With Standard-of-care Radiation and Temozolomide for Patients With Glioblastoma","sponsor":"Jethro Hu","sponsorClass":"OTHER","phases":["PHASE1"],"status":"COMPLETED","interventions":["Standard-of-care Temozolomide"],"startDate":"2018-04-13","firstPosted":"2018-03-02","lastUpdated":"2026-04-15","primaryCompletion":"2021-09-03","enrollment":21,"officials":[{"name":"Jethro Hu, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Cedars-Sinai Medical Center Samuel Oschin Comprehensive Cancer Institute"}],"conditions":["GBM","Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT02866747","title":"A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma","acronym":"STERIMGLI","sponsor":"Institut Claudius Regaud","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"COMPLETED","interventions":["Durvalumab"],"startDate":"2017-01-17","firstPosted":"2016-08-15","lastUpdated":"2026-04-14","primaryCompletion":"2024-11-02","enrollment":108,"officials":[],"conditions":["Glioblastoma"],"siteCountries":["France","France","France","France","France","France","France","France","France","France"]},{"nctId":"NCT01507506","title":"Phase III Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma","acronym":"SPECTRO GLIO","sponsor":"Institut Claudius Regaud","sponsorClass":"OTHER","phases":["PHASE3"],"status":"TERMINATED","interventions":[],"startDate":"2011-03-15","firstPosted":"2012-01-11","lastUpdated":"2026-04-14","primaryCompletion":"2020-01-02","enrollment":180,"officials":[],"conditions":["Glioblastoma"],"siteCountries":["France","France","France","France","France","France","France","France","France","France","France","France"]},{"nctId":"NCT07185880","title":"A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients","acronym":"STAR-GBM","sponsor":"Myosin Therapeutics Inc.","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["MT-125"],"startDate":"2026-04-01","firstPosted":"2025-09-22","lastUpdated":"2026-04-14","primaryCompletion":"2026-10-31","enrollment":36,"officials":[],"conditions":["Glioblastoma (GBM)"],"siteCountries":["United States","United States","United States"]},{"nctId":"NCT06419946","title":"Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma","sponsor":"Vastra Gotaland Region","sponsorClass":"OTHER","phases":["PHASE3"],"status":"RECRUITING","interventions":["Temozolomide","Lomustine"],"startDate":"2025-02-01","firstPosted":"2024-05-17","lastUpdated":"2026-04-13","primaryCompletion":"2031-12-15","enrollment":200,"officials":[{"name":"Annika Malmström, MD, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University Hospital, Linkoeping"}],"conditions":["Glioblastoma, IDH-wildtype","MGMT-Methylated Glioblastoma"],"siteCountries":["Austria","Austria","Austria","Austria","Denmark","Norway","Norway","Norway","Norway","Norway","Sweden","Sweden","Sweden","Sweden","Sweden","Sweden","Sweden","Sweden","Sweden","Sweden"]},{"nctId":"NCT02800486","title":"Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA","sponsor":"Northwell Health","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":["Intra-arterial Cetuximab","Intra-arterial Mannitol"],"startDate":"2016-05","firstPosted":"2016-06-15","lastUpdated":"2026-04-13","primaryCompletion":"2035-05","enrollment":37,"officials":[{"name":"John Boockvar, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Northwell Health"}],"conditions":["Glioblastoma","Anaplastic Astrocytoma","Anaplastic Oligoastrocytoma","Glioma","Brain Neoplasm","Brain Cancer","Brain Tumor","Brain Tumor, Recurrent","Brain Neoplasm, Malignant"],"siteCountries":["United States"]},{"nctId":"NCT05168423","title":"CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM","sponsor":"University of Pennsylvania","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["CART-EGFR-IL13Ra2 Cells"],"startDate":"2023-02-24","firstPosted":"2021-12-23","lastUpdated":"2026-04-13","primaryCompletion":"2039-12-19","enrollment":67,"officials":[{"name":"Stephen Bagley, MD, MSCE","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of Pennsylvania"}],"conditions":["Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT02381886","title":"A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations","sponsor":"Novartis Pharmaceuticals","sponsorClass":"INDUSTRY","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["IDH305"],"startDate":"2015-03-06","firstPosted":"2015-03-06","lastUpdated":"2026-04-13","primaryCompletion":"2016-12-07","enrollment":166,"officials":[{"name":"Novartis Pharmaceuticals","role":"STUDY_DIRECTOR","affiliation":"Novartis Pharmaceuticals"}],"conditions":["Advanced Malignancies That Harbor IDHR132 Mutations"],"siteCountries":["United States","United States","United States","United States","United States","Australia","Australia","Belgium","Canada","Germany","Germany","Germany","Netherlands","Netherlands","Singapore","Spain"]},{"nctId":"NCT07523529","title":"Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors","acronym":"SELECT-2CAR","sponsor":"Beijing Biotech","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["Autologous dual-target CAR-T cells selected from the predefined target library.","Fludarabine","Cyclophosphamide"],"startDate":"2026-03-02","firstPosted":"2026-04-13","lastUpdated":"2026-04-13","primaryCompletion":"2027-04-14","enrollment":72,"officials":[],"conditions":["Advanced Unresectable","Metastatic"],"siteCountries":["China"]},{"nctId":"NCT06496971","title":"A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients","sponsor":"NaviFUS Corporation","sponsorClass":"INDUSTRY","phases":["PHASE3"],"status":"RECRUITING","interventions":["Bevacizumab","Microbubble"],"startDate":"2024-11-08","firstPosted":"2024-07-11","lastUpdated":"2026-04-09","primaryCompletion":"2026-12-31","enrollment":32,"officials":[],"conditions":["Glioblastoma Multiforme","Glioblastoma","Glioblastoma Multiforme, Adult","Glioma","Brain Tumor","Brain Tumor, Recurrent","Neoplasms","Neoplasms, Nerve Tissue"],"siteCountries":["Taiwan","Taiwan"]},{"nctId":"NCT07134842","title":"A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.","acronym":"WinGlio-ipi","sponsor":"University College, London","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":["Ipilimumab (3 mg/kg)"],"startDate":"2025-07-10","firstPosted":"2025-08-21","lastUpdated":"2026-04-09","primaryCompletion":"2027-01-01","enrollment":16,"officials":[{"name":"Paul Mulholland, MBBS, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University College, London"}],"conditions":["Glioblastoma","Gliosarcoma, Adult","Glioblastoma - Category"],"siteCountries":["United Kingdom"]},{"nctId":"NCT07511725","title":"Prophylactic Regimen With Intrathecal Thiotepa in SVZ-positive or Meningeal-risk Glioblastoma","acronym":"PRISM","sponsor":"Second Affiliated Hospital, Zhejiang University, School of Medicine","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":["Preventive Intrathecal Thiotepa"],"startDate":"2026-01-04","firstPosted":"2026-04-06","lastUpdated":"2026-04-06","primaryCompletion":"2028-01-04","enrollment":38,"officials":[],"conditions":["Glioblastoma (GBM)"],"siteCountries":["China"]},{"nctId":"NCT07497373","title":"A Phase I Study to Evaluate the Safety and Tolerability of JL15003 Injection in Patients With Recurrent Glioblastoma","acronym":"JL15003","sponsor":"Jecho Biopharmaceuticals Co., Ltd.","sponsorClass":"INDUSTRY","phases":["PHASE1"],"status":"COMPLETED","interventions":["JL15003 Injection"],"startDate":"2022-11-16","firstPosted":"2026-03-27","lastUpdated":"2026-04-03","primaryCompletion":"2024-05-23","enrollment":17,"officials":[],"conditions":["Recurrent Glioblastoma Multiforme(GBM)"],"siteCountries":["China","China","China"]},{"nctId":"NCT05789394","title":"Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy","sponsor":"Mayo Clinic","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":["Allogeneic Adipose-derived Mesenchymal Stem Cells"],"startDate":"2023-06-16","firstPosted":"2023-03-29","lastUpdated":"2026-04-02","primaryCompletion":"2027-07-24","enrollment":20,"officials":[{"name":"Alfredo Quinones-Hinojosa, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Mayo Clinic"}],"conditions":["Recurrent Glioblastoma, IDH-Wildtype","Recurrent Astrocytoma, IDH-Mutant, Grade 4","Astrocytoma, Grade IV"],"siteCountries":["United States"]},{"nctId":"NCT05986851","title":"Azeliragon in MGMT Unmethylated Glioblastoma","sponsor":"Cantex Pharmaceuticals","sponsorClass":"INDUSTRY","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Azeliragon"],"startDate":"2023-09-12","firstPosted":"2023-08-14","lastUpdated":"2026-03-31","primaryCompletion":"2026-09-30","enrollment":30,"officials":[{"name":"Stephen G Marcus, MD","role":"STUDY_CHAIR","affiliation":"Cantex Pharmaceuticals"}],"conditions":["Glioblastoma"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT06650605","title":"Phase 1 Open-label Study of 123I-ATT001 in Subjects With Relapsed Glioblastoma","acronym":"CITADEL-123","sponsor":"Theragnostics Ltd","sponsorClass":"INDUSTRY","phases":["PHASE1"],"status":"COMPLETED","interventions":["123I-ATT001"],"startDate":"2024-07-04","firstPosted":"2024-10-21","lastUpdated":"2026-03-31","primaryCompletion":"2026-03-01","enrollment":7,"officials":[{"name":"Paul Mulholland","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University College London Hospitals"}],"conditions":["Glioma Glioblastoma Multiforme"],"siteCountries":["United Kingdom","United Kingdom"]},{"nctId":"NCT03603405","title":"HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM","sponsor":"The Methodist Hospital Research Institute","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["ADV/HSV-tk (gene therapy)"],"startDate":"2018-02-28","firstPosted":"2018-07-27","lastUpdated":"2026-03-30","primaryCompletion":"2026-12-31","enrollment":62,"officials":[{"name":"David S. Baskin, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Houston Methodist Neurological Institute"}],"conditions":["Glioblastoma","Anaplastic Astrocytoma"],"siteCountries":["United States"]},{"nctId":"NCT03663725","title":"Treatment Intensification With Temozolomide in Adults With a Glioblastoma","acronym":"StrateGlio","sponsor":"Centre Oscar Lambret","sponsorClass":"OTHER","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Intensified protocol","Stupp protocol"],"startDate":"2019-03-13","firstPosted":"2018-09-10","lastUpdated":"2026-03-30","primaryCompletion":"2027-06","enrollment":486,"officials":[{"name":"Florence LEFRANC, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"ERASME"},{"name":"Bruno CHAUFFERT, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"CHU Amiens"}],"conditions":["Glioblastoma"],"siteCountries":["France","France","France","France","France","France","France","France","France","France","France","France","France","France","France","France","France"]},{"nctId":"NCT07431216","title":"A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression","sponsor":"Starlight Therapeutics Inc.","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","interventions":["STAR-001 (LP-184) will be administered via IV infusion over 30 (± 5) minutes on Day 1 and Day 8 of each 21-day cycle.","Spironolactone (drug)"],"startDate":"2026-05-01","firstPosted":"2026-02-24","lastUpdated":"2026-03-30","primaryCompletion":"2027-05-01","enrollment":68,"officials":[{"name":"Marc M.D. Chamberlain, MD","role":"STUDY_DIRECTOR","affiliation":"Starlight Therapeutics Inc."}],"conditions":["Glioblastoma (GBM)"]},{"nctId":"NCT03596086","title":"HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM","sponsor":"David Baskin MD","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["ADV/HSV-tk (gene therapy)"],"startDate":"2017-12-11","firstPosted":"2018-07-23","lastUpdated":"2026-03-30","primaryCompletion":"2026-12-30","enrollment":62,"officials":[{"name":"David S Baskin, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Houston Methodist Neurological Institute"}],"conditions":["Glioblastoma Multiforme","Astrocytoma, Grade III"],"siteCountries":["United States"]},{"nctId":"NCT04559230","title":"Sacituzumab Govitecan in Recurrent Glioblastoma","sponsor":"The University of Texas Health Science Center at San Antonio","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":["Sacituzumab Govitecan"],"startDate":"2022-01-06","firstPosted":"2020-09-22","lastUpdated":"2026-03-30","primaryCompletion":"2027-02","enrollment":32,"officials":[{"name":"William Kelly, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Mays Cancer Center, UT Health San Antonio"}],"conditions":["Recurrent Glioblastoma"],"siteCountries":["United States","United States","United States"]},{"nctId":"NCT04801147","title":"Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Newly Diagnosed Glioblastoma Multiforme","acronym":"DENDR1","sponsor":"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"COMPLETED","interventions":["Dendritic Cells Vaccine"],"startDate":"2010-06-26","firstPosted":"2021-03-16","lastUpdated":"2026-03-27","primaryCompletion":"2023-12","enrollment":76,"officials":[],"conditions":["Glioblastoma"],"siteCountries":["Italy"]},{"nctId":"NCT01743950","title":"A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab","sponsor":"University of Wisconsin, Madison","sponsorClass":"OTHER","phases":["PHASE2"],"status":"TERMINATED","interventions":["Bevacizumab"],"startDate":"2012-12-03","firstPosted":"2012-12-06","lastUpdated":"2026-03-25","primaryCompletion":"2024-12-24","resultsFirstPosted":"2026-03-25","whyStopped":"slow accrual","enrollment":49,"officials":[{"name":"Steve Howard, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of Wisconsin, Madison"},{"name":"H. Ian Robins, MD, Ph.D","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of Wisconsin, Madison"}],"conditions":["Glioma"],"siteCountries":["United States"]},{"nctId":"NCT04574856","title":"Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma","sponsor":"University of Michigan Rogel Cancer Center","sponsorClass":"OTHER","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Temozolomide","Adjuvant temozolomide"],"startDate":"2020-11-04","firstPosted":"2020-10-05","lastUpdated":"2026-03-25","primaryCompletion":"2026-11-19","enrollment":30,"officials":[{"name":"Michelle Kim, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of Michigan"}],"conditions":["Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT02586857","title":"A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)","sponsor":"Acerta Pharma BV","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["ACP-196"],"startDate":"2016-01-25","firstPosted":"2015-10-27","lastUpdated":"2026-03-25","primaryCompletion":"2020-06-26","resultsFirstPosted":"2020-07-29","enrollment":24,"officials":[{"name":"Acerta Clinical Trials","role":"STUDY_DIRECTOR","affiliation":"1-888-292-9613; acertamc@dlss.com"}],"conditions":["Glioblastoma Multiforme"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT04417088","title":"Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy","sponsor":"InSightec","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"COMPLETED","interventions":["Carboplatin"],"startDate":"2020-11-06","firstPosted":"2020-06-04","lastUpdated":"2026-03-20","primaryCompletion":"2023-11-30","enrollment":28,"officials":[],"conditions":["Recurrent Glioblastoma"],"siteCountries":["United States","United States","United States","United States"]},{"nctId":"NCT02852655","title":"A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma","sponsor":"Dana-Farber Cancer Institute","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["MK-3475"],"startDate":"2016-09-21","firstPosted":"2016-08-02","lastUpdated":"2026-03-20","primaryCompletion":"2022-06-02","resultsFirstPosted":"2024-11-26","enrollment":60,"officials":[{"name":"Patrick Wen, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Dana-Farber Cancer Institute"}],"conditions":["Brain Cancer"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT07480941","title":"Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma","acronym":"DUAL-CAR-NK-GB","sponsor":"Beijing Biotech","sponsorClass":"INDUSTRY","phases":["PHASE1"],"status":"RECRUITING","interventions":["Dual-target CAR-NK cells","Cyclophosphamide","Fludarabine"],"startDate":"2026-02-02","firstPosted":"2026-03-18","lastUpdated":"2026-03-18","primaryCompletion":"2027-02-18","enrollment":36,"officials":[],"conditions":["Glioblastoma","High-grade Glioma","Malignant Glioma","Recurrent Glioblastoma","Recurrent High-grade Glioma"],"siteCountries":["China"]},{"nctId":"NCT06926075","title":"Early Phase Study of KESONOTIDE™in Participants With Solid Tumours","acronym":"ADVICE","sponsor":"Filamon LTD","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["A novel hGIIA-Vimentin Inhibitor","Dose expansion"],"startDate":"2025-11-07","firstPosted":"2025-04-13","lastUpdated":"2026-03-17","primaryCompletion":"2027-10-26","enrollment":80,"officials":[],"conditions":["Prostate Cancers","Breast Cancer","Lung Cancers","Ovarian Cancer","Glioblastoma Multiforme (GBM)","Pancreas Cancer","Skin Cancer"],"siteCountries":["Australia","Australia","Australia"]},{"nctId":"NCT07476794","title":"Daily Temozolomide for Elderly Patients With Unmethylated MGMT- Promoter Newly Diagnosed GliOblatoma","acronym":"TEMPO","sponsor":"Sunnybrook Health Sciences Centre","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":["Daily TMZ"],"startDate":"2025-11-01","firstPosted":"2026-03-17","lastUpdated":"2026-03-17","primaryCompletion":"2027-10","enrollment":118,"officials":[],"conditions":["Glioblastoma"],"siteCountries":["Canada"]},{"nctId":"NCT05753007","title":"A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients","sponsor":"Mclean Hospital","sponsorClass":"OTHER","phases":["PHASE2"],"status":"TERMINATED","interventions":["Cannabidiol (CBD)","Placebo"],"startDate":"2024-02-15","firstPosted":"2023-03-03","lastUpdated":"2026-03-16","primaryCompletion":"2025-02-11","resultsFirstPosted":"2026-03-16","whyStopped":"Study terminated by sponsor due to low enrollment.","enrollment":2,"officials":[],"conditions":["Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT03475186","title":"Testing Ramipril to Prevent Memory Loss in People With Glioblastoma","sponsor":"Wake Forest University Health Sciences","sponsorClass":"OTHER","phases":["PHASE2"],"status":"COMPLETED","interventions":["Ramipril"],"startDate":"2019-03-25","firstPosted":"2018-03-23","lastUpdated":"2026-03-13","primaryCompletion":"2025-03-25","resultsFirstPosted":"2026-03-13","enrollment":75,"officials":[{"name":"Glenn Lesser, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Wake Forest University Health Sciences"}],"conditions":["Glioblastoma","Radiotherapy; Complications","Cognitive Decline","Chemoradiation"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","Guam"]},{"nctId":"NCT03749187","title":"BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas","acronym":"PNOC017","sponsor":"University of California, San Francisco","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["PARP Inhibitor BGB-290","Temozolomide (TMZ)"],"startDate":"2019-04-03","firstPosted":"2018-11-21","lastUpdated":"2026-03-13","primaryCompletion":"2026-06-30","enrollment":78,"officials":[{"name":"Sabine Mueller, MD, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of California, San Francisco"}],"conditions":["Glioblastoma","IDH1 Gene Mutation","IDH2 Gene Mutation","Low Grade Glioma","Malignant Glioma","Recurrent Glioblastoma","Recurrent WHO Grade II Glioma","Recurrent WHO Grade III Glioma","WHO Grade II Glioma","WHO Grade III Glioma"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT06504381","title":"DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma","sponsor":"University of California, San Francisco","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["DB107-RRV","DB107-FC","Temozolomide"],"startDate":"2025-01-08","firstPosted":"2024-07-16","lastUpdated":"2026-03-11","primaryCompletion":"2028-01-31","enrollment":70,"officials":[{"name":"Nicholas Butowski, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of California, San Francisco"},{"name":"Noriyuki Kasahara, MD, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of California, San Francisco"}],"conditions":["High Grade Glioma","MGMT-Unmethylated Glioblastoma","MGMT-Methylated Glioblastoma"],"siteCountries":["United States","United States","United States","United States","United States"]},{"nctId":"NCT04044937","title":"Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms","acronym":"UC-GlioFET","sponsor":"Thomas Hope","sponsorClass":"OTHER","phases":["PHASE2"],"status":"COMPLETED","interventions":["F-18 Fluoroethyltyrosine (FET)"],"startDate":"2018-10-29","firstPosted":"2019-08-05","lastUpdated":"2026-03-11","primaryCompletion":"2024-03-31","enrollment":143,"officials":[{"name":"Thomas A Hope, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of California, San Francisco"}],"conditions":["Intracranial Neoplasm","Low Grade Glioma","Recurrent Glioblastoma","Recurrent World Health Organization (WHO) Grade II Glioma","Recurrent WHO Grade III Glioma"],"siteCountries":["United States"]},{"nctId":"NCT07461948","title":"Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients","sponsor":"Jonsson Comprehensive Cancer Center","sponsorClass":"OTHER","phases":["PHASE3"],"status":"RECRUITING","interventions":["Ferumoxytol"],"startDate":"2025-10-27","firstPosted":"2026-03-10","lastUpdated":"2026-03-10","primaryCompletion":"2028-10-27","enrollment":15,"officials":[{"name":"Jingwen Yao","role":"PRINCIPAL_INVESTIGATOR","affiliation":"UCLA / Jonsson Comprehensive Cancer Center"}],"conditions":["Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT04716699","title":"Systemic and Local Levels of Lidocaine During Surgery for the Removal of Glioblastoma","sponsor":"University of California, Davis","sponsorClass":"OTHER","phases":["PHASE1"],"status":"COMPLETED","interventions":["Lidocaine"],"startDate":"2021-01-20","firstPosted":"2021-01-20","lastUpdated":"2026-03-10","primaryCompletion":"2021-12-26","enrollment":12,"officials":[{"name":"Kiarash Shahlaie","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of California, Davis"}],"conditions":["Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT07457307","title":"Integrating Biology for Safe Intensification of Glioblastoma Hypofractionated Treatment on the MR-Linac","acronym":"INSIGHT MRL","sponsor":"NYU Langone Health","sponsorClass":"OTHER","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","interventions":["Temozolomide"],"startDate":"2026-06","firstPosted":"2026-03-09","lastUpdated":"2026-03-09","primaryCompletion":"2028-06","enrollment":20,"officials":[{"name":"Jonathan Yang, MD, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"NYU Langone Health"}],"conditions":["High-grade Glioma"],"siteCountries":["United States"]},{"nctId":"NCT07455045","title":"A Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG)","sponsor":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","sponsorClass":"INDUSTRY","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","interventions":["FZ-AD005"],"startDate":"2026-03-01","firstPosted":"2026-03-06","lastUpdated":"2026-03-06","primaryCompletion":"2027-12-01","enrollment":40,"officials":[],"conditions":["High Grade Glioma (III or IV)","Diffuse Midline Glioma (DMG)","Glioblastoma (GBM)"],"siteCountries":["China"]},{"nctId":"NCT04661384","title":"Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma","sponsor":"City of Hope Medical Center","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes"],"startDate":"2021-03-05","firstPosted":"2020-12-10","lastUpdated":"2026-03-05","primaryCompletion":"2027-01-12","enrollment":10,"officials":[{"name":"Lisa A Feldman","role":"PRINCIPAL_INVESTIGATOR","affiliation":"City of Hope Medical Center"}],"conditions":["Ependymoma","Glioblastoma","Medulloblastoma","Recurrent Metastatic Malignant Neoplasm in the Leptomeninges"],"siteCountries":["United States"]},{"nctId":"NCT03152318","title":"A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2","acronym":"rQNestin","sponsor":"Dana-Farber Cancer Institute","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["rQNestin","Cyclophosphamide"],"startDate":"2017-07-18","firstPosted":"2017-05-15","lastUpdated":"2026-03-04","primaryCompletion":"2027-01","enrollment":62,"officials":[{"name":"E. Antonio Chiocca, MD, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Brigham and Women's Hospital"}],"conditions":["Malignant Glioma of Brain","Astrocytoma","Malignant Astrocytoma","Oligodendroglioma","Anaplastic Oligodendroglioma of Brain (Diagnosis)","Mixed Oligo-Astrocytoma","Ependymoma","Ganglioglioma","Pylocytic/Pylomyxoid Astrocytoma","Brain Tumor","Glioma","Brain Cancer","Glioblastoma","Glioblastoma Multiforme"],"siteCountries":["United States","United States","United States","United States","United States"]},{"nctId":"NCT04238819","title":"A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma","sponsor":"Eli Lilly and Company","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"COMPLETED","interventions":["Abemaciclib","Irinotecan","Temozolomide","Dinutuximab","GM-CSF"],"startDate":"2020-11-09","firstPosted":"2020-01-23","lastUpdated":"2026-03-02","primaryCompletion":"2024-03-15","resultsFirstPosted":"2025-08-06","enrollment":47,"officials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","role":"STUDY_DIRECTOR","affiliation":"Eli Lilly and Company"}],"conditions":["Relapsed Solid Tumor","Refractory Solid Tumor"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","Australia","Belgium","France","France","France","Germany","Germany","Germany","Italy","Japan","Spain","Spain","Spain"]},{"nctId":"NCT06665724","title":"Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy (ALA SDT GLIOMA 401)","sponsor":"Universität Münster","sponsorClass":"OTHER","phases":["PHASE1"],"status":"COMPLETED","interventions":["5-Aminolevulinic acid Hydrochloride (Gliolan®)"],"startDate":"2025-01-27","firstPosted":"2024-10-30","lastUpdated":"2026-02-27","primaryCompletion":"2026-02-09","enrollment":16,"officials":[{"name":"Walter Stummer, Univ.-Prof. Dr. med.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Department of Neurosurgery, University Hospital Münster, Münster, Germany, 48149"}],"conditions":["Anaplastic Astrocytoma (AA)","Anaplastic Oligodendroglioma (AO)","Glioblastoma (GBM)"],"siteCountries":["Germany"]},{"nctId":"NCT01068782","title":"Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse","sponsor":"Exelixis","sponsorClass":"INDUSTRY","phases":["PHASE2"],"status":"TERMINATED","interventions":["Cabozantinib"],"startDate":"2010-04","firstPosted":"2010-02-15","lastUpdated":"2026-02-25","primaryCompletion":"2011-05","resultsFirstPosted":"2026-02-25","whyStopped":"Enrollment in this study was terminated for business development reasons before completing one third of the expected subject population, no formal statistical testing was performed.","enrollment":19,"officials":[],"conditions":["Astrocytic Tumors"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","Canada","Canada"]},{"nctId":"NCT02669173","title":"Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma","sponsor":"Case Comprehensive Cancer Center","sponsorClass":"OTHER","phases":["PHASE1"],"status":"COMPLETED","interventions":["Capecitabine","Bevacizumab"],"startDate":"2016-10-11","firstPosted":"2016-02-01","lastUpdated":"2026-02-23","primaryCompletion":"2025-01-07","enrollment":12,"officials":[{"name":"David Peereboom, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center"}],"conditions":["Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT02942264","title":"Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma","sponsor":"National Cancer Institute (NCI)","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"TERMINATED","interventions":["Zotiraciclib (TG02)","Temozolomide (TMZ)"],"startDate":"2016-12-14","firstPosted":"2016-10-24","lastUpdated":"2026-02-23","primaryCompletion":"2020-08-26","resultsFirstPosted":"2021-09-28","whyStopped":"Unable to supply investigational agent, Zotiraciclib (TG02).","enrollment":53,"officials":[{"name":"Jing Wu, M.D.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"National Cancer Institute (NCI)"}],"conditions":["Brain Tumor","Astrocytoma","Astroglioma","Glioblastoma","Gliosarcoma"],"siteCountries":["United States"]},{"nctId":"NCT06058988","title":"Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer","sponsor":"Memorial Sloan Kettering Cancer Center","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":["Trastuzumab deruxtecan"],"startDate":"2023-09-22","firstPosted":"2023-09-28","lastUpdated":"2026-02-23","primaryCompletion":"2027-09-22","enrollment":30,"officials":[{"name":"Nelson Moss, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Memorial Sloan Kettering Cancer Center"}],"conditions":["Brain Cancer","Glioblastoma","Metastatic Cancer","Leptomeningeal Metastasis","Recurrent Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT07410494","title":"Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors","acronym":"SELECT-CAR-NK","sponsor":"Essen Biotech","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["EB-SELECT Single-Target CAR-NK Cells","Dual-Target Antigen-Selected CAR-NK"],"startDate":"2026-02-01","firstPosted":"2026-02-13","lastUpdated":"2026-02-18","primaryCompletion":"2027-12-28","enrollment":85,"officials":[],"conditions":["Cancer","Breast Cancer","Non-Small Cell Lung Cancer (NSCLC)","Colorectal Cancer (Locally Advanced or Metastatic)","Prostate Cancer - Recurrent","Pancreatic Ductal Adenocarcinoma (PDAC)","Ovarian Cancer","Glioblastoma","Melanoma (Skin Cancer)","Acute Myeloid Leukemia (AML)","Non Hodgkin Lymphoma","Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma","Liver Cancer"],"siteCountries":["China"]},{"nctId":"NCT07410676","title":"EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors","acronym":"EBNK-ST-001","sponsor":"Essen Biotech","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["EBNK-001 + IL-15 + Pembrolizumab"],"startDate":"2026-02-01","firstPosted":"2026-02-13","lastUpdated":"2026-02-18","primaryCompletion":"2028-12-21","enrollment":83,"officials":[],"conditions":["Cancer","Sarcoma","Leukaemia","Breast Cancer (Locally Advanced or Metastatic)","Lung Cancer (Diagnosis)","Colorectal Cancer","Melanoma (Skin Cancer)","Bladder Cancer","Kidney Cancer","Pancreatic Cancer Metastatic","Liver Cancer (Primary and Metastatic)","Ovarian Cancer","Esophageal Cancer","Glioblastoma","Non-Melanoma Skin Cancer"],"siteCountries":["China"]},{"nctId":"NCT07318818","title":"A Clinical Trial of P134 Cells in Recurrent Glioblastoma","sponsor":"Tasly Pharmaceutical Group Co., Ltd","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["P134 cell injection"],"startDate":"2026-01-05","firstPosted":"2026-01-06","lastUpdated":"2026-02-18","primaryCompletion":"2028-02-29","enrollment":26,"officials":[{"name":"Zhang Wei, Prof.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Beijing Tiantan Hospital, Capital Medical University, Beijing, P.R.China"}],"conditions":["Recurrent Glioblastoma IDH Wildtype"],"siteCountries":["China"]},{"nctId":"NCT05938387","title":"Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma","sponsor":"CureVac","sponsorClass":"INDUSTRY","phases":["PHASE1"],"status":"COMPLETED","interventions":["CV09050101 mRNA vaccine (CVGBM) 12 μg","CV09050101 mRNA vaccine (CVGBM) 25 μg","CV09050101 mRNA vaccine (CVGBM) 50 μg","CV09050101 mRNA vaccine (CVGBM) 100 μg","CV09050101 mRNA vaccine RDE 100 μg","CV09050101 mRNA vaccine (CVGBM) 6 μg"],"startDate":"2023-06-01","firstPosted":"2023-07-10","lastUpdated":"2026-02-18","primaryCompletion":"2026-02-02","enrollment":37,"officials":[{"name":"Clinical Trial Information","role":"STUDY_DIRECTOR","affiliation":"CureVac SE"}],"conditions":["Glioblastoma"],"siteCountries":["Belgium","Belgium","Germany","Germany","Germany","Germany","Germany","Germany","Germany","Germany","Germany","Germany","Netherlands"]},{"nctId":"NCT07218367","title":"Phase I Trial of pH Resections of GBM at VA","sponsor":"VA Office of Research and Development","sponsorClass":"OTHER","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","interventions":[],"startDate":"2026-07-01","firstPosted":"2025-10-20","lastUpdated":"2026-02-13","primaryCompletion":"2031-07-01","enrollment":12,"officials":[{"name":"Kunal S Patel","role":"PRINCIPAL_INVESTIGATOR","affiliation":"VA Greater Los Angeles Healthcare System, West Los Angeles, CA"}],"conditions":["Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT07263438","title":"Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial","acronym":"Phenix","sponsor":"Centre Hospitalier Universitaire Vaudois","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":["Trimipramine","Cohort 1: Atezolizumab","Bevacizumab","Cohort 2: Atezolizumab","Cohort 2: Bevacizumab"],"startDate":"2025-11-03","firstPosted":"2025-12-04","lastUpdated":"2026-02-13","primaryCompletion":"2028-03-30","enrollment":59,"officials":[],"conditions":["Glioblastoma","Recurrence Tumor"],"siteCountries":["Switzerland","Switzerland","Switzerland","Switzerland","Switzerland","Switzerland","Switzerland"]},{"nctId":"NCT03529448","title":"TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma","acronym":"GEINOCANN","sponsor":"Grupo Español de Investigación en Neurooncología","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"COMPLETED","interventions":["TN-TC11G","Temozolomide Oral Product"],"startDate":"2023-08-18","firstPosted":"2018-05-18","lastUpdated":"2026-02-12","primaryCompletion":"2025-11-13","enrollment":33,"officials":[{"name":"Manuel Benavides, M.D., Ph.D.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Hospital Universitario y Regional de Málaga y Virgen de la Victoria"}],"conditions":["Glioblastoma"],"siteCountries":["Spain","Spain","Spain","Spain","Spain","Spain","Spain","Spain"]},{"nctId":"NCT03681028","title":"Feasibility of Individualized Therapy for Recurrent Glioblastoma","sponsor":"Jennifer Clarke","sponsorClass":"OTHER","phases":["PHASE1"],"status":"COMPLETED","interventions":["Individualized therapy"],"startDate":"2018-12-19","firstPosted":"2018-09-21","lastUpdated":"2026-02-12","primaryCompletion":"2023-11-30","enrollment":30,"officials":[{"name":"Jennifer Clarke, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of California, San Francisco"}],"conditions":["Recurrent Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT04482933","title":"HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma","sponsor":"Pediatric Brain Tumor Consortium","sponsorClass":"OTHER","phases":["PHASE2"],"status":"WITHDRAWN","interventions":["Biological G207"],"startDate":"2025-09-01","firstPosted":"2020-07-23","lastUpdated":"2026-02-10","primaryCompletion":"2025-12-18","whyStopped":"The PBTC lost federal funding and will cease operations in March 2026.PBTC-061 was permanently closed on 10/24/2025 with no patients enrolled.","enrollment":0,"officials":[{"name":"Gregory Friedman, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"M.D. Anderson Cancer Center"}],"conditions":["Neoplasms","High Grade Glioma","Glioblastoma Multiforme","Malignant Glioma of Brain","Anaplastic Astrocytoma of Brain","High-grade Glioma","Anaplastic Glioma","Giant Cell Glioblastoma"],"siteCountries":["United States","United States","United States","United States","United States"]},{"nctId":"NCT04478279","title":"A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors","sponsor":"Sapience Therapeutics","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["ST101","Temozolomide"],"startDate":"2020-07-01","firstPosted":"2020-07-20","lastUpdated":"2026-02-09","primaryCompletion":"2026-12","enrollment":125,"officials":[{"name":"Abi Vainstein-Haras, MD","role":"STUDY_CHAIR","affiliation":"CMO"}],"conditions":["Glioblastoma","Melanoma Stage IV","Breast Cancer","Prostate Cancer","Glioblastoma Multiforme","GBM","Brain Cancer","Metastatic Breast Cancer","Metastatic Melanoma","Metastatic Prostate Cancer","Melanoma Recurrent","Prostate Cancer Metastatic","Recurrent Glioblastoma","Newly Diagnosed Glioblastoma"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United Kingdom","United Kingdom","United Kingdom","United Kingdom"]},{"nctId":"NCT03405792","title":"Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)","acronym":"2-THE-TOP","sponsor":"University of Florida","sponsorClass":"OTHER","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Temozolomide (TMZ)","Pembrolizumab"],"startDate":"2018-02-23","firstPosted":"2018-01-23","lastUpdated":"2026-02-06","primaryCompletion":"2022-11-26","resultsFirstPosted":"2024-04-15","enrollment":40,"officials":[{"name":"Ashley Ghiaseddin, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of Florida"}],"conditions":["Glioblastoma","Glioblastoma, WHO Grade IV"],"siteCountries":["United States"]},{"nctId":"NCT07391215","title":"5G-PEARL: Paxalisib in Malignant Brain Tumours","acronym":"5G-PEARL","sponsor":"Institute of Cancer Research, United Kingdom","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["Paxalisib","Temozolomide capsule"],"startDate":"2026-01-19","firstPosted":"2026-02-05","lastUpdated":"2026-02-05","primaryCompletion":"2029-01-19","enrollment":64,"officials":[{"name":"Juanita Lopez, MD, PhD","role":"STUDY_DIRECTOR","affiliation":"National Health Service, United Kingdom"}],"conditions":["Malignant Primary Gliomas","Glioblastoma Multiforme (GBM)"],"siteCountries":["United Kingdom"]},{"nctId":"NCT03389230","title":"Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma","sponsor":"City of Hope Medical Center","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["HER2(EQ)BBζ/CD19t+ T cells"],"startDate":"2018-08-14","firstPosted":"2018-01-03","lastUpdated":"2026-02-04","primaryCompletion":"2026-12-29","enrollment":29,"officials":[{"name":"Behnam Badie","role":"PRINCIPAL_INVESTIGATOR","affiliation":"City of Hope Medical Center"}],"conditions":["Glioblastoma","Malignant Glioma","Recurrent Glioma","Refractory Glioma","WHO Grade III Glioma"],"siteCountries":["United States"]},{"nctId":"NCT05653635","title":"Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study","acronym":"ReciDOPA","sponsor":"Centre Paul Strauss","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":[],"startDate":"2026-03-01","firstPosted":"2022-12-16","lastUpdated":"2026-02-04","primaryCompletion":"2028-09-01","enrollment":54,"officials":[],"conditions":["Glioblastoma"],"siteCountries":["France","France"]},{"nctId":"NCT07385846","title":"Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency","sponsor":"Jennifer Leddon","sponsorClass":"OTHER","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","interventions":["Pembrolizumab"],"startDate":"2026-06-01","firstPosted":"2026-02-04","lastUpdated":"2026-02-04","primaryCompletion":"2028-06-01","enrollment":8,"officials":[],"conditions":["Glioblastoma","Mismatch Repair Deficiency"],"siteCountries":["United States"]},{"nctId":"NCT05653622","title":"Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operated Glioblastoma","acronym":"SIB-DOPA","sponsor":"Centre Paul Strauss","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":[],"startDate":"2025-06-23","firstPosted":"2022-12-16","lastUpdated":"2026-02-04","primaryCompletion":"2028-07-01","enrollment":75,"officials":[{"name":"Caroline BUND","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Centre Paul Strauss"}],"conditions":["Glioblastoma Multiforme, Adult"],"siteCountries":["France","France","France"]},{"nctId":"NCT02394626","title":"Surgery for Recurrent Glioblastoma","acronym":"RESURGE","sponsor":"Insel Gruppe AG, University Hospital Bern","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":[],"startDate":"2015-05-01","firstPosted":"2015-03-20","lastUpdated":"2026-02-02","primaryCompletion":"2028-12","enrollment":120,"officials":[{"name":"Philippe Schucht, Prof. Dr. med.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Dep. of Neurosurgery, Inselspital Bern"}],"conditions":["Glioblastoma"],"siteCountries":["Austria","Austria","Austria","France","France","France","France","France","France","France","France","Germany","Germany","Greece","Netherlands","Netherlands","Netherlands","Portugal","Spain","Sweden","Sweden","Switzerland","Switzerland","Switzerland","Switzerland"]},{"nctId":"NCT05683808","title":"Venous Thromboembolism Prevention in Outpatients With Glioma","acronym":"VTE-POG","sponsor":"University of Vermont Medical Center","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":["Apixaban"],"startDate":"2023-01-16","firstPosted":"2023-01-13","lastUpdated":"2026-01-30","primaryCompletion":"2026-12-30","enrollment":40,"officials":[{"name":"Alissa A Thomas, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of Vermont Medical Center"}],"conditions":["Glioblastoma","Astrocytoma","Venous Thromboembolism"],"siteCountries":["United States"]},{"nctId":"NCT04752813","title":"A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)","sponsor":"BPGbio","sponsorClass":"INDUSTRY","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["BPM31510","Temozolomide (TMZ)"],"startDate":"2022-08-22","firstPosted":"2021-02-12","lastUpdated":"2026-01-26","primaryCompletion":"2026-08-25","enrollment":50,"officials":[],"conditions":["Glioblastoma","Glioblastoma Multiforme"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT07365280","title":"Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed Glioblastoma","sponsor":"ZSky Biotech Inc","sponsorClass":"INDUSTRY","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","interventions":["Personalized Dendritic Cell Vaccine ZSNeo-DC1.1","Temozolomide (TMZ)"],"startDate":"2026-01-09","firstPosted":"2026-01-26","lastUpdated":"2026-01-26","primaryCompletion":"2028-12-24","enrollment":78,"officials":[],"conditions":["Glioblastoma"]},{"nctId":"NCT07364786","title":"Effect of Salovum® on Pressure, Oxygen and Inflammation in Glioblastoma","acronym":"AFGBMBiop","sponsor":"Peter Siesjö","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":[],"startDate":"2024-10-07","firstPosted":"2026-01-23","lastUpdated":"2026-01-23","primaryCompletion":"2026-10","enrollment":10,"officials":[{"name":"Peter Siesjö, MD, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Skane University Hospital"}],"conditions":["Glioblastoma"],"siteCountries":["Sweden"]},{"nctId":"NCT05084430","title":"Study of Pembrolizumab and M032 (NSC 733972)","sponsor":"University of Alabama at Birmingham","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["M032","Pembrolizumab"],"startDate":"2022-02-25","firstPosted":"2021-10-19","lastUpdated":"2026-01-22","primaryCompletion":"2027-03-01","enrollment":28,"officials":[{"name":"James Markert, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"The University of Alabama at Birmingham"}],"conditions":["Glioblastoma Multiforme","Anaplastic Astrocytoma","Gliosarcoma"],"siteCountries":["United States"]},{"nctId":"NCT06193174","title":"Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1)","sponsor":"University of Alabama at Birmingham","sponsorClass":"OTHER","phases":["PHASE1"],"status":"TERMINATED","interventions":["C134 Re-Administration"],"startDate":"2024-06-21","firstPosted":"2024-01-05","lastUpdated":"2026-01-22","primaryCompletion":"2025-03-07","whyStopped":"Not enough eligible participants to enroll.","enrollment":1,"officials":[{"name":"James Markert, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"The University of Alabama at Birmingham"}],"conditions":["Recurrent Malignant Glioma","Glioblastoma Multiforme of Brain","Gliosarcoma of Brain","Anaplastic Astrocytoma of Brain"],"siteCountries":["United States"]},{"nctId":"NCT07143812","title":"A Study to Evaluate the Safety of a Stem Cell-Based Gene and Cell Therapy in Patients With Newly Diagnosed Glioblastoma","sponsor":"CHA University","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":["MSC11FCD"],"startDate":"2025-10-23","firstPosted":"2025-08-27","lastUpdated":"2026-01-22","primaryCompletion":"2026-12-31","enrollment":10,"officials":[{"name":"Jaejoon Lim, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"CHA University"}],"conditions":["Glioblastoma (GBM)","Newly Diagnosed Glioblastoma Multiforme"],"siteCountries":["South Korea"]},{"nctId":"NCT06630260","title":"5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours","acronym":"5G-RUBY","sponsor":"Institute of Cancer Research, United Kingdom","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["Avutometinib","Defactinib","Temozolomide"],"startDate":"2024-11-15","firstPosted":"2024-10-08","lastUpdated":"2026-01-21","primaryCompletion":"2029-09-30","enrollment":182,"officials":[{"name":"Juanita Lopez, MD, PhD","role":"STUDY_DIRECTOR","affiliation":"National Health Service, UK"}],"conditions":["Glioblastoma Multiforme (GBM)","Glioblastoma Multiform (Grade IV Astrocytoma)","Diffuse Hemispheric Glioma, H3 G34-Mutant","Malignant Primary Gliomas"],"siteCountries":["United Kingdom","United Kingdom","United Kingdom"]},{"nctId":"NCT04440358","title":"Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM","sponsor":"InSightec","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"COMPLETED","interventions":["Carboplatin"],"startDate":"2020-10-13","firstPosted":"2020-06-19","lastUpdated":"2026-01-20","primaryCompletion":"2023-11-30","enrollment":13,"officials":[],"conditions":["Recurrent Glioblastoma"],"siteCountries":["Canada","Italy","South Korea"]},{"nctId":"NCT06105619","title":"A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).","sponsor":"Beijing Pearl Biotechnology Limited Liability Company","sponsorClass":"INDUSTRY","phases":["PHASE2","PHASE3"],"status":"ACTIVE_NOT_RECRUITING","interventions":["PLB1001","Temozolomide","Cisplatin combined with Etoposide"],"startDate":"2018-10-08","firstPosted":"2023-10-27","lastUpdated":"2026-01-20","primaryCompletion":"2023-04-01","enrollment":84,"officials":[{"name":"Wenbin Li","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Beijing Tiantan Hospital"},{"name":"Xiaoguang Qiu","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Beijing Tiantan Hospital"}],"conditions":["Glioblastoma"],"siteCountries":["China"]},{"nctId":"NCT07347210","title":"Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT Glioblastoma","acronym":"MATVAC-1","sponsor":"Centre Hospitalier Universitaire de Besancon","sponsorClass":"OTHER","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","interventions":["UCPVax","Pembrolizumab","Temozolomide"],"startDate":"2026-01","firstPosted":"2026-01-16","lastUpdated":"2026-01-16","primaryCompletion":"2029-01","enrollment":98,"officials":[{"name":"Olivier ADOTEVI, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University Hospital of Besançon"},{"name":"Antoine CARPENTIER, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University Hospital of Besançon"}],"conditions":["Primary Glioblastoma"],"siteCountries":["France","France","France","France"]},{"nctId":"NCT05083754","title":"Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":["Retifanlimab","Temozolomide"],"startDate":"2022-08-31","firstPosted":"2021-10-19","lastUpdated":"2026-01-09","primaryCompletion":"2028-01","enrollment":50,"officials":[{"name":"Lawrence Kleinberg, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Johns Hopkins University"}],"conditions":["Glioblastoma Multiforme"],"siteCountries":["United States"]},{"nctId":"NCT05669820","title":"Antisecretory Factor Glioblastoma Phase 2","acronym":"AFGB2","sponsor":"Peter Siesjö","sponsorClass":"OTHER","phases":["PHASE2","PHASE3"],"status":"RECRUITING","interventions":[],"startDate":"2024-01-15","firstPosted":"2023-01-03","lastUpdated":"2026-01-09","primaryCompletion":"2026-12-01","enrollment":300,"officials":[{"name":"Charlotte Edwardsson","role":"STUDY_CHAIR","affiliation":"Skane University Hospital"},{"name":"Erik Ehinger, MD","role":"STUDY_CHAIR","affiliation":"Skane University Hospital"}],"conditions":["Glioblastoma"],"siteCountries":["Sweden"]},{"nctId":"NCT04221503","title":"Niraparib/TTFields in GBM","sponsor":"Abramson Cancer Center at Penn Medicine","sponsorClass":"OTHER","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Niraparib"],"startDate":"2019-12-30","firstPosted":"2020-01-09","lastUpdated":"2026-01-08","primaryCompletion":"2026-01","enrollment":30,"officials":[],"conditions":["Glioblastoma","Recurrent Glioblastoma","GBM"],"siteCountries":["United States"]},{"nctId":"NCT03743662","title":"Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma","sponsor":"Memorial Sloan Kettering Cancer Center","sponsorClass":"OTHER","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Bevacizumab","Nivolumab"],"startDate":"2018-11-12","firstPosted":"2018-11-16","lastUpdated":"2026-01-07","primaryCompletion":"2026-11","enrollment":39,"officials":[{"name":"Christian Grommes, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Memorial Sloan Kettering Cancer Center"}],"conditions":["Glioblastoma"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT02617745","title":"Impact of the Platelet Level in Patients Treated for Glioblastoma With Temozolomid","acronym":"GLIOPLAK","sponsor":"Centre Henri Becquerel","sponsorClass":"OTHER","phases":["PHASE2"],"status":"COMPLETED","interventions":[],"startDate":"2015-11-30","firstPosted":"2015-12-01","lastUpdated":"2026-01-02","primaryCompletion":"2022-11-28","enrollment":244,"officials":[{"name":"Frederic Di Fiore, MD, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Centre Henri Becquerel"}],"conditions":["Glioblastoma"],"siteCountries":["France"]},{"nctId":"NCT04959500","title":"Newly Diagnosed Glioblastoma","sponsor":"Sun Yat-sen University","sponsorClass":"OTHER","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Anlotinib Hydrochloride","Placebo","Temozolomide"],"startDate":"2021-07-21","firstPosted":"2021-07-13","lastUpdated":"2026-01-02","primaryCompletion":"2026-12-31","enrollment":150,"officials":[{"name":"Zhongping Chen, Doctor","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Sun Yat-Sen University Cancer Center"}],"conditions":["Glioblastoma"],"siteCountries":["China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China"]},{"nctId":"NCT02709226","title":"Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma","sponsor":"National Cancer Institute (NCI)","sponsorClass":"OTHER","phases":["PHASE1"],"status":"COMPLETED","interventions":[],"startDate":"2016-06-15","firstPosted":"2016-03-16","lastUpdated":"2025-12-31","primaryCompletion":"2022-12-16","enrollment":17,"officials":[{"name":"Kevin A Camphausen, M.D.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"National Cancer Institute (NCI)"}],"conditions":["Astrocytoma, Grade IV","Giant Cell Glioblastoma","Glioblastoma Multiforme","Gliosarcoma"],"siteCountries":["United States"]},{"nctId":"NCT05267106","title":"Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations","acronym":"FIGHT-209","sponsor":"Incyte Corporation","sponsorClass":"INDUSTRY","phases":["PHASE2"],"status":"TERMINATED","interventions":["Pemigatinib"],"startDate":"2022-05-20","firstPosted":"2022-03-04","lastUpdated":"2025-12-30","primaryCompletion":"2024-12-17","resultsFirstPosted":"2025-12-30","whyStopped":"Recruitment ceased after a pre-planned futility interim analysis indicated a low probability to confer a clinically meaningful improvement in objective response when compared to currently available therapies. There were no safety related concerns.","enrollment":83,"officials":[{"name":"Victoria Ebiana, MD","role":"STUDY_DIRECTOR","affiliation":"Incyte Corporation"}],"conditions":["Glioblastoma","Adult-type Diffuse Gliomas"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","Denmark","Denmark","Denmark","France","France","France","France","Germany","Germany","Germany","Germany","Italy","Italy","Italy","Italy","Italy","Italy","Japan","Japan","Japan","Japan","Japan","Japan","Netherlands","Netherlands","Spain","Spain","Spain","Spain","Spain","Spain","Spain","Spain","Spain","Spain","Spain","Spain","Spain","Spain","United Kingdom","United Kingdom","United Kingdom","United Kingdom","United Kingdom","United Kingdom","United Kingdom","United Kingdom"]},{"nctId":"NCT04474353","title":"Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma","sponsor":"Stanford University","sponsorClass":"OTHER","phases":["PHASE1"],"status":"COMPLETED","interventions":["Gadolinium","Temozolomide"],"startDate":"2021-05-21","firstPosted":"2020-07-16","lastUpdated":"2025-12-26","primaryCompletion":"2024-11-14","enrollment":12,"officials":[{"name":"Scott G Soltys","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Stanford Universiy"}],"conditions":["Glioblastoma","Newly Diagnosed Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT04165941","title":"Novel Gamma-Delta (γδ)T Cell Therapy for Treatment of Patients With Newly Diagnosed Glioblastoma","acronym":"DRI","sponsor":"University of Alabama at Birmingham","sponsorClass":"OTHER","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["DRI cell therapy"],"startDate":"2020-02-11","firstPosted":"2019-11-18","lastUpdated":"2025-12-26","primaryCompletion":"2026-12-31","enrollment":22,"officials":[{"name":"Louis B Nabors, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of Alabama at Birmingham"}],"conditions":["Brain Tumor Adult"],"siteCountries":["United States"]},{"nctId":"NCT05977322","title":"A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.","sponsor":"Novartis Pharmaceuticals","sponsorClass":"INDUSTRY","phases":["PHASE1"],"status":"TERMINATED","interventions":["68Ga-FF58","177Lu-FF58"],"startDate":"2023-10-06","firstPosted":"2023-08-04","lastUpdated":"2025-12-24","primaryCompletion":"2024-12-13","whyStopped":"The decision was not based on any safety concerns","enrollment":24,"officials":[{"name":"Novartis Pharmaceuticals","role":"STUDY_DIRECTOR","affiliation":"Novartis Pharmaceuticals"}],"conditions":["Pancreatic Ductal Adenocarcinoma","Gastroesophageal Adenocarcinoma","Glioblastoma Multiforme"],"siteCountries":["Israel","Netherlands","Spain","Spain","Switzerland"]},{"nctId":"NCT04116411","title":"A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients","acronym":"VIGAS2","sponsor":"Cecilia Soderberg-Naucler","sponsorClass":"OTHER","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Valganciclovir Tablets","Temozolomide 120 mg","Placebo oral tablet"],"startDate":"2019-09-04","firstPosted":"2019-10-04","lastUpdated":"2025-12-22","primaryCompletion":"2027-09-16","enrollment":220,"officials":[{"name":"Giuseppe Stragliotto, MD, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Karolinska University Hospital"}],"conditions":["Glioblastoma Multiforme"],"siteCountries":["Norway","Norway","Sweden"]},{"nctId":"NCT04691960","title":"A Pilot Study of Ketogenic Diet and Metformin in Glioblastoma: Feasibility and Metabolic Imaging","sponsor":"Weill Medical College of Cornell University","sponsorClass":"OTHER","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Metformin"],"startDate":"2016-08","firstPosted":"2020-12-31","lastUpdated":"2025-12-19","primaryCompletion":"2026-06","enrollment":18,"officials":[{"name":"Howard Fine, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Weill Medical College of Cornell University"}],"conditions":["Glioblastoma"],"siteCountries":["United States","United States"]},{"nctId":"NCT07145047","title":"Clinical Study of Oncolytic Virus in Glioblastoma","sponsor":"Mianyang Central Hospital","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["oncolytic virus"],"startDate":"2023-11-02","firstPosted":"2025-08-28","lastUpdated":"2025-12-19","primaryCompletion":"2025-12-31","enrollment":20,"officials":[],"conditions":["Glioblastoma (GBM)"],"siteCountries":["China"]},{"nctId":"NCT06359379","title":"Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter","sponsor":"Shuttle Pharmaceuticals, Inc.","sponsorClass":"INDUSTRY","phases":["PHASE2"],"status":"TERMINATED","interventions":["Ropidoxuridine"],"startDate":"2024-09-02","firstPosted":"2024-04-11","lastUpdated":"2025-12-18","primaryCompletion":"2025-12-01","whyStopped":"Terminated due to the sponsor's decision.","enrollment":30,"officials":[],"conditions":["Glioblastoma, IDH-wildtype"],"siteCountries":["United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT05686798","title":"Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.","sponsor":"Henry Ford Health System","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":["Ad5-yCD/mutTKSR39rep-ADP adenovirus and fractionated stereotactic radiosurgery (fSRS)"],"startDate":"2022-11-29","firstPosted":"2023-01-17","lastUpdated":"2025-12-16","primaryCompletion":"2027-01","enrollment":18,"officials":[{"name":"Tobias Walbert, MD, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Henry Ford Health System"}],"conditions":["Malignant Glioma of Brain","Astrocytoma","Malignant Astrocytoma","Brain Tumor","Glioma","Brain Cancer","Glioblastoma","Glioblastoma Multiforme","GBM"],"siteCountries":["United States"]},{"nctId":"NCT05956821","title":"Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age","sponsor":"University of Miami","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["SIACI of cetuximab and bevacizumab"],"startDate":"2025-06-19","firstPosted":"2023-07-21","lastUpdated":"2025-12-08","primaryCompletion":"2029-10-01","enrollment":20,"officials":[{"name":"Heather McCrea, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of Miami"}],"conditions":["Glioblastoma Multiforme","Anaplastic Astrocytoma","Fibrillary Astrocytomas","Oligodendroglioma","Diffuse Intrinsic Brainstem Glioma","Diffuse Intrinsic Pontine Glioma","DIPG Brain Tumor","H3 K27M"],"siteCountries":["United States"]},{"nctId":"NCT04391062","title":"Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma","acronym":"DOSINDYGO","sponsor":"University Hospital, Lille","sponsorClass":"OTHER","phases":["PHASE2"],"status":"COMPLETED","interventions":["Gliolan"],"startDate":"2021-09-28","firstPosted":"2020-05-18","lastUpdated":"2025-12-05","primaryCompletion":"2024-03-25","enrollment":14,"officials":[{"name":"Nicolas Reyns, MD,PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University Hospital, Lille"}],"conditions":["Glioblastoma"],"siteCountries":["Belgium","France"]},{"nctId":"NCT04116658","title":"First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma","acronym":"ROSALIE","sponsor":"Enterome","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"COMPLETED","interventions":["Multiple dose of EO2401"],"startDate":"2020-07-13","firstPosted":"2019-10-04","lastUpdated":"2025-11-28","primaryCompletion":"2024-03-04","resultsFirstPosted":"2025-11-28","enrollment":100,"officials":[{"name":"Jean-Michel Paillarse","role":"STUDY_DIRECTOR","affiliation":"Enterome"}],"conditions":["Glioblastoma, Adult"],"siteCountries":["United States","France","France","Germany","Germany","Germany","Germany","Germany","Spain","Spain"]},{"nctId":"NCT03224104","title":"Multi-kinase Inhibitor TG02 (TG02) in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma.","acronym":"STEAM","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","sponsorClass":"OTHER","phases":["PHASE1"],"status":"COMPLETED","interventions":["TG02","Temozolomide"],"startDate":"2018-06-12","firstPosted":"2017-07-21","lastUpdated":"2025-11-26","primaryCompletion":"2022-05-05","resultsFirstPosted":"2025-11-26","enrollment":71,"officials":[{"name":"Emilie Le Rhun","role":"PRINCIPAL_INVESTIGATOR","affiliation":"CHRU de Lille"}],"conditions":["Astrocytoma, Grade III","Glioblastoma"],"siteCountries":["Austria","France","France","France","Germany","Germany","Germany","Germany","Netherlands","Switzerland"]},{"nctId":"NCT01582269","title":"A Study in Recurrent Glioblastoma (GB)","sponsor":"Eli Lilly and Company","sponsorClass":"INDUSTRY","phases":["PHASE2"],"status":"COMPLETED","interventions":["Galunisertib","Lomustine","Placebo"],"startDate":"2012-04-26","firstPosted":"2012-04-20","lastUpdated":"2025-11-24","primaryCompletion":"2014-07-26","resultsFirstPosted":"2025-11-24","enrollment":158,"officials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","role":"STUDY_DIRECTOR","affiliation":"Eli Lilly and Company"}],"conditions":["Glioblastoma"],"siteCountries":["United States","United States","United States","United States","United States","Australia","Australia","Australia","Belgium","Belgium","Belgium","Canada","Canada","France","France","France","France","France","Germany","Germany","Germany","Germany","Italy","Italy","Italy","Netherlands","Netherlands","Poland","Spain"]},{"nctId":"NCT03233152","title":"A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma.","acronym":"GlitIpNi","sponsor":"Universitair Ziekenhuis Brussel","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Ipilimumab (YervoyTM, 50 mg/10 mL solution)","Nivolumab (OpdivoTM, 40 mg/4mL solution)","Autologous CD1c(BDCA-1)+ /CD141(BDCA-3)+ myDC"],"startDate":"2016-11-17","firstPosted":"2017-07-28","lastUpdated":"2025-11-21","primaryCompletion":"2026-11-17","enrollment":110,"officials":[],"conditions":["Glioblastoma"],"siteCountries":["Belgium"]},{"nctId":"NCT03532295","title":"Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas","sponsor":"Washington University School of Medicine","sponsorClass":"OTHER","phases":["PHASE2"],"status":"COMPLETED","interventions":["Epacadostat","Bevacizumab","Retifanlimab"],"startDate":"2020-04-20","firstPosted":"2018-05-22","lastUpdated":"2025-11-21","primaryCompletion":"2024-07-26","resultsFirstPosted":"2025-08-07","enrollment":51,"officials":[{"name":"Milan Chheda, M.D.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Washington University School of Medicine"}],"conditions":["Glioma","Glioblastoma"],"siteCountries":["United States","United States","United States","United States"]},{"nctId":"NCT04945148","title":"Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide","acronym":"OPTIMUM","sponsor":"Hopital Foch","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":["Metformin","Temozolomide"],"startDate":"2024-05-10","firstPosted":"2021-06-30","lastUpdated":"2025-11-21","primaryCompletion":"2028-05","enrollment":640,"officials":[{"name":"Anna Luisa DI STEFANO, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Foch Hospital"}],"conditions":["Glioblastoma, IDH-wildtype"],"siteCountries":["France","France","France","France","France","Italy","Italy"]},{"nctId":"NCT04250922","title":"LAM561 With RT and TMZ for Adults With Glioblastoma","acronym":"CLINGLIO","sponsor":"Laminar Pharmaceuticals","sponsorClass":"INDUSTRY","phases":["PHASE2","PHASE3"],"status":"ACTIVE_NOT_RECRUITING","interventions":["LAM561","TMZ"],"startDate":"2019-12-01","firstPosted":"2020-01-31","lastUpdated":"2025-11-20","primaryCompletion":"2026-01-15","enrollment":144,"officials":[],"conditions":["Primary Glioblastoma","Glioblastoma Multiforme"],"siteCountries":["France","France","France","France","Israel","Italy","Italy","Italy","Italy","Spain","Spain","Spain","Spain","Spain","Spain","Spain","Spain","Spain","United Kingdom","United Kingdom","United Kingdom","United Kingdom"]},{"nctId":"NCT07193628","title":"B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma","sponsor":"Second Affiliated Hospital, Zhejiang University, School of Medicine","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":["EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 1)","EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 2)","EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 3)","EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 4)"],"startDate":"2025-09-26","firstPosted":"2025-09-26","lastUpdated":"2025-11-18","primaryCompletion":"2027-12-31","enrollment":14,"officials":[{"name":"Feng Yan, MD & PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Department of Neurosurgery, the Second Affiliated Hospital of Zhejiang University School of Medicine"}],"conditions":["Refractory Glioblastoma","Recurrent Glioblastoma"],"siteCountries":["China"]},{"nctId":"NCT03746080","title":"Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma","sponsor":"Lawrence D Recht","sponsorClass":"OTHER","phases":["PHASE2"],"status":"COMPLETED","interventions":["Plerixafor","Temozolomide"],"startDate":"2018-12-04","firstPosted":"2018-11-19","lastUpdated":"2025-11-14","primaryCompletion":"2022-05-31","resultsFirstPosted":"2024-06-26","enrollment":21,"officials":[{"name":"Lawrence Recht","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Stanford Cancer Institute Palo Alto"}],"conditions":["Glioblastoma","Glioblastoma With Primitive Neuronal Component","Gliosarcoma","Malignant Glioma","Oligodendroglial Component Present"],"siteCountries":["United States"]},{"nctId":"NCT03107780","title":"Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer","sponsor":"National Cancer Institute (NCI)","sponsorClass":"OTHER","phases":["PHASE1"],"status":"TERMINATED","interventions":["Navtemadlin"],"startDate":"2018-07-09","firstPosted":"2017-04-11","lastUpdated":"2025-11-13","primaryCompletion":"2025-08-15","whyStopped":"Drug supply issues","enrollment":32,"officials":[{"name":"Eudocia Lee","role":"PRINCIPAL_INVESTIGATOR","affiliation":"National Cancer Institute (NCI)"}],"conditions":["Glioblastoma","Gliosarcoma","MGMT-Unmethylated Glioblastoma","Recurrent Glioblastoma"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT06521567","title":"A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer","sponsor":"GlaxoSmithKline","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Cobolimab","Dostarlimab"],"startDate":"2025-03-06","firstPosted":"2024-07-26","lastUpdated":"2025-11-12","primaryCompletion":"2026-10-13","enrollment":83,"officials":[{"name":"GSK Clinical Trials","role":"STUDY_DIRECTOR","affiliation":"GlaxoSmithKline"}],"conditions":["Melanoma","Hodgkin Lymphoma","High and Low Grade Glioma","Glioblastoma Multiforme (GBM)","Diffuse Intrinsic Pontine Glioma (DIPG)","Ependymoma","Osteosarcoma","Hepatic Tumors","Hepatoblastoma","Hepatocellular Carcinoma (HCC)","Fibrolamellar Carcinoma","Rhabdomyosarcoma"],"siteCountries":["United States","United States","United States","United States","United States","United States","Czechia","Czechia","Denmark","France","France","France","France","France","Italy","Italy","Spain","Spain","Spain","Spain"]},{"nctId":"NCT04209790","title":"Neoadjuvant Chemoradiation for Resectable Glioblastoma","acronym":"NeoGlio","sponsor":"Geisinger Clinic","sponsorClass":"OTHER","phases":["PHASE2"],"status":"TERMINATED","interventions":["Drug Therapy with Temozolomide (benzolamide) (Standard of Care)"],"startDate":"2020-04-01","firstPosted":"2019-12-24","lastUpdated":"2025-11-10","primaryCompletion":"2022-09-14","resultsFirstPosted":"2025-11-10","whyStopped":"Suspended to identify a permanent PI at site level. Decision to Terminate was made on 7/29/25 because no other PI able to take on project.","enrollment":2,"officials":[{"name":"Michel Lacroix, M.D.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Geisinger Clinic"}],"conditions":["Glioblastoma","Surgery","High Grade Glioma"],"siteCountries":["United States","United States"]},{"nctId":"NCT05341947","title":"Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma","sponsor":"Jeremy Rudnick, M.D","sponsorClass":"OTHER","phases":["PHASE1"],"status":"WITHDRAWN","interventions":["Activated T cells"],"startDate":"2026-06","firstPosted":"2022-04-22","lastUpdated":"2025-10-22","primaryCompletion":"2027-12","whyStopped":"Lack of Funding","enrollment":0,"officials":[{"name":"Jeremy Rudnick, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Cedars-Sinai Medical Center"}],"conditions":["Recurrent Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT04826393","title":"ASP8374 + Cemiplimab in Recurrent Glioma","sponsor":"Dana-Farber Cancer Institute","sponsorClass":"OTHER","phases":["PHASE1"],"status":"COMPLETED","interventions":["ASP8374","cemiplimab"],"startDate":"2022-03-09","firstPosted":"2021-04-01","lastUpdated":"2025-10-22","primaryCompletion":"2022-10-31","enrollment":14,"officials":[{"name":"David A Reardon, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Dana-Farber Cancer Institute"}],"conditions":["Glioblastoma","Recurrent Glioblastoma"],"siteCountries":["United States","United States","United States","United States"]},{"nctId":"NCT02711137","title":"Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies","sponsor":"Incyte Corporation","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"TERMINATED","interventions":["INCB057643","Gemcitabine","Paclitaxel","Rucaparib","Abiraterone","Ruxolitinib","Azacitidine"],"startDate":"2016-05-18","firstPosted":"2016-03-17","lastUpdated":"2025-10-21","primaryCompletion":"2019-02-13","resultsFirstPosted":"2022-04-28","whyStopped":"Study terminated due to safety issues.","enrollment":137,"officials":[{"name":"Fred Zheng, MD, PhD","role":"STUDY_DIRECTOR","affiliation":"Incyte Corporation"}],"conditions":["Solid Tumors"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","Belgium","France"]},{"nctId":"NCT04373785","title":"NG101m Adjuvant Therapy in Glioblastoma Patients","sponsor":"NeuGATE Theranostics","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","interventions":["Temozolomide","NG101m"],"startDate":"2027-01-01","firstPosted":"2020-05-04","lastUpdated":"2025-10-21","primaryCompletion":"2030-07-30","enrollment":52,"officials":[{"name":"Yvonne Kew, MD, PhD","role":"STUDY_DIRECTOR","affiliation":"NeuGATE Theranostics"}],"conditions":["Glioblastoma Multiforme"],"siteCountries":["United States"]},{"nctId":"NCT02685605","title":"Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme","acronym":"INTRAGO-II","sponsor":"Universitätsmedizin Mannheim","sponsorClass":"OTHER","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Temozolomide"],"startDate":"2016-12-09","firstPosted":"2016-02-19","lastUpdated":"2025-10-14","primaryCompletion":"2025-11","enrollment":314,"officials":[{"name":"Frank A. Giordano, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Department of Radiation Oncology, University Medical Center Mannheim, University of Heidelberg, Germany"},{"name":"Kevin Petrecca, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Department of Neurosurgery, Montréal Neurological, Institute and Hospital, Montréal, Canada"}],"conditions":["Glioblastoma"],"siteCountries":["United States","United States","United States","United States","United States","Brazil","Canada","China","Germany","Germany","Germany","Germany","Germany","Germany","Germany","South Korea","Spain","Spain","United Kingdom"]},{"nctId":"NCT04982926","title":"A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer","sponsor":"Taiho Oncology, Inc.","sponsorClass":"INDUSTRY","phases":["PHASE1"],"status":"TERMINATED","interventions":["TAS2940","TAS2940"],"startDate":"2021-09-16","firstPosted":"2021-07-29","lastUpdated":"2025-10-14","primaryCompletion":"2025-02-26","whyStopped":"After careful review of Taiho's ongoing portfolio and data obtained so far in the context of broader landscape of clinical development in NSCLC HER2mut, Sponsor has made a strategic decision to terminate this study and not based on safety concerns.","enrollment":29,"officials":[],"conditions":["Solid Tumor","Glioblastoma","Non-small Cell Lung Cancer","Breast Cancer"],"siteCountries":["United States","United States","France"]},{"nctId":"NCT00807027","title":"Clinical Trial to Assess the Efficacy and Safety of 'Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea","sponsor":"GC Cell Corporation","sponsorClass":"INDUSTRY","phases":["PHASE3"],"status":"COMPLETED","interventions":["Activated T lymphocyte(Immuncell-LC)"],"startDate":"2008-12-05","firstPosted":"2008-12-11","lastUpdated":"2025-10-10","primaryCompletion":"2012-10","resultsFirstPosted":"2025-10-10","enrollment":180,"officials":[{"name":"Chunghyun Kim, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Hanyang University"}],"conditions":["Glioblastoma"],"siteCountries":["South Korea","South Korea","South Korea","South Korea","South Korea","South Korea","South Korea"]},{"nctId":"NCT03426891","title":"Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","sponsorClass":"OTHER","phases":["PHASE1"],"status":"COMPLETED","interventions":["Pembrolizumab","Vorinostat","Temozolomide"],"startDate":"2018-03-16","firstPosted":"2018-02-08","lastUpdated":"2025-10-06","primaryCompletion":"2021-10-18","resultsFirstPosted":"2025-10-06","enrollment":21,"officials":[{"name":"Peter Forsyth, M.D.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"H. Lee Moffitt Cancer Center and Research Institute"}],"conditions":["Glioblastoma","Brain Tumor","GBM"],"siteCountries":["United States"]},{"nctId":"NCT06439420","title":"CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial","acronym":"CBT-I in PBT","sponsor":"Virginia Commonwealth University","sponsorClass":"OTHER","phases":["PHASE2"],"status":"COMPLETED","interventions":[],"startDate":"2024-07-08","firstPosted":"2024-06-03","lastUpdated":"2025-10-01","primaryCompletion":"2025-09-25","enrollment":70,"officials":[{"name":"Ashlee Loughan, Ph.D","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Virginia Commonwealth University"}],"conditions":["Primary Brain Tumor","Glioblastoma","Astrocytoma","Oligodendroglioma","Meningioma","Primary Central Nervous System (CNS) Lymphoma"],"siteCountries":["United States"]},{"nctId":"NCT07193654","title":"Stupp Treatment With Intrathecal Injection of Thiotepa for Glioblastoma With Advanced Spread","sponsor":"Second Affiliated Hospital, Zhejiang University, School of Medicine","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":["Intrathecal injection of thiotepa","Stupp regimen (oral temozolomide)"],"startDate":"2025-04-01","firstPosted":"2025-09-26","lastUpdated":"2025-09-26","primaryCompletion":"2027-04-01","enrollment":38,"officials":[],"conditions":["Glioblastoma (GBM)"],"siteCountries":["China"]},{"nctId":"NCT05608395","title":"11C-methionine in Diagnostics and Management of Glioblastoma Multiforme Patients (GlioMET)","acronym":"GlioMET","sponsor":"Masaryk Memorial Cancer Institute","sponsorClass":"OTHER","phases":["PHASE2"],"status":"COMPLETED","interventions":["11C-Methionine PET/CT"],"startDate":"2020-12-04","firstPosted":"2022-11-08","lastUpdated":"2025-09-25","primaryCompletion":"2024-06-20","enrollment":33,"officials":[{"name":"Radek Lakomy, MD, Ph.D.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Masaryk Memorial Cancer Institute, Dept. of Comprehensive Cancer Care"}],"conditions":["Glioblastoma Multiforme"],"siteCountries":["Czechia"]},{"nctId":"NCT05941507","title":"A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors","sponsor":"LigaChem Biosciences, Inc.","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["LCB84","Anti-PD-1 monoclonal antibody"],"startDate":"2023-10-05","firstPosted":"2023-07-12","lastUpdated":"2025-09-24","primaryCompletion":"2027-01","enrollment":300,"officials":[{"name":"Rodrigo Ruiz-Soto, MD","role":"STUDY_DIRECTOR","affiliation":"AntibodyChem Biosciences"}],"conditions":["Advanced Solid Tumors"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","Canada"]},{"nctId":"NCT06835803","title":"Enhanced Local Intensified Radiation Therapy in Elderly Glioblastoma: A Phase 2 Hybrid Randomized Trial","acronym":"ELITE-GBM","sponsor":"Brigham and Women's Hospital","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":[],"startDate":"2025-04-14","firstPosted":"2025-02-19","lastUpdated":"2025-09-18","primaryCompletion":"2028-03-31","enrollment":56,"officials":[],"conditions":["Glioblastoma (GBM)"],"siteCountries":["United States","United States","United States"]},{"nctId":"NCT07179328","title":"Focused Ultrasound Blood-Brain Barrier Disruption for the Treatment of High-Grade Glioma in Patients Undergoing Standard Chemotherapy","sponsor":"Sunnybrook Health Sciences Centre","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":["Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension"],"startDate":"2025-06-04","firstPosted":"2025-09-17","lastUpdated":"2025-09-17","primaryCompletion":"2027-07","enrollment":10,"officials":[{"name":"Nir Lipsman","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Sunnybrook Health Sciences Centre"}],"conditions":["GBM","Glioblastoma Multiforme (GBM)","Glioblastoma Multiforme of Brain","Glioblastoma Multiforme Glioma","HGG","Glioma","Brain Tumor Adult","Brain Tumor, Primary"],"siteCountries":["Canada"]},{"nctId":"NCT07141732","title":"Combined Treatment of Patients With Newly Diagnosed Glioblastoma Using the Xoft® Axxent® Electronic Brachytherapy (eBx®) System for Intraoperative Balloon Electronic Brachytherapy","sponsor":"Joint Stock Company European Medical Centre","sponsorClass":"OTHER","phases":["PHASE1"],"status":"RECRUITING","interventions":["Resection of newly diagnosed glioblastoma combined with intraoperative balloon electronic brachytherapy using the Xoft® Axxent® Electronic Brachytherapy (eBx®) System"],"startDate":"2025-09-01","firstPosted":"2025-08-26","lastUpdated":"2025-09-16","primaryCompletion":"2026-03-01","enrollment":15,"officials":[{"name":"Aleksey Krivoshapkin, Professor M.D.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Joint-Stock Company European Medical Center"},{"name":"Alexey Gaitan, Candidate of Medical Sciences","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Joint-Stock Company European Medical Center"}],"conditions":["Glioblastoma"],"siteCountries":["Russia"]},{"nctId":"NCT01811121","title":"MEDICO-ECONOMIC EVALUATION OF SURGERY GUIDED BY FLUORESCENCE FOR THE OPTIMIZATION OF RESECTION OF GLIOBLASTOMAS","acronym":"RESECT","sponsor":"Hospices Civils de Lyon","sponsorClass":"OTHER","phases":["PHASE3"],"status":"COMPLETED","interventions":["5-aminolévulinique acid (5-ALA)","Placebo"],"startDate":"2013-02","firstPosted":"2013-03-14","lastUpdated":"2025-09-15","primaryCompletion":"2013-03","enrollment":170,"officials":[{"name":"Jacques GUYOTAT, MD","role":"STUDY_DIRECTOR","affiliation":"Hospices Civils de Lyon"}],"conditions":["Glioblastoma"],"siteCountries":["France"]},{"nctId":"NCT01107522","title":"Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas","sponsor":"Tactical Therapeutics, Inc.","sponsorClass":"INDUSTRY","phases":["PHASE1"],"status":"UNKNOWN","interventions":["CTO","CTO and Temodar®","CTO, Temodar®, Radiation therapy"],"startDate":"2010-05","firstPosted":"2010-04-21","lastUpdated":"2025-09-09","primaryCompletion":"2025-01","enrollment":100,"officials":[{"name":"Matthew Taylor, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Oregon Health and Sciences University"},{"name":"Elena Pentsova, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Memorial Sloan Kettering Cancer Center"},{"name":"Walter Urba, MD, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Providence Health & Services"},{"name":"Katharine McNeill, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"NYU MEDICAL CENTER"},{"name":"Lisa DeAngelis, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Memorial Sloan Kettering Cancer Center"},{"name":"Timothy Chan, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Memorial Sloan Kettering Cancer Center"}],"conditions":["Solid Tumors, Glioblastoma, Recurrent Malignant Gliomas"],"siteCountries":["United States","United States","United States","United States"]},{"nctId":"NCT03347617","title":"Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma","sponsor":"OHSU Knight Cancer Institute","sponsorClass":"OTHER","phases":["PHASE2"],"status":"TERMINATED","interventions":["Ferumoxytol","Pembrolizumab"],"startDate":"2017-12-20","firstPosted":"2017-11-20","lastUpdated":"2025-09-09","primaryCompletion":"2023-12-31","resultsFirstPosted":"2025-09-09","whyStopped":"Principal investigator transition","enrollment":52,"officials":[{"name":"Leslie Muldoon, Ph.D.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"OHSU Knight Cancer Institute"}],"conditions":["Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT06102525","title":"A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma","sponsor":"Rznomics, Inc.","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["RZ-001","VGCV"],"startDate":"2024-10-08","firstPosted":"2023-10-26","lastUpdated":"2025-09-05","primaryCompletion":"2029-03","enrollment":43,"officials":[],"conditions":["Glioblastoma"],"siteCountries":["South Korea","South Korea","South Korea","South Korea","South Korea","South Korea"]},{"nctId":"NCT03050736","title":"Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression","sponsor":"Kintara Therapeutics, Inc.","sponsorClass":"INDUSTRY","phases":["PHASE2"],"status":"COMPLETED","interventions":["VAL-083 (Dianhydrogalactitol)"],"startDate":"2017-12-17","firstPosted":"2017-02-13","lastUpdated":"2025-09-04","primaryCompletion":"2021-11-22","enrollment":29,"officials":[{"name":"Chen Zhong-ping, M.D., Ph.D.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Sun Yat-sen University"}],"conditions":["Glioma","Glioblastoma","Glioblastoma Multiforme","GBM","Brain Cancer"],"siteCountries":["China"]},{"nctId":"NCT03149575","title":"VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM","acronym":"STAR-3","sponsor":"DelMar Pharmaceuticals, Inc.","sponsorClass":"INDUSTRY","phases":["PHASE3"],"status":"TERMINATED","interventions":["VAL-083, Dianhydrogalactitol","Physician's Choice of Salvage Therapy - temozolomide","Physician's Choice of Salvage Therapy - lomustine","Physician's Choice of Salvage Therapy - carboplatin"],"startDate":"2017-10-27","firstPosted":"2017-05-11","lastUpdated":"2025-09-04","primaryCompletion":"2019-05-31","whyStopped":"Change in clinical development plan","enrollment":2,"officials":[{"name":"Nicholas Butowski, M.D.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of California, San Francisco, California, USA 94143"}],"conditions":["Glioblastoma Multiforme","Glioblastoma","Glioma","GBM","Brain Cancer"],"siteCountries":["United States","United States","United States","United States","United States"]},{"nctId":"NCT05190315","title":"Chlorpromazine and Standard of Care in Glioblastoma","sponsor":"Mohammed Milhem","sponsorClass":"OTHER","phases":["PHASE1"],"status":"COMPLETED","interventions":["Chlorpromazine","Temozolomide"],"startDate":"2022-01-28","firstPosted":"2022-01-13","lastUpdated":"2025-09-02","primaryCompletion":"2023-04-25","enrollment":10,"officials":[{"name":"Mohammed Milhem, MBBS","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of Iowa Hospitals and Clinics Holden Comprehensive Cancer Center"}],"conditions":["Glioblastoma Multiforme"],"siteCountries":["United States"]},{"nctId":"NCT02717962","title":"Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting","sponsor":"Kintara Therapeutics, Inc.","sponsorClass":"INDUSTRY","phases":["PHASE2"],"status":"COMPLETED","interventions":["VAL-083, Dianhydrogalactitol"],"startDate":"2017-01-20","firstPosted":"2016-03-24","lastUpdated":"2025-08-29","primaryCompletion":"2024-12-30","enrollment":118,"officials":[{"name":"Barbara O'Brien, M.D.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of Texas, MDAnderson Cancer Center, Houston, Texas, USA 77030"}],"conditions":["Glioma","Glioblastoma","Glioblastoma Multiforme","GBM","Brain Cancer"],"siteCountries":["United States"]},{"nctId":"NCT01478178","title":"Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma","sponsor":"Kintara Therapeutics, Inc.","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"COMPLETED","interventions":["VAL-083 (Dianhydrogalactitol)"],"startDate":"2011-10","firstPosted":"2011-11-23","lastUpdated":"2025-08-29","primaryCompletion":"2015-12","enrollment":55,"officials":[{"name":"Howard A Burris, M.D.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Sarah Cannon Research Institute; Nashville, Tennessee 37203, USA"},{"name":"Manish Patel, M.D.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Florida Cancer Specialists, Sarasota, Florida 34232, USA"},{"name":"Nicholas Butowski, M.D.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of California, San Francisco, 94143, USA"},{"name":"Sani Kizilbash, M.D.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Mayo Clinic, Rochester, Minnesota 55905, USA"},{"name":"Gerald Falchook, M.D.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Sarah Cannon Research Institute; Denver, Colorado 80218 USA"}],"conditions":["Glioma","Glioblastoma","Glioblastoma Multiforme","GBM","Brain Cancer"],"siteCountries":["United States","United States","United States","United States","United States"]},{"nctId":"NCT03679754","title":"Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102","sponsor":"Alaunos Therapeutics","sponsorClass":"INDUSTRY","phases":["PHASE1"],"status":"COMPLETED","interventions":["Ad-RTS-hIL-12","veledimex"],"startDate":"2018-09-05","firstPosted":"2018-09-20","lastUpdated":"2025-08-28","primaryCompletion":"2019-04-02","resultsFirstPosted":"2025-08-28","enrollment":36,"officials":[{"name":"Jaymes Holland","role":"STUDY_DIRECTOR","affiliation":"Alaunos Therapeutics"}],"conditions":["Glioblastoma"],"siteCountries":["United States","United States","United States","United States"]},{"nctId":"NCT04863950","title":"Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma","sponsor":"The University of Texas Health Science Center at San Antonio","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":["Lomustine","Imipramine Hydrochloride"],"startDate":"2022-05-25","firstPosted":"2021-04-28","lastUpdated":"2025-08-27","primaryCompletion":"2026-08","enrollment":25,"officials":[{"name":"William Kelly, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"The University of Texas Health Science Center - Mays Cancer Center"}],"conditions":["Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT04587830","title":"ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme","acronym":"GBM","sponsor":"Polaris Group","sponsorClass":"INDUSTRY","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["ADI-PEG 20","Temozolomide","Placebo"],"startDate":"2020-09-14","firstPosted":"2020-10-14","lastUpdated":"2025-08-26","primaryCompletion":"2027-02-28","enrollment":100,"officials":[{"name":"Kuo-Chen Wei, M.D.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Chang Gung Memorial Hospital"}],"conditions":["Glioblastoma Multiforme (GBM)"],"siteCountries":["South Korea","South Korea","South Korea","South Korea","South Korea","Taiwan","Taiwan","Taiwan","Taiwan","Taiwan"]},{"nctId":"NCT05376800","title":"A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma","sponsor":"Boehringer Ingelheim","sponsorClass":"INDUSTRY","phases":["PHASE1"],"status":"COMPLETED","interventions":["BI 907828 (Brigimadlin)"],"startDate":"2022-11-30","firstPosted":"2022-05-17","lastUpdated":"2025-08-24","primaryCompletion":"2025-07-31","enrollment":24,"officials":[],"conditions":["Glioblastoma"],"siteCountries":["United States","United States","United States","United States","Belgium","Spain","Spain"]},{"nctId":"NCT07138001","title":"Phase 2 Clinical Trial of KH617","sponsor":"Sichuan Honghe Biotechnology Co., Ltd.","sponsorClass":"INDUSTRY","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","interventions":["KH617+TMZ","KH617","TPC: TMZ or Platinum (cisplatin or carboplatin)+VP-16"],"startDate":"2025-08","firstPosted":"2025-08-22","lastUpdated":"2025-08-22","primaryCompletion":"2027-09","enrollment":60,"officials":[{"name":"Wenbin Li","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Beijing Titan Hospital,Capital Medical University"}],"conditions":["Recurrent Glioblastoma"]},{"nctId":"NCT04747145","title":"Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma","sponsor":"Medical College of Wisconsin","sponsorClass":"OTHER","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["Concurrent Chemotherapy (Temozolomide)","Adjuvant Chemotherapy (Temozolomide)"],"startDate":"2021-06-03","firstPosted":"2021-02-10","lastUpdated":"2025-08-21","primaryCompletion":"2025-03-05","enrollment":38,"officials":[{"name":"Michael Straza, MD, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Medical College of Wisconsin"}],"conditions":["Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT07130149","title":"Sonodynamic-Chemoradiotherapy Integration in Glioblastoma","sponsor":"Yingjuan Zheng","sponsorClass":"OTHER","phases":["PHASE2"],"status":"ENROLLING_BY_INVITATION","interventions":[],"startDate":"2024-10-01","firstPosted":"2025-08-19","lastUpdated":"2025-08-19","primaryCompletion":"2028-08-01","enrollment":230,"officials":[],"conditions":["Glioblastoma (GBM)"],"siteCountries":["China"]},{"nctId":"NCT04910022","title":"Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma","sponsor":"Nerviano Medical Sciences","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","interventions":["NMS-03305293","Temozolomide"],"startDate":"2021-12-01","firstPosted":"2021-06-02","lastUpdated":"2025-08-19","primaryCompletion":"2027-05-30","enrollment":150,"officials":[],"conditions":["Glioblastoma","Diffuse Glioma"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","Italy","Italy","Italy","Italy","Netherlands","Puerto Rico","Switzerland"]},{"nctId":"NCT05222802","title":"A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)","sponsor":"Katmai Pharmaceuticals Inc.","sponsorClass":"INDUSTRY","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","interventions":["ERAS-801"],"startDate":"2022-02-25","firstPosted":"2022-02-03","lastUpdated":"2025-08-17","primaryCompletion":"2025-08-31","enrollment":52,"officials":[{"name":"Les Brail","role":"STUDY_DIRECTOR","affiliation":"Medical Director"}],"conditions":["Glioblastoma Multiforme"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT02327078","title":"A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)","sponsor":"Incyte Corporation","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"COMPLETED","interventions":["Nivolumab","Epacadostat","Chemotherapy"],"startDate":"2014-11-26","firstPosted":"2014-12-30","lastUpdated":"2025-08-14","primaryCompletion":"2020-06-16","resultsFirstPosted":"2023-04-26","enrollment":307,"officials":[{"name":"Lance Leopold","role":"STUDY_DIRECTOR","affiliation":"Incyte Corporation"}],"conditions":["B-cell Malignancies","Colorectal Cancer (CRC)","Head and Neck Cancer","Lung Cancer","Lymphoma","Melanoma","Ovarian Cancer","Glioblastoma"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United Kingdom","United Kingdom"]},{"nctId":"NCT07120620","title":"PriCoTTF Study: TTFields Before and During Radiotherapy for Newly Diagnosed Glioblastoma","acronym":"PriCoTTF","sponsor":"Sied Kebir","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"COMPLETED","interventions":[],"startDate":"2019-06-25","firstPosted":"2025-08-13","lastUpdated":"2025-08-13","primaryCompletion":"2023-08-28","enrollment":33,"officials":[],"conditions":["Glioblastoma Multiforme (GBM)"],"siteCountries":["Germany"]},{"nctId":"NCT03636477","title":"A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102","sponsor":"Alaunos Therapeutics","sponsorClass":"INDUSTRY","phases":["PHASE1"],"status":"COMPLETED","interventions":["Ad-RTS-hIL-12","veledimex","Nivolumab"],"startDate":"2018-06-18","firstPosted":"2018-08-17","lastUpdated":"2025-08-12","primaryCompletion":"2020-10-15","resultsFirstPosted":"2025-08-12","enrollment":21,"officials":[{"name":"Jaymes Holland","role":"STUDY_DIRECTOR","affiliation":"Alaunos Therapeutics"}],"conditions":["Glioblastoma"],"siteCountries":["United States","United States","United States","United States"]},{"nctId":"NCT03330197","title":"A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG","sponsor":"Alaunos Therapeutics","sponsorClass":"INDUSTRY","phases":["PHASE1","PHASE2"],"status":"TERMINATED","interventions":["Ad-RTS-hIL-12","Oral Veledimex - Arm 1 (Pediatric Brain Tumor)","Oral Veledimex - Arm 2 (DIPG)"],"startDate":"2017-09-26","firstPosted":"2017-11-06","lastUpdated":"2025-08-12","primaryCompletion":"2021-09-10","resultsFirstPosted":"2025-08-12","whyStopped":"Sponsor decision due to slow accrual","enrollment":6,"officials":[{"name":"Jaymes Holland","role":"STUDY_DIRECTOR","affiliation":"Alaunos Therapeutics"}],"conditions":["Pediatric Brain Tumor","Diffuse Intrinsic Pontine Glioma"],"siteCountries":["United States","United States","United States"]},{"nctId":"NCT04388475","title":"Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma","sponsor":"Oblato, Inc.","sponsorClass":"INDUSTRY","phases":["PHASE2"],"status":"COMPLETED","interventions":["OKN-007","Temozolomide (TMZ)"],"startDate":"2020-06-12","firstPosted":"2020-05-14","lastUpdated":"2025-08-12","primaryCompletion":"2024-05-08","enrollment":57,"officials":[],"conditions":["Recurrent Malignant Glioma","Brain Glioblastoma"],"siteCountries":["United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States","United States"]},{"nctId":"NCT04118036","title":"Abemaciclib + Pembrolizumab In Glioblastoma","sponsor":"Dana-Farber Cancer Institute","sponsorClass":"OTHER","phases":["PHASE2"],"status":"WITHDRAWN","interventions":["Pembrolizumab","Abemaciclib"],"startDate":"2021-12-01","firstPosted":"2019-10-07","lastUpdated":"2025-08-11","primaryCompletion":"2023-12-01","whyStopped":"safety concerns","enrollment":0,"officials":[{"name":"Patrick Wen, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Dana-Farber Cancer Institute"}],"conditions":["Glioblastoma"],"siteCountries":["United States","United States"]},{"nctId":"NCT01931098","title":"Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab","sponsor":"National Cancer Institute (NCI)","sponsorClass":"OTHER","phases":["PHASE2"],"status":"COMPLETED","interventions":["topotecan","pazopanib"],"startDate":"2015-12-10","firstPosted":"2013-08-29","lastUpdated":"2025-08-11","primaryCompletion":"2019-09-12","resultsFirstPosted":"2020-09-18","enrollment":35,"officials":[{"name":"Kevin Camphausen, M.D.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"National Cancer Institute (NCI)"}],"conditions":["Glioblastoma","Glioblastoma Multiforme","Gliosarcoma","Brain Neoplasms","Central Nervous System Neoplasms"],"siteCountries":["United States"]},{"nctId":"NCT03672721","title":"IA Carboplatin + Radiotherapy in Relapsing GBM","sponsor":"Université de Sherbrooke","sponsorClass":"OTHER","phases":["PHASE1","PHASE2"],"status":"RECRUITING","interventions":["IA Carbo+ Radiation"],"startDate":"2018-07-10","firstPosted":"2018-09-14","lastUpdated":"2025-08-11","primaryCompletion":"2025-12-10","enrollment":35,"officials":[{"name":"David Fortin, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"CRC-CHUS"}],"conditions":["Glioblastoma Multiforme","Relapse"],"siteCountries":["Canada"]},{"nctId":"NCT03018288","title":"Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)","sponsor":"National Cancer Institute (NCI)","sponsorClass":"OTHER","phases":["PHASE2"],"status":"TERMINATED","interventions":["Pembrolizumab","HSPPC-96","Temozolomide"],"startDate":"2017-09-21","firstPosted":"2017-01-12","lastUpdated":"2025-08-08","primaryCompletion":"2022-12-20","resultsFirstPosted":"2024-02-28","whyStopped":"Study closed early due to poor accrual.","enrollment":90,"officials":[{"name":"Kevin Camphausen, M.D.","role":"PRINCIPAL_INVESTIGATOR","affiliation":"National Cancer Institute (NCI)"}],"conditions":["Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT06356883","title":"Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma","sponsor":"Université de Sherbrooke","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":["IA Carboplatin + IA Caelyx","IA Carboplatin + IA Etoposide Phosphate"],"startDate":"2025-08","firstPosted":"2024-04-10","lastUpdated":"2025-08-07","primaryCompletion":"2027-04","enrollment":120,"officials":[{"name":"David Fortin, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Estrie University Integrated Health and Social Services Center - University Hospital of Sherbrooke"}],"conditions":["Glioblastoma Multiforme","Relapse"],"siteCountries":["Canada"]},{"nctId":"NCT04963413","title":"RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.","sponsor":"University of Florida","sponsorClass":"OTHER","phases":["PHASE1"],"status":"TERMINATED","interventions":["Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF"],"startDate":"2022-01-13","firstPosted":"2021-07-15","lastUpdated":"2025-08-06","primaryCompletion":"2023-09-28","whyStopped":"Terminated by mutual agreement by sponsor and institution.","enrollment":6,"officials":[{"name":"Ashley Ghiaseddin, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of Florida"}],"conditions":["Glioblastoma"],"siteCountries":["United States"]},{"nctId":"NCT03137888","title":"Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma","sponsor":"Emory University","sponsorClass":"OTHER","phases":["PHASE2"],"status":"COMPLETED","interventions":["Temozolomide"],"startDate":"2017-09-20","firstPosted":"2017-05-03","lastUpdated":"2025-08-03","primaryCompletion":"2024-09-09","resultsFirstPosted":"2025-08-03","enrollment":30,"officials":[{"name":"Hui-Kuo Shu, MD, PhD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Emory University/Winship Cancer Institute"}],"conditions":["Glioblastoma","Gliosarcoma"],"siteCountries":["United States","United States","United States"]},{"nctId":"NCT05929495","title":"Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma","sponsor":"University of Milano Bicocca","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":["Metformin"],"startDate":"2024-02-12","firstPosted":"2023-07-03","lastUpdated":"2025-07-25","primaryCompletion":"2026-01-01","enrollment":25,"officials":[],"conditions":["Glioblastoma, IDH-wildtype","Metformin","Malignancies"],"siteCountries":["Italy"]},{"nctId":"NCT03890952","title":"Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma","sponsor":"Ulrik Lassen","sponsorClass":"OTHER","phases":["PHASE2"],"status":"COMPLETED","interventions":["Nivolumab","Bevacizumab"],"startDate":"2018-10-01","firstPosted":"2019-03-26","lastUpdated":"2025-07-24","primaryCompletion":"2023-02-01","enrollment":40,"officials":[{"name":"Ulrik Lassen, MD, PHD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Copenhagen University Hospital, Rigshospitalet"}],"conditions":["Recurrent Adult Brain Tumor"],"siteCountries":["Denmark"]},{"nctId":"NCT05909618","title":"Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases","acronym":"14","sponsor":"Sheba Medical Center","sponsorClass":"OTHER","phases":["PHASE2"],"status":"RECRUITING","interventions":["Crizanlizumab-Tmca 10 MG/1 ML Intravenous Solution [ADAKVEO]","Nivolumab 10 MG/1 ML Intravenous Solution [OPDIVO]"],"startDate":"2023-07-11","firstPosted":"2023-06-18","lastUpdated":"2025-07-22","primaryCompletion":"2028-07-30","enrollment":33,"officials":[{"name":"Ronnie Shapira Frommer, Dr","role":"PRINCIPAL_INVESTIGATOR","affiliation":"Ronnie Shapira, MD Study Principal Investigator Ronnie.Shapira@sheba.health.gov.il"}],"conditions":["Advanced Glioblastoma","Metastatic Melanoma in the Central Nervous System","MGMT-Unmethylated Glioblastoma"],"siteCountries":["Israel"]},{"nctId":"NCT06501911","title":"A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High Grade Glioma","sponsor":"University of Nebraska","sponsorClass":"OTHER","phases":["PHASE1"],"status":"WITHDRAWN","interventions":["Bicalutamide"],"startDate":"2025-04-08","firstPosted":"2024-07-15","lastUpdated":"2025-07-22","primaryCompletion":"2025-07-17","whyStopped":"PI leaving institution.","enrollment":0,"officials":[{"name":"Chi Zhang, MD","role":"PRINCIPAL_INVESTIGATOR","affiliation":"University of Nebraska"}],"conditions":["Recurrent Glioblastoma","Recurrent High-grade Glioma"],"siteCountries":["United States"]},{"nctId":"NCT04523688","title":"Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate in Glioblastoma","acronym":"Combi G-Vax","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","sponsorClass":"OTHER","phases":["PHASE2"],"status":"UNKNOWN","interventions":["Autologous Dendritic Cells (DC) vaccine","Temozolomide"],"startDate":"2021-03-25","firstPosted":"2020-08-24","lastUpdated":"2025-07-22","primaryCompletion":"2025-07","enrollment":28,"officials":[{"name":"Laura Ridolfi, DR","role":"STUDY_CHAIR","affiliation":"IRST IRCCS"}],"conditions":["Glioblastoma","Vaccination"],"siteCountries":["Italy"]}],"source":"ClinicalTrials.gov","fetchedAt":"2026-11-11T16:09:34.130Z"}